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Summary
An improved understanding of the factors which regulate normal bone turnover is essential 
for effective management of many bone diseases, and for the treatment of bone defects and 
inherited disorders using autologous cell therapy. Involutional osteoporosis is 
characterised by a decrease in skeletal mass and structural integrity, and is thought to occur 
due to a reduction in the number of bone forming cells, osteoblasts, at sites of skeletal 
remodelling. Osteoblasts are derived from mesenchymal stem cells, termed colony 
forming units-fibroblastic (CFU-F), which are situated within the bone marrow stroma. In 
this study the influence of culture conditions and bone-anabolic agents on the colony 
formation, proliferation and differentiation of human bone marrow-derived CFU-F was 
determined in vitro, with particular emphasis on cells of the osteoblastic lineage.
Findings demonstrate that the continuous presence of L-ascorbate was essential for the 
proliferation of the clonogenic cells in culture. All factors tested had little influence on the 
number of colonies formed, and this was highly variable and dependent on the individual 
donor sample. Donor age provided little prediction of colony forming efficiency, although 
marrow stromal tissue from females was found to contain fewer osteogenic precursors than 
from males. Platelet-derived growth factor was demonstrated to be a candidate mitogen 
for the ex-vivo expansion of human bone marrow stromal cells that retain an immature 
phenotype but possess osteogenic potential, and might be used for tissue reconstruction 
and the healing of bone defects. In addition, further understanding of the osteoblast 
lineage is potentially attainable through conditionally immortalised cell lines derived from 
marrow stromal cells. Thus, this work has developed the understanding of factors that can 
be used to manipulate colony formation and expansion of human marrow stromal cells in 
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Bone is a highly specialised connective tissue. Functionally, bone serves three main roles in 
vertebrates: it acts as a mechanical support for the body and a site of muscle attachment for 
locomotion, it provides a protective barrier safeguarding vital organs such as the brain, lungs 
and spinal cord from external trauma, and it is a metabolic organ, providing a reservoir for 
the body calcium and phosphorous. Additionally, bone marrow serves as a site of 
haematopoiesis and a source of connective tissue stem cells (Baron, 1993).
Under non-pathological conditions the adult skeleton exists as two architecturally divergent 
bone types. Cortical bone forms the external surface of all bones and represents 80% of 
total bone mass and has a porosity of -10% . It primarily fulfils the mechanical and 
protective function of the marrow. Trabecular bone has a porosity of -75%. It occurs in the 
metaphyses and epiphyses of long and flat bones and forms the bulk of the vertebral bone 
mass. It is composed of a network of anatomising struts that are continuous with the inner 
surface of the cortex (endosteum) and are orientated to provide maximum resistance to 
tensile and compressive forces. The spaces enclosed by these thin trabeculae are filled with 
bone marrow (Baron, 1993).
Like other sub-types of connective tissue, bone is composed of cells embedded in a matrix 
of osteoid and fibres. The cells and matrix of bone tissue are organised to maximise the 
relationship between structure and function. Bone rigidity is provided by the deposition of 
inorganic salts such as calcium phosphate and calcium carbonate in the osteoid. In the 
matrix these form hydroxyapatite crystals which may be ionised when required to provide 
calcium and phosphate to satisfy transient bodily needs. The organisation of collagenous 
fibres in the matrix contribute towards bone strength and flexibility.
The bones of the skeleton have two embryological origins. Flat bones, particularly those of 
the skull and face, are formed by intramembranous ossification, following the direct 
differentiation of mesenchymal cells into osteoblasts. In the bones of the axial and 
apendicular skeleton, cartilaginous tissue formed by chondroblasts derived from the 
condensed embryonic mesenchyme, is progressively replaced with mineralised tissue by a 
process termed endochondral ossification. A more complete description of these processes 
is not appropriate in the context of this thesis and the interested reader is referred to a review 
chapter of Marks and Hermey (1996).
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1.2 Bone remodelling in the adult skeleton
The structure and functional integrity of bone in the adult skeleton is maintained by a 
continuous, life-long process termed remodelling. This process serves to prevent the 
accumulation of microdamage and allows the skeleton to adapt to changes in mechanical 
loading (Pead and Lanyon, 1989). This is achieved through a delicate balance of bone 
resorption and formation performed respectively by osteoclasts and osteoblasts. These two 
closely coupled cellular activities are highly co-ordinated in space and time, and are 
responsible for renewing the skeleton while maintaining its anatomical structure. The role of 
the skeleton as a mineral reservoir is also facilitated by the remodelling process (Manolagas 
and Jilka, 1995).
Osteoclasts, osteoblasts and their respective progenitor cells active in a remodelling cycle 
comprise the basic multicellular unit (BMU). The size, shape and individual identity of a 
BMU during its life-span, is co-ordinated spatially and temporally, and the relationship 
between its components maintained by the continued sequential recruitment of new bone 
cells (Puzas, 1993). The demand for osteoblasts is created by the number, size and location 
of the cavities made by osteoclasts. Under normal conditions remodelling takes place as a 
series of events summarised in figure 1.1. The duration of each of these events is indicated 
in figure 1 .2 .
1 .2 .1  Activation
In response to damage and/or changes in mechanical loading, bone lining cells retract, 
exposing the bone surface and allowing access to osteoclasts. Surface protein is removed 
by the release of a variety of proteolytic enzymes (Cheng et al, 1991, Chow and Chambers,
1992). Soluble mediators and cellular stimuli then recruit osteoclast precursors to the 
exposed bone surface (Fuller et al, 1992).
1 .2 .2  Resorption
As the mononuclear precursors approach the bone surface they fuse and become 
multinucleated osteoclasts. These become polarised and develop membrane specialisations 
(sealing zone and ruffled border) adjacent to the bone surface. Protons and acid proteases 
are secreted across the ruffled border into the extracellular space bonded by the sealing zone. 
Release of hydrogen ions and lysosomal enzymes by the activated osteoclasts degrades the 
mineralised matrix. During the resorption process previously sequestered growth and 
chemotactic factors are released in an active form and are thought to mediate recruitment and 
proliferation of osteoblast precursors. During the period of reversal, osteoclast activity is 
halted by mechanisms that remain poorly understood but which are thought to include an 
increase in intracellular calcium (Zaidi et al, 1992) and the release of TGFP or related 
peptides from the bone matrix (Chenu et al, 1988, Pfeilschifter et al, 1990a).
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1 .2 .3  Reversal
The reversal phase is characterised by the disappearance of osteoclasts and the appearance of 
a poorly characterised population of mononuclear phagocytes (Raisz, 1993). These appear 
to function in the removal of residual matrix protein, the deposition of the cement line, and 
possibly the coupling of resorption to formation.
1 .2 .4  F orm ation
This phase is characterised by the differentiation of osteoblasts which then proceed to 
deposit an amount of bone equivalent to that removed by the osteoclasts. In addition to 
producing the unmineralised bone (osteoid) osteoblasts are responsible for initiating its 
mineralisation by a mechanism that remains poorly understood.
It is important to appreciate that remodelling is the predominant form of bone turnover in the 
adult skeleton and that all losses or gains in bone mass are therefore a consequence of a focal 
imbalance between activities of osteoclasts and osteoblasts during each remodelling cycle.
osteocyte lin ing cell
'..w .V V .'v
*■ *■ — '
quiescent phase
formation phase resorptive phase
osteoblast
reversal phase
Figure 1.1 Illustration o f  the bone remodelling cycle
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1 81 '9 1 15 1 130 1
Dtration(days)
Figure 1.2 Illustration o f the events in the basic multicellular unit
Illustration of the events in the basic multicellular unit with the duration of each event stated in days (adapted from Remagen, 1989). POB, preosteoblasts.
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1.3 Osteoporosis
A disease that occurs due to disruption of bone turnover is osteoporosis. Osteoporosis, or 
brittle bone disease, is the most common metabolic disorder in developed countries. The 
prevalence of osteoporosis increases with age (Baron, 1993), and affects 1 in 4 post­
menopausal women and 1 in 8 elderly men. Osteoporotic patients develop an increased risk 
of fracture, particularly of the wrist, spine and hip, and the disease is implicated in more than
1.5 million fractures a year. Consequently, osteoporosis is a serious public health problem, 
particularly in the rapidly growing population of individuals over the age of 65. In 1994 it 
was calculated that the cost of treating osteoporotic fractures in the UK was 750 million 
pounds per annum (National Osteoporosis Society, 1996).
The World Health Organisation has defined osteoporosis as a decrease in bone mineral 
density of 2.5 standard deviations below the mean value for young adult females, with an 
accompanying deterioration of the skeletal microarchitecture. Two broad categories are 
recognised, primary and secondary, depending on the underlying aetiology. Primary 
osteoporosis is further categorised post-menopausal osteoporosis, type I, and age-related 
osteoporosis, type II (summarised in table 1.3), and is dependent on several factors 






Type I Post-menopausal Oestrogen Mainly trabecular Vertebral + Radial
women deficiency
Type II Men and women Ageing Cortical + trabecular Hip
Table 1.3 Summary o f the subtypes o f primary osteoporosis
In normal subjects, peak bone mass is achieved during the fourth decade, and remains 
relatively constant in both genders until middle age. At menopause women undergo an 
accelerated transient phase of bone loss that is most apparent over the subsequent decade and 
accounts for cancellous bone losses of 20-30% and cortical bone losses of 5-10% (Riggs 
and Melton, 1986). The cellular hallmark of the osteopenia caused by oestrogen deficit is an 
increase in bone turnover, with resorption increased to a greater extent than bone formation 
(Balena et al, 1993, Han et al, 1997). The accelerated phase of bone loss diminishes 
exponentially with time.
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Type II osteoporosis is manifested as a slow rate of bone loss due to changes in cellular 
response and function with ageing. Over a lifetime this accounts for losses of about 20-30% 
of cancellous bone and about 5-10% of cortical bone in both genders and continues 
indefinitely (Riggs and Melton, 1986). There is increasing evidence that the reduction in 
bone mass occurring in the osteoporotic skeleton does not result purely from an increase in 
bone resorption. Osteopenias associated with ageing appear to be due to a decrease in 
osteoblastic cell formation and defective recruitment of osteoblasts to the remodelling site. 
Factors implicated as causes of bone loss in the ageing population include secondary 
hyperparathyroidism, changes in local cytokines or systemic growth factors, and nutritional 
deficiency of vitamin D (Riggs et al, 1998).
Some of the causes of secondary osteoporosis are shown in table 1.4. Of these perhaps the 
factor of most importance in this study is that of glucocorticoid excess. This can arise due to 
endogenous hypersecretion (Cushings disease) or prolonged administration of high doses of 
exogenous glucocorticoids, for example in the treatment of chronic inflammatory disorders.
Some risk factors fo r  secondary osteoporosis
Genetic White or Asian decent 
Small, thin or tall, lean build 
Family history
Females more susceptible than males
Endocrine Early menopause 
Oestrogen deficiency 
Not giving birth
N utr it ion a l Calcium and vitamin D intake deficiency 
Excessive alcohol consumption
Drugs Glucocorticoids, thyroid medications, 
anticonvulsants, anticoagulants
L ife s ty le Cigarette smoking
Physical inactivity or immobilisation
Table 1.4 Risk factors fo r  secondary osteoporosis
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There is now general agreement that the rapid phase of bone loss associated with the loss of 
ovarian function in women is due to an increase in the number, activity and functional 
lifespan of osteoclasts (Sarma et al, 1998). This pattern of bone loss does not persist, 
however, and during the later stages of the disease and in age-related osteoporosis the 
predominant mechanism of bone loss appears to be a reduction in bone formation due 
primarily to a reduction in the number of osteoblasts. This is also believed to be the 
predominant mechanism of bone loss that is a frequent complication of chronic rheumatoid 
arthritis (Compston et al, 1989, Compston and Croucher, 1991). It follows therefore, that 
future prospects for the prevention and treatment of osteoporosis will depend on a precise 
understanding of the origin of osteoblasts in the adult skeleton and the identification of the 
factors that regulate their recruitment, proliferation and differentiation.
1.4 The cells of bone
1 .4 .1  O steoclasts
The cell type responsible for bone resorption is termed the osteoclast. These are giant 
multinucleated cells which secrete protons, and acidic and neutral proteases including 
collagenase, across their ruffled border into an extracellular hemivacuole adjacent to the bone 
surface. In the acidic microenvironment thus formed, the bone is demineralised, rendering 
the organic phase susceptible to proteolytic attack. The products of resorption are 
endocytosed at the ruffled border, transcytosed across the cell, and secreted from its 
basolateral surface (Nesbitt and Horton, 1977). The ultimate fate of osteoclasts is death by a 
process that bears the hallmarks of apoptosis (Hughes and Boyce, 1997). The ruffled 
border also provides a large surface area for the absorption of the degraded bone matrix. 
Osteoclasts develop via the fusion of circulating mononuclear precursors derived from 
haematopoietic stem cells (Kerby et al, 1992, Baron, 1993). It is currently unclear, 
however, whether the osteoclast is the product of a distinct cell lineage or merely an 
'offshoot' of the monocyte/macrophage lineage (Suda et al, 1996). The development of 
osteoclastic precursors in the marrow is regulated by growth factors and cytokines that are 
produced by cells of the stromal/osteoblastic lineage (Manolagas and Jilka, 1995).
1 .4 .2  O steoblasts
Osteoblasts are primarily responsible for the synthesis, deposition, and organisation of the 
bone extracellular matrix. Fully-differentiated osteoblasts are found adjacent to bone 
forming surfaces lining a layer of as yet unmineralised bone matrix (osteoid). They are 
cuboidal in shape and possess an eccentric nucleus with prominent nucleoli, a well 
developed golgi apparatus, and an abundance of ribosomes both free and associated with 
endoplasmic reticulum. At the end of their functional lifespan the majority of osteoblasts 
disappear, presumably by the process of apoptosis (Zimmerman, 1992, Jilka et al, 1998).
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1 .4 .3  O steocytes
As bone tissue is formed a proportion of the osteoblast population becomes entombed within 
the extra-cellular matrix. These entombed cells are termed osteocytes, and are the most 
abundant cell type in bone tissue (25,000/mm3). They possess long cell processes that 
extend through canaliculae in the bone matrix and make contact with other osteocytes and 
cells on bone surfaces. Evidence suggests that osteocytes are the mechanosensory cells of 
bone and play a central role in the dynamic adaptation of the tissue (van der Plas et al, 1994).
1 .4 .4  Bone lining cells
Terminally-differentiated osteoblasts may also become lining cells. These are present on 
quiescent endosteal bone surfaces, and although their function is unknown, they may be 
involved in osteoclast recruitment and/or regulate their access to the bone surface. The 
results of recent studies suggest that these cells may also have the ability to become 
biosynthetically active again, providing a source of osteoblasts at times of crises such as 
during fracture repair (Dobnig and Turner, 1995, Leaffer et al, 1995).
1.5 Factors affecting bone turnover
Bone turnover is regulated by an elaborate interplay between systemic hormones and a 
variety of locally-produced growth factors and cytokines, many of which become 
sequestered in an inactive form in the bone matrix (Rodan, 1991, Whitfield and Morely,
1995). Many of these factors may act as couplers between bone resorption and formation. 
Other factors influence the proliferation and differentiation of the bone cells. The local and 
systemic factors that regulate bone turnover include calcium regulating hormones, systemic 
hormones, cytokines, prostaglandins and growth factors. An in-depth description of all of 
the factors, systemic and local, that participate in this process is beyond the scope of this 
thesis. Instead, specific emphasis will be placed upon those factors employed in this 
investigation and for a wider overview the reader is referred to Bilezikian et al, 1996.
1 .5 .1  Glucocorticoids
Glucocorticoids have marked in vivo effects on bone and mineral metabolism, and 
osteoporosis is a common complication of patients with glucocorticoid excess, which has 
been attributed to increased bone resorption and decreased bone formation (Delany et al,
1994). The effect on bone resorption is indirect and is perhaps related to secondary 
hyperparathyroidism (Bikle et al, 1993). The decrease in bone formation is thought to occur 
through a direct inhibition of osteoblastic function in vivo (Reid et al, 1986). Paradoxically 
however, at physiological concentrations in vitro, glucocorticoids have been shown to 
promote osteogenic differentiation in primary marrow stromal cultures from a number of 
species and to induce formation of mineralised nodules in rat marrow stromal cell cultures
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(Maniatopoulos et al, 1988, Aubin et al, 1990, Bellows et al, 1990, Leboy et al, 1991, 
Davis et al, 1993, Beresford et al, 1994, Croisille et al, 1994, Cheng et al, 1994, Locklin et 
al, 1995). A decreased pharmacological dose in vivo can also stimulate bone formation, 
although this effect is species dependent (Chen et al, 1983, Beresford et al, 1994, Lian et al, 
1997, Bellows et al, 1998). The effects of glucocorticoids are described in chapter 3.
1 .5 .2  Prostaglandin E2
Bone cells, particularly osteoblasts, are abundant producers of prostaglandins, and 
prostaglandins of the E series were first found to be potent bone resorbers (Raisz et al, 
1990). The increase in bone resorption that occurs with immobilisation and inflammation 
can be reduced by non-steroidal antiinflammatories (NSAIDS) which inhibit bifunctional 
prostaglandin G/H synthase (PGHS, Pilbeam et al, 1995). Prostaglandins have since been 
shown to have both biphasic stimulatory and inhibitory effects on bone formation in cell and 
organ culture (Raisz and Fall, 1990, Mori et al, 1992). The effects of PGE2 on bone 
formation are described in further detail in chapter 4.
1 .5 .3  Growth factors
The bone mineral matrix is the most abundant source of growth factors in the body. During 
osteoclastic resorption, sequestered growth factors are released from the matrix into the 
extracellular fluid in an active form where they are available to act on the local cell 
populations or enter the circulation. The growth factors are produced by many of the cell 
types present in bone, including osteoblasts, endothelial cells and macrophages. Osteoblasts 
also express receptors for the majority of these growth factors, indicating that they can 
function in an autocrine as well as paracrine manner. A large number of growth factors have 
been identified in skeletal tissue and the fact that there are so many makes it difficult to 
assess their individual roles. Many of the growth factors and cytokines exert influences on 
the production of other factors, and/or their receptors, with which they can interact positively 
or negatively. Thus the effects of the growth factors on bone turnover are highly complex 
and it has often proved difficult to distinguish between their direct and indirect actions. A 
further complexity is that their production and/or incorporation into the bone matrix is 
affected by ageing and disease status, frequently resulting in adverse changes in resorption 
and formation. Growth factors associated with the control of osteoblast activity are 
summarised in table 1.5, and those that have been used in this thesis are discussed below.
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Growth factor kDa Concentration Proliferation* Differentiation*  
in matrix 
(ng/g)
Insulin-like growth factor-II 7.5 1500 I I
Transforming growth factor P 50 450 I I
Insulin-like growth factor-I 7.7 100 I I
Platelet-derived growth factor 35 60 I D
Fibroblast growth factor 33 60 I D
Table 1.5 Summary o f the effect o f growth factors on osteoblasts
Adapted from Canalis et al, 1989, Bay link et al, 1993. * I, increase, D, decrease.
1 .5 .3 .1  Insulin-like growth factor type I
IGF-I and II are abundant, anabolic peptides, which are structurally and functionally related 
to insulin (Delany et al, 1994). IGFs are available to skeletal tissues through de novo 
synthesis by bone cells and by the release of stored peptide from the bone matrix. 
Circulating IGF-I and IGF-II constitute a family of growth hormone dependent insulin-like 
peptides that are bound to specific IGF binding proteins (IGFBP) and mediate the growth 
promoting actions of growth hormones. Bone cells produce IGF-I, IGF-II and all known 
IGFBP, except IGFBP-1, which can positively and negatively influence IGF actions 
(Mohan, 1993). IGF-I is expressed by mature osteoblasts with little or no expression in 
preosteoblasts or osteocytes (Middleton et al, 1995), and its production is subject to 
regulation by systemic hormones including parathyroid hormone (PTH). In vitro IGF-I 
stimulates osteoblast-like cell proliferation and protein synthesis as well as the recruitment 
and differentiation of osteoblast (Shinar et al, 1993, Middleton et al, 1995, Wang et al,
1995) and osteoclast (Mochizuki et al, 1992) precursors. IGF-I receptors have also been 
found on osteoclasts actively engaged in bone resorption (Middleton et al, 1995). 
Pharmacologically administered IGF-I has been shown to increase the level of bone 
formation markers in the circulation (Ebeling et al, 1992).
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1 .5 .3 .2  Platelet-derived growth factor
A growth factor with significant growth potential in bone is platelet-derived growth factor 
(PDGF). The principal polypeptide in mammalian serum, it is known to have growth 
promoting activity for a variety of target cells of mesenchymal origin (Ross et al, 1974, 
Heldin et al, 1992). The matrix bound PDGF fraction, released during bone resorption, has 
been postulated to promote the migration and/or proliferation of osteogenic precursors 
associated with the marrow the stroma (Centrella et al, 1989, Pfeilschifter et al, 1990, 
Gilardetti et al, 1991). PDGF induces the formation of new bone in vivo (Lynch, 1989). 
The activity of PDGF released in vivo may be modulated by association with a high 
molecular weight protein plasma binding component thought to be a 2 -macroglobulin 
(Huang et al, 1984, Raines et al, 1992, Cochran et al, 1993). PDGF is known to cause its 
effects through interaction with other mesenchymal growth factors such as IGF-I. 
Considered as a whole, current knowledge suggests that is unlikely that PDGF A or B play a 
role in the maintenance of bone mass, however, the actions of PDGF on bone cell replication 
suggest a possible role in fracture healing and repair.
1.6 Osteogenic precursors and the stromal system of bone and marrow
In the postnatal vertebrate, osteogenic precursors are found associated with the bone marrow 
stroma. This is composed of a heterogeneous mixture of haematopoietic and stromal cells 
surrounded by a delicate supporting mesh of collagen fibres and other extracellular matrix 
components (Bianco and Riminucci, 1998). The whole tissue is richly supplied with thin- 
walled blood vessels. In this environment the precursor cells are in intimate contact with the 
endocortical and cancellous bone surfaces as well as with marrow monocytes, 
haematoprogenitors and the endothelial cells lining the blood vessels of the extra vascular 
intersinusoidal space (Jilka, 1998).
Bone marrow stromal cells (BMSC) are essential for the formation of the bone and the 
haematopoietic microenvironment, and direct influences between stromal cells and 
haematopoietic cell growth have been described (Song et al, 1985, Dexter, 1982). It is 
known that the two populations interact, with each other, and with the extracellular matrix, 
through a variety of adhesion molecules. Although bone precursor cells coexist among a 
population of haematopoietic progenitor cells, it is currently accepted that they are 
ontogenically distinct, and do not, as has frequently been suggested, share a common origin 
in the postnatal vertebrate (Simmons et al, 1987, Beresford, 1989).
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1.6.1  Colony Forming Units-Fibroblastic (CFU-F)
The pioneering studies of Friedenstein et al (1970) demonstrated that osteogenic precursors 
are derived from a population of cells termed Colony Forming Units-Fibroblastic (CFU-F), 
that exist in close association with the soft, fibrous tissue of the marrow stroma and are 
concentrated near the bone surfaces (Beresford, 1989). These were first identified on the 
basis of their ability to form fibroblastic colonies in cultures of marrow cells (Friedenstein et 
a l, 1970, each of which is derived from a single cell type (Friedenstein et al, 1976, 
Friedenstein, 1980). Friedenstein later showed (1987) that marrow-derived CFU-F 
reproducibly form an osteogenic tissue comprised of cartilage and bone when transplanted in 
vivo within diffusion chambers. Subsequently, marrow stromal cells from a number of 
species have since been shown to form bone in assays of osteogenesis (Benayahu et al, 
1989, Mardon et al, 1987, Nakahara et al, 1990, Gundle et al, 1995).
A subset of the CFU-F population exhibit stem cell-like characteristics in that they are 
capable of extensive self-renewal, and of giving rise to cells of multiple marrow stromal cell 
lineages including those necessary for the formation of bone and the recreation of the 
haematopoietic microenvironment (Dexter et al, 1977, Patt et al, 1982). More recently, 
Kuznetsov et al (1997) have shown that even after long term cultivation and multiple 
passages in vitro, human marrow stromal cells form at least five types of connective tissue 
upon transplantation in vivo.
The results of several studies indicate that cells of the different marrow lineages show 
considerable plasticity of phenotype (Bianco and Riminucci, 1998). Perhaps the best 
example of this is the interconversion of marrow adipocytes into bone forming osteoblasts 
(Beresford et al, 1992). Considerable progress has been made in recent years concerning 
the transcription regulation of lineage commitment. Thus MyoD (Filvarov and Derynck,
1996), peroxisome proliferator-activated receptor gamma (PPARy, Tontonoz et al, 1994, 
Nuttall et al, 1998) and core binding factor alpha-1 (CBFA-1, Banerjee et al, 1997) have 
been identified as key regulators of the commitment o f myoblasts, adipocytes and 
osteoblasts respectively (Rodan and Harada, 1997).
In vitro investigations have showed that CFU-F are a heterogeneous population of stem and 
progenitor cells which vary both in their potential to differentiate into multiple phenotypes, 
and in their sensitivity to inductive factors (Friedenstein et al, 1976, Owen, 1988, 
Kuznetsov et al, 1997a). Commitment and differentiation of the progenitors can be modified 
at the colony level, and under the appropriate culture conditions, colonies of specific lineages 
may be generated. However, the factors which regulate lineage commitment and by 
inference, therefore, the expression of the genes for these transcription factors, have yet to 
be fully elucidated in detail.
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1.6 .2  The differentiation of cells of the osteoblast lineage
Upon receipt of an appropriate signal, it is thought that the stem cells from which osteoblasts 
ultimately derive give rise to proliferative progenitors for the specific cell lineages, 
sometimes referred to as transit amplifying cells (Hall and Watt, 1989). The progenitor cells 
then undergo a number of population doublings to increase the size of the precursor 
population prior to cellular maturation. The existence of a progenitor cell compartment 
amplifies the effect of each stem cell division so that a relatively small number of rounds of 
stem cell division results in the production of a large number of terminally differentiated 
cells. A diagrammatic representation of the differentiation of cells of the osteoblast lineage is 
shown in figure 1.6 . Following commitment, it has been calculated that a osteoprogenitor 
cells goes through 6 -8  population doublings (Bellows and Aubin, 1989) before exiting the 
cell cycle and acquiring the functional characteristics of the mature osteoblast.
1.7 Stage specific markers of osteoblast differentiation
The differentiation of osteoblasts is a multistep process proceeding through defined stages 
(Aubin et al, 1993). Studies in vitro and in vivo established that the expression of bone 
related proteins, cell surface antigens and the receptors for systemic hormones and local 
factors, is ordered and sequential during the course of osteoblast maturation (reviewed in 
Stein et al, 1990, Owen et al, 1990). The earliest identifiable precursors produce low levels 
of collagens type I and III. The upregulation of collagen type I production and concomitant 
down regulation of collagen III is essential for proliferation and further differentiation. Once 
differentiation has begun, the other osteoblast marker genes are activated in a clear temporal 
sequence (Stein et al, 1990). Cells which are committed to the osteoblast lineage express 
alkaline phosphatase during the proliferative stage. Post-proliferatively there is an up­
regulation in the expression of genes that support the maturation and organisation of the 
bone extracellular matrix (e.g. osteonectin). Subsequently genes that facilitate extracellular 
mineralisation (osteopontin and osteocalcin) are expressed. The mature osteoblast 
phenotype is characterised by high levels of expression of type I collagen, alkaline 
phosphatase, osteopontin, osteonectin, bone sialoprotein and osteocalcin, and most notably 
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Figure 1.6 The differentiation pathways o f  mesenchymal stem cells
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It has been shown in culture that expression patterns of bone-related proteins are also 
regulated in a temporal manner during the successive developmental stages (Choi et al,
1996). These stages can be followed from CFU-F through to mature osteoblasts via 
detection of specific marker proteins and for their messenger RNAs (figure 1.7). The 
definitive test for the differentiation of osteoblasts remains, however, the formation of a well 
ordered extracellular matrix that mineralises (Beresford et al, 1993). A brief description of 
the most commonly used stage specific markers of osteoblast differentiation follows.
1 .7 .1  Core binding factor A -l (CBFA-1)
One potential marker of osteoblastic commitment and differentiation is the recently 
discovered osteoblast specific factor type 2 (OSF-2) otherwise known as the human core 
binding factor alpha-1 (CBFA-1). CBFA-1 is one of a three member family of mammalian 
transcription factors which is related to the drosophyla segmentation gene product, runt 
(Banerjee et al, 1997). In recent studies this protein has been shown to bind an osteoblast 
specific cis-acting element termed OSE-2 in the osteocalcin promoter (Geoffroy et al, 1995, 
Banerjee et al, 1995), and is an example of an osteoblast specific transcription factor. 
CBFA-1 expression is initiated in the mesenchymal condensation of the developing skeleton, 
is strictly restricted to cells of the osteoblast lineage thereafter, and is regulated by 
osteoblastic differentiating agents such as bone morphogenetic proteins (Ducy et al, 1997). 
Heterozygous loss of CBFA-1 function in humans occurs in the skeletal disorder 
cleidocranial dysplasia (CCD, Otto et al, 1997, Rodan and Harada, 1997). This is an 
autosomal-dominant condition characterised by hypoplasia/aplasia of clavicles, patent 
fontanels, short stature and supernumerary teeth. Homozygous inactivation of the cbfa-1 
gene has revealed its critical role in bone formation and knockout mice have a complete lack 
of ossification due to the maturational arrest of osteoblasts (Komori et al, 1997).
1 .7 .2  Stromal cell marker, STRO-1
The monoclonal antibody STRO-1 was generated by Simmons and Torok-Storb (1991) and 
recognises an antigenic epitope present on a subset of assayable CFU-F. STRO-1+ CFU-F 
proliferate extensively and give rise to cells of multiple marrow stromal cell lineages, 
including osteoblasts (Simmons and Torok-Storb, 1991, Gronthos et al, 1994). STRO-1 
antibody recognises a trypsin-resistant, cell surface antigen of unknown identity. The 
results of recent studies suggest that the antigen is expressed during the early stages of 
osteoblast differentiation up to and including the stage at which alkaline phosphatase is first 
expressed (Stewart et al, 1998). As the cells undergo further maturation, however, its 
expression is down-regulated.
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1.7 .3  Alkaline phosphatase
Alkaline phosphatase (AP) EC 3.1.3.1, is a ubiquitously expressed ectoenzyme, the 
physiological function of which is essentially unknown. In the human, three isoenzymes 
exist. These are the intestinal, placental and bone/liver/kidney (BLK) forms which are 
encoded by distinct genes. The BLK enzymes differ only by post-translation modification 
of cell surface carbohydrate moieties, and the bone isoform can be identified experimentally 
by lectin binding properties (Harris, 1990). The enzyme is covalently bound to 
phosphatidyl inositol complexes in the plasma membrane where it functions to hydrolyse 
monophosphate esters at alkaline pH (Aubin et al, 1993). In bone, AP is thought to be 
important in the process of skeletal mineralisation, confirmed by the finding that a mutation 
in its gene is the cause of hypophosphatasia, a disease characterised by defective skeletal 
mineralisation (Cheng et al, 1996). During bone formation a proportion of AP is released 
into the circulation and, clinically, serum alkaline phosphatase is the most commonly used 
marker of bone formation. AP is widely accepted as a marker of osteogenic differentiation 
which increases in activity as the cell population shifts to a more differentiated state. As 
such, it is routinely used in in vitro experiments as a marker of osteoblast differentiation 
(Aronow et al, 1990). An increase in AP expression is one of the earliest indications that 
cells have an initiated programme of osteogenic differentiation and expression persists 
through cell stages up to and including osteoblasts, but is down-regulated in lining cells and 
osteocytes.
1 . 7 . 4  Parathyroid hormone/Parathyroid hormone-related protein receptor
Parathyroid hormone binds to specific, G protein coupled receptors in the bone, through 
which it increases osteoblast proliferation and differentiation (Nishida et al, 1994). 
Expression of the parathyroid hormone receptor (PTHR1) has been found to increase with 
osteoblastic differentiation (McCauley et al, 1995, McCauley et al, 1996), being first 
detected in the osteoprogenitor population coincident with or shortly after, the upregulation 
of AP activity (Rouleau et al, 1988, Rouleau et al, 1990).
1 . 7 . 5  Bone sialoprotein
Bone sialoprotein (BSP) is an acidic glycoprotein which contains an arginine-glycine- 
aspartic acid (RGD) integrin binding motif (Oldberg et al, 1986). It is present in the 
mineralised matrix and in bone its expression is restricted to osteoid and almost exclusively 
produced by osteoblasts, osteocytes and hypertrophic chondrocytes (Bianco et al, 1993). In 
vivo it is first expressed coincident with the onset of mineralisation (Bianco et al, 1991), and 
in human bone the expression of BSP has been localised to mature osteoblasts (Aubin et al,
1993). BSP supports the attachment of osteoclasts and may modulate their activity 
(Miyauchi et al, 1991).
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Figure 1.7 The proposed lineage markers fo r  cells o f the osteoblastic lineage (adapted from  Bruder et al, 1997)
A diagrammatical representation of the osteogenic cell lineage. Expression of selected cell surface and extracellular matrix molecules reported by various 
investigators. The beginning of each arrow reflects the stage of differentiation where expression is first detected, and the arrowheads show the point where 
expression is no longer detected. Original references: 1, Haynesworth et al, 1992, 2, Filshie et al, 1998, 3, Bruder et al, 1998, 4, Stewart et al, 1996, 5, Joyner 
et al, 1997, 6, Ducy et al, 1997, 7, Bruder and Caplan, 1990, Turksen and Aubin, 1992, 8, Rouleau et al, 1990, McCauley et al, 1996, 9, Bruder et al, 1997, 
10, Bianco et al, 1988, 11, Aubin et al, 1996, 12, Mark et al, 1987, 13, Bruder and Caplan, 1990a, 14, Bodine et al, 1998, 15, Bruder and Caplan, 1989, 16, 
Chen et al, 1991, 17, Bronckers et al, 1987, Mark et al, 1987, 18, Wetterwald et al, 1996, 19, Bruder and Caplan, 1990a.
1.7 .6  Oestrogen receptor
For many years the effects of oestrogens on bone were thought to be indirect, but it is now 
known that low levels of the oestrogen receptor alpha (ERa) are expressed by cells of the 
osteoblast lineage in vivo and in vitro (Bodine et al, 1998, Hoyland et al, 1997). In vitro, 
expression of the E R a is first detected coincident with the upregulation of AP activity. 
Thereafter its levels increase with further maturation reaching a peak in the osteoblast 
population and decreasing thereafter (Bodine et al, 1998). The expression of high levels of 
E R a mRNA and protein has also been detected in osteoblasts in situ. It has recently been 
determined that there also exists a P type receptor (Mosselman et al, 1996). Expression of 
ERP mRNA has been found to increase with osteoblastic differentiation (Arts et al, 1997).
1 . 7 . 7  Osteocalcin
Osteocalcin (OC), also called bone GLA protein, is a small (7 kDa) noncollagenous protein 
and is the most abundant non-collagenous protein of the bone extracellular matrix 
constituting 10%-20% of the total non-collagenous protein (Robey et al, 1993). The 
distinguishing feature of OC is the presence of three y-carboxy glutamic acid residues, which 
are dependent on vitamin K for their carboxylation. The synthesis of osteocalcin is 
upregulated by 1,25-dihydroxyvitamin D 3 (Markose et al, 1990) and glucocorticoids 
(Shalhoub et al, 1998). A fraction is released into the circulation, where it can be measured 
for clinical analysis of bone formation. Two osteocalcin genes have been isolated from the 
mouse genome and a third osteocalcin-related gene has also been described (Rahman et al,
1993). The human osteocalcin gene is considered to be the most specific osteoblast-related 
gene (Stein et al, 1990, Cheng et al, 1996, Weinreb et al, 1990). It is produced at the very 
end stage of bone formation perhaps even after mineralisation, and in man is a marker of the 
osteoblast-osteocyte transition (Owen et al, 1990, Pockwinse et al, 1992, Kasai et al,
1994). Recently, OC has been shown to be a determinant of bone formation in OC deficient 
mice which have a higher bone mass and bones of improved functional quality (Ducy et al,
1996) with an observed increase in bone formation, but no impairment of bone resorption.
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1.7.8 Other markers for human cells of the osteoblast lineage
Many other markers of osteoblast differentiation exist, but three which have recently been 
found are MUC18, SB10 and HOP-26. MUC18 (CD146) is present on freshly isolated 
bone marrow cells (Filshie et al, 1998). It recognises a subset of cells that co-express 
STRO-1 and contains essentially all assayable CFU-F in vitro. However, this antigen is 
widely expressed on other cell types and is therefore likely to have only limited utility as 
stage specific marker of osteoblast differentiation. SB 10 reacts with an epitope expressed by 
mesenchymal stromal cells and osteoprogenitors (Bruder et al, 1997). The antigen 
recognised by SB 10 has recently been cloned and demonstrated to be activated leukocyte cell 
adhesion marker type 1 (ALCAM-1/CD 166, Bruder et al, 1998). HOP-26 (Joyner et al,
1997) is strongly reactive with cells in marrow stromal colonies at an early stage of 
differentiation, prior to the induction of AP expression.
1.8 Ex-vivo expansion o f CFU-F
Cells within the fibroblastic compartment of bone marrow stroma constitute a potential 
source of mesenchymal stem cells. Ex-vivo expansion of mesenchymal cells by isolation 
and mitotic expansion of human bone marrow stromal cells in vitro could provide 
autologous tissue of mesenchymal origin for therapeutic treatment of many medical 
conditions. For example, production of monolayers of mesenchymal cells could be used as 
a source of grafts for bums, muscle in compound fractures, or bone for non-union fractures 
or fusion of joints. Culture conditions could be adapted to provide cellular matter to replace 
necrotic tissue, tissue lost to surgical resection, or for use in reconstructive surgery. 
Expanded stromal cells could also be used as a delivery system for gene therapy.
The expansion of primitive marrow stromal cells whilst maintaining their maximum 
developmental potential would allow for the systemic administration of immature cells which 
might home to bone. If successful, this would result in long term reconstitution of the 
precursor cell populations, from which the patients would have a renewed cache of 
precursor cells for the different marrow stromal cell lineages, and progenitor cells could be 
recruited as necessary. Autologous therapy of this kind has recently been proposed for the 
treatment of certain types of osteogenesis imperfecta (Marini and Gerba 1997), and may 
even be applicable to the treatment of osteoporosis.
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1.9 Experimental work and aims
Understanding the cause(s) of the decline in osteoblast numbers in vivo would represent a 
significant advance in the prevention of bone loss and, of equal importance, to restore bone 
mass in patients presenting with established osteoporosis. This would also contribute to the 
development of new therapeutic regimens that could stimulate bone formation and restore the 
structural integrity of the skeleton. Additionally, an improved understanding of the factors 
which regulate normal bone turnover, in particular the proliferation and differentiation of 
osteogenic precursors, is essential for effective management of many bone diseases and for 
the treatment of bone defects and inherited disorders using autologous cell therapy.
Methods have previously been described for the isolation of colony forming units- 
fibroblastic from human bone marrow by density gradient centrifugation and adherence to 
plastic (Gartner and Kaplan, 1980, Long et al, 1990). The CFU-F assay provides a 
quantitative measure of a compartment of relatively undifferentiated stromal precursors. The 
purpose of this investigation was to identify factors that influence colony formation and the 
proliferation of adult human marrow stromal cells in vitro with particular emphasis on cells 
of the osteoblastic lineage.
The specific aims were as follows:
- to attempt to improve the CFE and proliferation of human marrow cells by manipulating 
the isolation procedures and conditions of culture.
- to determine the influence of PGE2 on the recruitment of CFU-F from the non-adherent 
population of cultured BMSC.
- to determine the effect of PDGF isoforms on CFE, proliferation and the osteogenic 
differentiation of BMSC.
- to determine the influence of age and gender on CFE, proliferation and the osteogenic 
differentiation of BMSC.
- to attempt the generation of immortalised strains of BMSC by transfection with plasmid 




2.1 Materials and reagents
2 . 1 . 1  Human bone marrow samples
Samples were obtained from the Bristol Royal Infirmary and Frenchay Hospital, Bristol. 
Adult human bone fragments were collected from the operating theatre within 4 hours of 
surgery. Samples were most commonly rib from patients undergoing cardio-thoracic 
surgery, only bone which would otherwise have been discarded was used and its use was 
approved by the Local Ethics Committee. Selection criteria excluded bone from patients 
who were suffering underlying bone disease or being prescribed corticosteroids. For each 
patient the age, sex, recent drug history, underlying pathology and site of skeletal origin was 
recorded (the characteristics of samples used in this study are shown in appendix III). For 
shipment to the laboratory the bone was placed into sterile flasks, submerged in sterile 
Dulbecco's modified Eagle's medium (DMEM) and delivered via courier. Bone was 
received and processed within 8 hours of its removal from the patient.
2 . 1 . 2  Use of cell lines
Mesenchymal-derived cell lines were utilised to evaluate methods or provide control 
samples. The selected cells lines used were: MG-63 cells (ATCC, CRL 1427), 
M R C 5S V 1T G 1 cells (ECACC #85042501), and Chinese hamster ovary cells (CHO, 
ECACC #5050302). MG-63 are a human osteosarcoma cell-line which express some of the 
characteristics of osteoblast-like cells isolated from the surface of human trabecular bone. 
MRC5SV 1TG 1 is an SV40 transformed human foetal lung cell-line which has a fibroblastic 
morphology and expresses SV40 large T antigen. CHO cells have an epithelial morphology 
and were used for optimising stable transfection techniques.
2 . 1 . 3  Handling and culture of cellular material
Tissue preparation, cell culture and work requiring sterile conditions was carried out in a 
Microflow Class 2 Biological Safety Cabinet, MDH, U.K. The cabinet was cleaned with 
neat Ambisan solution (Deb Ltd., U.K.) and 70% ethanol (Hayman Ltd., U.K.) once a 
month. The incubator used was a CO2 incubator (Borolabs, U.K.). Cells were cultured at 
37°C in a humidified atmosphere of 95% air : 5% carbon dioxide.
2 . 1 . 4  Plastics
All tissue culture plastic disposables were obtained from Becton Dickinson Labwear, N.J.
2 . 1 . 5  Reagents
Unless stated otherwise all reagents were prepared in ultra pure water (Milli-Q Water 
System, reagent grade, Millipore (U.K.) Ltd.)
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2 . 1 . 5 . 1  General laboratory chemicals
All chemical reagents were purchased from Sigma Chemical or BDH Ltd. unless otherwise 
indicated, and were of molecular or AnalaR grade.
2 . 1 . 5 . 2  Tissue culture reagents
These were supplied by Gibco BRL Life Technologies, U.K. unless stated otherwise.
2 . 1 . 5 . 3  Growth factors and inhibitors
Recombinant human platelet-derived growth factor (PDGF)-BB and AA were obtained from 
R & D Systems, and resuspended in 4 mM hydrochloric acid (HC1) containing 0.1% bovine 
serum albumin (BSA).
Recombinant human aIGF-1 (R & D Systems) was dissolved in 10 mM acetic acid with 
0.1% BSA.
Anti-IGF (aIR-3) antibody was obtained from Dr F. C. Kull, Glaxo Welcome Inc., USA. 
PGE2 stored under ethanol was a kind gift from Dr A. Scutt, University of Sheffield.
2 . 1 . 5 . 4  Antibodies
Hybridomas for the monoclonal mouse anti-human antibodies, STRO-1 and AP (B4-78) 
were obtained from Dr. P. Simmons, University of Adelaide, Australia and the 
Developmental Studies Hybridoma Bank, University of Iowa (Simmons and Torok-Storb, 
1991 and Lanson et al, 1985 respectively). These were cultured and the supernatants 
containing secreted antibody collected for use. The AP antibody was purified by protein G 
column separation by Dr. Carolyn Jefferiss. IgGl was supplied by Sigma, and OB/L was 
raised in-house by Dr. Susan Walsh. The goat anti-mouse secondary conjugates, anti-IgGl 
RPE and anti-IgM FITC were supplied by Southern Biotechnology Associates Inc.
Rabbit polyclonal IgGs against PDGF receptor a  chain (C-20, #sc-338) and PDGF receptor 
P chain (958, #sc-432) were obtained from Santa Cruz Biotechnology Inc. These were 
specific for epitopes corresponding to amino acids 1065-1084 and 958-1106 mapping at the 
carboxy terminal domain of the precursor form of human PDGF receptor type a  and (3 
respectively.
1.5 mg/ml pAblOl mouse IgG2a, isotype specific for the human C-terminal of SV40 large 
T antigen, was obtained from ATCC #TIB 117 and prepared in DMEM with 20% FCS. The 
antibody was used at a concentration of 5 pg/ml.
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2 .1 .5 .5  E nzym es
Collagenase VII (Sigma) was made up in DMEM with 5 mM CaCl2, and stored in 1 ml 
aliquots of 2500 U/ml at -20°C for up to 1 year.
Trypsin-EDTA was a 1 x stock solution of 0.5g Trypsin, 0.2g EDTA, 0.85g NaCl per litre, 
from Gibco BRL.
Superscript ™ RNase H" Reverse Transcriptase was supplied at 200 U/pl by Gibco BRL 
Taq DNA Polymerase was supplied in storage buffer A, at 5 units/pl (Promega #M1861).
2 .1 .5 .6  cDNA prim ers
The following primers were used in preparation of cDNA:
T arget
cDNA
Prim er sequence (5 '-3 ') A m plim er 
size (bp)
GAPDH 5’: GGTGAAGGTCGGAGTCAACGG 
3': TAGCACCTTCCTGAGTACTGG
570
PTH R 5': AG A AG A AGT ACCTGTGGGGCTTC AC AG 
3': GCTTGCGGTACTGCTGCCGTGTGTCAC
275
B SP 5': GCAGCCGGATCCTCATGCATTGGCTCCAGTGACACT 
3 ’: GG A ATTCTGCTC AGC A ITT1GGG A AT
700
OC 5': ATGAGAGCCCTCACACTCCTCG 
3': CT AG ACCGGGCCGT AG A AGCG
285
ER 5’: CAGTGAAGCTTCGATGATGATGG 
3': T ACT AC ATCGGTCGTCGT AC
300
PDGF A 5': AGAAGTCCAGGTGAGGTTAGAGGAGCAT 
3’: CTGCTTC ACCG AGTGCT AC A ATACTTGCT
304
PDGF B 5’: GAAGGAGCCTGGGTTCCCTG 
3’: TTTCTCACCTGGACAGGTCG
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2 .1 .5 .7  R ad io iso to p es
[3H]-thymidine was obtained from ICN, Ltd. U.K. at 37 kBq /pi in aqueous solution.
I32P]-adenosine 5 '-triphosphate was supplied in aqueous solution at 370 kBq/pl by 
Amersham Life Sciences, U.K. Ltd.
2 .1 .5 . 8  S o lu tio n s
The preparation of solutions described in these methods are shown in appendix I.
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2.2 Tissue Culture
2 . 2 . 1  Isolation and culture of human bone-derived cells
2 . 2 . 1 . 1  Bone marrow stromal cells (BMSC) and marrow cell populations
Human bone was submerged in Dulbecco's modified Eagle's medium (DMEM) in a petri- 
dish and the periosteum and all other extraneous connective tissue were removed by scraping 
with a sterile scalpel blade. Once clean, the bone was placed into fresh medium and split 
open lengthways with bone cutters. Fragments of bone, and the DMEM containing marrow 
tissue were transferred to a sterile 50 ml polypropylene tube (Falcon, Becton Dickinson). 
Marrow tissue was liberated from the rib by vortexing the sample in at least three volumes of 
DMEM until the bone was blanched. After each wash the supernatant was decanted into a 
fresh tube. An aliquot of the extracted marrow was placed aside and termed a whole marrow 
(WM) sample. The marrow cells were then pelleted by centrifugation at 514 x g for 5 mins 
in a Beckman GPR Centrifuge (rotor GH 3.7, Beckman, U.K). The fatty layer was 
aspirated off and the supernatant removed and retained as a subpopulation for further 
investigation, termed the 'wash'. The marrow cells were then resuspended in 25 ml 
DMEM, layered over 20 ml Lymphoprep™ (1.077 g/ml) and subjected to equilibrium- 
density centrifugation for 30 mins at 913 x g with the centrifuge brake off. The 
mononuclear cells were collected by transferring the opaque interface into a fresh tube 
whereupon 30 ml of DMEM were added and the cells spun again at 1430 x g for 10 mins to 
wash out any remaining Lymphoprep. This isolate contained bone marrow stromal cells 
(BMSC). The pellet obtained post-density gradient centrifugation was submitted to a second 
round of density-gradient centrifugation (double-ficolled). The isolated population of 
erythrocytes (RBC) were resuspended in serum-free medium.
The recovered marrow cell populations were resuspended in 15 ml of DMEM and filtered 
through a 70 pm filter (Falcon) to obtain suspensions of single cells. The number of viable 
mononuclear cells in each population was determined using trypan-blue exclusion and a 
haemocytometer (section 2.3.2), and using an electronic particle counter (Coulter Counter®, 
Multisizer II, Coulter Electronics, U.K., section 2.3.1). Each marrow cell population was 
seeded at 2 x l0 4 single cells/cm2 in petri-dishes or flasks and cultured in standard medium; 
DMEM supplemented with 15% (v/v) of foetal calf serum (FCS, see appendix I for selected 
lots), with or without 10-4 M L-ascorbate 2-phosphate (ASP) as required. Following 4 
days incubation non-adherent cells were aspirated under low vacuum pressure and adherent 
cells washed with 2 x 5 ml of phosphate buffered saline (PBS). Thereafter, medium was 
replaced bi-weekly until 18 days when the cultures were fixed, or passaged for further 
study. Cultures were maintained at 37°C in a humidified atmosphere of 5% CO2 in air.
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2 . 2 . 1 . 2  Human bone-derived cells (HBDC)
The explant procedure followed was essentially that described by Gundle and Beresford 
(1995). Briefly, following removal of the bone marrow (section 2.2.1.1) trabecular bone 
was scraped from the endosteal bone surface into PBS and cut into fragments ~3 mm in 
diameter using a sterile scalpel blade. Fragments of bone were transferred to sterile 50 ml 
polypropylene tubes and washed by vortexing vigorously in 3 volumes of PBS to remove 
remaining blood and marrow tissue. Once free of contaminating marrow elements, the 
fragments of trabecular bone were returned to a petri-dish and covered in PBS. Bone pieces 
were divided into piles of 1 cm2 x 0.5 cm. Each pile was placed into a 75 cm2 flask with 12 
ml of standard medium (10% (v/v) FCS in DMEM). The explants were then left 
undisturbed in an incubator at 37°C in a humidified atmosphere of 5% CO2 in air. The 
medium was replaced at 7 days, then twice weekly thereafter with care taken to not dislodge 
the bone fragments. Cellular outgrowths were generally observed at between 7-14 days and 
cells reached confluence at 4 to 6  weeks.
2 . 2 . 1 . 3  Cell lines
A cryovial containing cells of a cell-line was removed from liquid nitrogen storage and 
defrosted rapidly at 37°C. 0.5 ml aliquots were transferred to two 75 cm2 flasks with 15 ml 
of standard medium (10% FCS in DMEM for MG-63 and MRC5SV1TG1 cells). CHO cells 
were cultured with 10% FCS in glutamine-free DMEM. The contents of the flask were 
swirled gently and incubated overnight in a humidified incubator at 37°C. The medium was 
replaced the following day to remove traces of dimethylsulphoxide (DMSO). Thereafter, 
the cultures were fed every 2-3 days until the cells reached confluence (10-14 days).
2 . 2 . 2  Passaging cultured cells 
BMSC and HBDC:
Bone marrow and trabecular cultures required pre-incubation with bacterial collagenase to 
degrade the collagen rich extracellular matrix before digestion with trypsin-EDTA was 
possible. The protocol employed has been described previously (Gallagher et al, 1996). 
Briefly, the culture medium was aspirated under low vacuum pressure and the cell 
monolayer washed by addition of 2 x 5 ml serum-free DMEM to remove residual FCS. 50 
(il/cm2 of 25 U/ml collagenase VII in serum-free DMEM supplemented with 2 mM CaCl2 
was then added and the cells incubated for one hour at 37°C. At the end of this period, and 
following examination to ensure that the cells had not detached, the collagenase solution 
was removed and the cell layer washed twice in PBS.
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50 pl/cm 2 1 x trypsin-EDTA (Gibco BRL) was then layered over the cells and the flask 
incubated at 37°C for 5-10 mins. The process of cellular detachment was observed by 
microscopy (x 100) throughout subculture. A cell suspension was produced by gently 
pipetting up and down with a sterile 2 ml pipette to break down large clumps of cells. The 
suspension was transferred to a fresh 50 ml polypropylene tube containing 1% FCS to 
neutralise the trypsin activity. The flask was rinsed with 2 ml DMEM and the washings 
pooled with the cell suspension. Cells were recovered by centrifugation at 514 x g for 5 
mins at 4°C. The cell pellet was resuspended in a small volume of DMEM, typically 2 ml 
per 50 cm2 monolayer. The resulting cell suspension was filtered through a 70 Jim filter 
(Becton Dickinson) to remove clumped cells and matrix material, then counted electronically 
(2.3.1). BMSC and HBDC were subcultured at lxlO 4 cells/cm2.
Cell-lines:
Cell-lines (2.2.1.3) were subcultured when monolayers reached 80% confluence (generally 
twice weekly) at a split ratio of 1:5. Medium was aspirated and the cell monolayer washed 
with 2 x 5 ml DMEM. Cells were detached from the substratum by trypsin-EDTA 
digestion, and the above protocol was followed.
2 . 2 . 3  Cryogenic storage of cell-lines
Following passage of cultures, cells were stored to maintain stocks. 5 x l0 6 cells were 
resuspended in 0.5 ml freezing medium containing 10% (v/v) DMSO, 50% (v/v) FCS, and 
40% (v/v) DMEM. 0.5 ml of cell suspension was placed in a cryovial and slowly frozen 
through 4°C (30 mins), -20°C (2 hours) and -70°C overnight, before transferring to liquid 
nitrogen for long term storage.
2 . 2 . 4  Redistribution of bone cells and terminology of passaged cultures
The first flask of cells grown from BMSC are referred to as the primary culture, and 
proliferation at this stage is predominantly clonal. The growth of the colonies is rapid for 
the first 14-18 days of culture, but slows as the cells become densely packed and exit from 
the cell-cycle and/or begin to differentiate. To maintain proliferation, cells within the 
colonies were redistributed after 18 days, with the additional benefit that the yield of cells 
(after 21-28 days) is increased. Cells were redistributed using sequential collagenase- 
trypsin-EDTA treatment described previously (section 2.2.2). Standard medium was added 
to the cells which were left to resettle and grow for 14 days. Cultures treated in this way are 
termed redistributed primary cultures. If many cells were required, redistributed cultures 
were passaged after a further 14 days, seeded at lxlO 4 cells/cm2 (passage 1), and then 
grown until 75% confluent. They were not passaged further.
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2.3 Counting cells
2 .3 . 1  Electronic particle counting
A Coulter Counter detects particles of a defined size suspended in an electrolyte passing 
through an aperture over which there is a potential difference. The particles in the aperture 
displace electrolyte and alter the resistance between electrodes. The method has advantages 
over the haemocytometer method as the counter determines the number of cells 
electronically (preventing human error), is 40 times more sensitive (i.e. it can detect as few 
as 1250 cells per ml) and can be attenuated to count cells of a certain size range. It does not, 
however distinguish viable from dead cells. 2 0 0  pi of cell suspension was mixed with 10 
ml azide-free isotonic buffer (Isoton® II, Coulter Euro Diagnostics GMBH) in a 20 ml vial 
(Coulter) and the number of cells in 1 ml of suspension were determined electronically 
(Coulter Counter®, Multisizer II, Coulter Electronics, U.K.). The total number of cells in 
suspension was calculated as the number of events in 1 ml Isoton suspension, corrected for 
the dilution factor (10.2 ml/ 0.2 ml = 51), times the volume of the original suspension (ml).
2 . 3 . 2  Measurement of cell viability
The number of viable cells in a cell suspension (excluding freshly isolated bone marrow cell 
suspensions) was determined by mixing 10 pi cell suspension, 10 pi trypan blue (0.5% 
solution in 85% saline, Flow Laboratories Inc.) and 30 pi serum-free DMEM. The mixture 
was allowed to stand for 2 mins, then 15 pi were loaded onto a haemocytometer and 
counted. Exclusion of trypan blue and a highly refractive appearance indicated cellular 
viability. Viable cells lying within the haemocytometer grid were counted, including cells 
lying to the left vertically or the top horizontally. A count was taken until at least 50 viable 
cells had been counted. This number was multiplied by 10,000 to account for the 
dimensions of the haemocytometer, and again by 5 to compensate for dilution.
To count nucleated cells in freshly isolated bone marrow stromal cell preparations, a 3% 
(v/v) acetic acid solution in water stained with 0 .0 1 % (w/v) methylene blue was mixed 1:10 
with a cell suspension. This stains all nucleated cells and destroys red blood cells. 15 pi 
were loaded onto a haemocytometer and counted as above.
2.4 Experiments on primary cell cultures
For each treatment group in an experiment the following parameters were determined, i) 
total number of colonies, ii) proportion of total colonies expressing alkaline phosphatase, 
iii) the mean size of the colonies and, iv) the total number of cells per flask. Each treatment 
was carried out in quadruplicate. Unless stated otherwise the test factors were added to the 
cells at the time of explantation, and maintained in culture until analysis.
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2 . 4 . 1  Determination of colony forming efficiency (CFE)
BMSC were prepared and cultured in 55 mm diameter petri-dishes as described in section 
2.2.1.1. At 18 days post-explantation the medium was aspirated, and the cells washed in 
two volumes of PBS. Colonies were fixed in a solution of 10% (v/v) neutral buffered 
formalin (NBF) for 15 mins at 4°C and then stained sequentially to identify colonies of 
fibroblastic or osteoblastic cells. Cellular foci containing > 50 cells were defined as 
colonies. Foci containing < 50 cells were defined as clusters and not scored. Use of a 15 x 
objective (microscope model SZ-CTV, Olympus, Japan) aided counting. Mean area per 
colony was determined by measuring the colony diameter with a ruler and calculating the 
area using Ttr2. The area of all colonies in a dish was totalled and divided by the number of 
colonies.
2 . 4 . 2  Expression of alkaline phosphatase (Dakopatts protocol, Denmark)
Substrate solution was prepared by dissolving naphthol AS-MX phosphate in N,N- 
dimethylformamide at 10 mg/ml in a glass tube, and diluting 1 in 50 with 0.1 M Tris buffer, 
pH 8.2. Fast-red TR salt (1 mg/ml) was dissolved in the substrate solution and filtered 
(paper #1, Whatman) immediately prior to use. Colonies were covered with 2 ml of Fast- 
red TR solution and incubated for 30 mins at 37°C. The stain was rinsed off with tap water 
and the dishes air dried. Colonies were scored as AP positive if greater than 20 % of the 
cells were stained with Fast-red TR.
2 . 4 . 3  Demonstration of mineral deposition
The presence of deposited mineral was detected using von Kossa reagent. The method is 
based on the substitution of calcium bound to phosphate and carbonate groups by silver 
ions. A method modified by Rungby et al (1993) was followed to reduce background 
staining. Colonies were cultured from fresh human bone marrow stromal cell explants as 
previously described (2 .2 .1).
To facilitate matrix mineralisation, 5 mM inorganic phosphate (Pi) was added to standard 
medium on day 12 for 5 days. Following aspiration of the medium, colonies were rinsed 
once with PBS and then fixed in 10% NBF for 15 mins at 4°C. The fixative was removed 
and the cultures rinsed with distilled water for 1 x 1 minute, and 1 x 1 5  mins. The colonies 
were stained with a solution of 0.5% (w/v) silver lactate for 20 mins in daylight. The stain 
was rinsed away with distilled water and the colonies then immersed in 0.5% (w/v) 
hydroquinone for 2 mins, and 5% (w/v) sodium thiosulphate for 2 mins. The dishes were 
rinsed twice in distilled water and the cells counter stained with 0 .1% (w/v) toluidine blue O 
for 2 seconds. The staining solution was washed away with 3 volumes of tap water and the 
dishes air dried. Mineralisation was indicated by the presence of a black deposit on or 
surrounding fixed cells.
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2 . 4 . 4  Methylene blue stain of total BMSC colonies
Visualisation of total colonies was facilitated histochemically by staining fixed cells with 
methylene blue. Following AP and/or von Kossa stain, fixed cultures were washed with 
borate buffer (10 mM, pH 8 .8 ), stained with 1% (w/v) methylene blue solution prepared in 
borate buffer for 3 mins, then rewashed with 3 volumes of borate buffer. The dishes were 
air dried and the methylene blue positive colonies were counted as total colony number. As 
an indirect estimate of total cell number, methylene blue was eluted and the OD measured at 
650 nm (Currie, 1981). This was achieved by eluting dye with 500 pi of 1% HC1 in 
ethanol. The dishes were rinsed in a further 500 pi acidified ethanol and the volumes 
pooled. 50pl of eluate was transferred to a 96 well microtitre plate and the absorbance read 
in a Dynatech MR5000 scanning multiwell spectrophotometer at 650 nm against acidified 
ethanol blanks.
2.5 Cell proliferation experiments
Cell proliferation was expressed as the mean number of cells per cm2 for n = 4 flasks. 
Following 28 days incubation the culture medium was aspirated and the cells washed in two 
volumes of PBS. Cells were detached from the plastic by sequential collagenase, trypsin- 
EDTA treatment (section 2.2.2), collected by centrifugation (514 x g for 5 mins) and 
resuspended in 2 ml of medium. The cell suspension was filtered and the number of cells in 
suspension determined electronically using a Coulter Counter (section 2.3.1).
2 . 5 . 1  Tritiated thymidine incorporation and scintillation counting
Cells were harvested, washed in medium and resuspended at a concentration of lx l0 6 
cells/ml. The cells were then aliquotted into wells of a 96-well flat bottomed plate (lxlO 5 
cells/well) along with the factors being investigated. DNA synthesis was measured through 
incorporation of [3H]-thymidine. Cells were incubated in 200 pi medium at 37°C in 95% 
air, 5% CO2 for 72 hours in the presence of test factors and then pulsed with [3H]- 
thymidine. Stock [3H]-thymidine (1 pCi/pl) was diluted 1 in 50 in medium. 25 pi of 
diluted [3H]-thymidine were added to the cells which were incubated at 37°C for a further 24 
hours. The medium was aspirated and replaced with 100 pi of 0.1% SDS in H2O. The cell 
lysate was harvested onto glass filters using a semiautomatic cell harvester (Filtermate 196, 
Packard). The filters were dried, and immersed in 500 pi of Optiscint HiSafe in scintillation 
vials. The amount of incorporated [3H]-thymidine was measured as scintillation counts per 
minute (CPM) on a LKB 1209 Rackbeta liquid scintillation counter.
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2.6 The effect of growth factors on osteoblastic differentiation
2 . 6 . 1  Preparation of cell protein extracts
Protein lysates were used for biochemical analysis of alkaline phosphatase, dot blots and 
western blot studies. Bone-derived cells were harvested at 75% confluence as described in 
section 2 .2 .2 . l x l 0 6 cells were aliquotted into sterile universal tubes and recovered by 
centrifugation at 514 x g for 5 mins. The cell pellet was washed in two volumes of PBS 
with added protease inhibitors, then resuspended in 100 pi of ice-cold Nonidet P-40 buffer 
(NP-40) + inhibitors. The cell suspension was transferred to a cooled microcentrifuge tube 
(Sigma). The suspension was left on ice for one hour to lyse the cells. The homogenate 
was then centrifuged for 10 mins at 10,000 x g in a bench-top centrifuge (4°C, Biofuge 
Fresco, Heraeus Instruments) to pellet the cell nuclei and insoluble material. The 
supernatant containing soluble proteins was placed in a fresh microcentrifuge tube and 
stored at -70°C.
2 . 6 . 2  Total protein determination in cell lysates
The DC Protein Assay (Biorad) was used for the determination of protein concentration in 
cell lysates. The assay is compatible with lysis buffers containing detergents (NP-40) and 
protease inhibitors. Protein dilutions of 0 - 3 mg/ml bovine y-globulin protein were 
prepared from a 2 0  mg/ml stock solution diluted in the buffer in which the samples were 
resuspended. Standards and samples (5 pi) were pipetted into wells of a clean dry 
microtitre plate and 25 pi of mixed Reagent A (sodium hydroxide, NaOH) was added to 
each well. If detergent was not present in the sample buffer, Reagent S (SDS, 20pl) was 
added to each ml of Reagent A required. 200 pi reagent B (Folin Reagent) was then added 
and the plate agitated to mix the reagents. After 15 mins the A750 nm was determined using 
an MR5000 plate reader (Dynatech) and the protein concentrations of the samples 
determined from the standard curve.
2 . 6 . 3  Biochemical analysis of alkaline phosphatase activity
Alkaline phosphatase activity in whole cell lysates was determined by measuring the 
formation of yellow p-nitrophenol (p-NP) by hydrolysis of colourless p-nitrophenyl 
phosphate (p-NPP) substrate at pH 10.3 for 30 mins at 37°C. Lysates of lxlO 6 cells were 
prepared as in section 2.6.1, although, cell pellets were resuspended in 500 pi PBS.
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A standard curve (range 10 nmol/ml - 2 pmol/ml) was prepared by diluting 10 pmol/ml p- 
NP standard solution in 221-Alkaline buffer solution (Sigma). 25 pi of standards and 
samples (equivalent to 5x l0 4 cells) were transferred to triplicate wells in a microtitre plate. 
Substrate buffer was made up by dissolving p-NPP (460 pg/ml) in 221-Alkaline buffer 
supplemented with 0.5% (v/v) Triton-X. 200 j l l I  substrate buffer was added to each 
standard and sample well. The plates were incubated at 37°C for 30 mins and then the 
reaction stopped by adding 20 pi of 10 M NaOH. The optical density equivalent to [p-NP] 
was read at 410 nm against blanks of substrate buffer in an MR5000 plate reader (Dynatech) 
and the concentration of p-NP calculated automatically from the standard curve. The results 
are expressed as nmole of p-NP produced per lxlO 6 cells per minute.
2 . 6 . 4  1,25-Dihydroxyvitamin D3 pulse in serum-free medium
To increase the synthesis and secretion of osteocalcin in osteoblastic cells, culture medium 
was aspirated from primary cells, the monolayer rinsed with 3 volumes of PBS to remove 
any Dx present in the culture. Medium was replaced under UV-free conditions with serum- 
free medium containing 1,25-dihydroxyvitamin D 3 (13 pg/ml stock, gift from Roche, 
Welwyn Garden City) and vitamin K both at a final concentration of lO 8 M for 48 hours.
2.6.5 Osteocalcin assay
After 48 hours treatment with 1,25-dihydroxyvitamin D3, 1 ml of culture supernatant was 
harvested and snap frozen in liquid nitrogen. All samples were stored at -70°C and were 
subjected to fewer than two freeze-thaw cycles. Osteocalcin levels in the culture supernatant 
was determined using a competitive immunoassay, specific for the intact protein 
(Novocalcin, Metra Biosystems Inc.). Before use, all reagents were warmed to room 
temperature. 25 pi of standards, samples and controls were added to osteocalcin coated 
strips of a microtitre plate and 125 pi of osteocalcin antiserum were added. The plate was 
gently swirled for 1 minute then tightly covered and incubated at room temperature for 2 
hours. Following incubation the plate was inverted and washed with 3 x 300 pi volumes of 
1 x wash buffer.
150 pi of reconstituted enzyme conjugate were added to each well and then incubated at 
room temperature for 1 hour. The strips were washed again, blotted dry and 150 pi of 
working substrate solution was added to each well. The plate was incubated for a further 35 
mins at room temperature, then the reaction stopped with 50 pi of 3M NaOH. The optical 
density was read within 15 mins of NaOH addition at 405 nm on an MR5000 plate reader 
(Dynatech), and absorbances compared with a 4-parameter calibration curve fitting equation.
33
2.6.6 Cyclic AMP detection
BMSC in 2° culture were grown to 70% confluence. The medium was removed and 
replaced with medium containing a range of [PGE2]. Cultures were treated for 15 mins. 
The medium was then diluted with 2 volumes of absolute ethanol at -20 °C, and transferred 
to a centrifuge tube. The medium was evaporated on a rotary evaporator (Jouan RC. 10.22) 
for 350 mins at 50°C. The residue was resuspended in assay buffer, and the amount of 
cyclic adenosine monophosphate (cAMP) present was measured using a commercially 
available kit (Biotrak, cAMP El A, Amersham Life Science). [cAMP] was normalised for 
the number of cells in the culture dish determined indirectly using the dye methylene blue 
(section 2.4.4).
2.7 Statistical analysis
CFE and cell number were determined using a minimum of 4 cultures and the data 
expressed either as the mean +/- SE or as the treatment/control (T/C) ratio, with the absolute 
values observed in the control groups stated in the text. Where experiments were performed 
with multiple donors and similar results were generated, summary data are expressed as 
percentages of control values and errors are equivalent to standard errors between the donor 
samples. Statistical analysis was carried out on all data shown.
2 . 7 . 1  Kruskal-Wallis test
No assumptions were made regarding the underlying distribution (parametric vs non- 
parametric) of the individual data points of colony formation or proliferation. For this 
reason statistical analysis of the data was performed using the Kruskal-Wallis test. This can 
be used to analyse more than three sample groups of varying sizes and, as it is based on a 
ranking system and compares the median values of the samples, the absolute magnitudes of 
the changes in parameter are not considered, merely whether or not a change was observed 
following treatment with one or more agent.
The H value is used to compare the median values between all the sample groups tested. A 
value determined experimentally shown to be equal to, or greater than the critical H value 
indicates a statistically significant result (Neave, 1981). H was calculated by the formula:
k
H=[12/N(N+1)]Z(R2 /n )-3 (N + l)
1
where N = total number of values analysed, k = the number of samples, 2  = sum of, R = 
rank of each sample, and n = size of each sample (number of repeats per treatment).
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The second stage of the Kruskal-Wallis test is to compare samples with each other by use of 
Q values. It is noted however, that testing for the value of Q was only performed where a 
statistically significant H value was obtained. Q values determine the statistical significance 
of the difference observed between individual sample medians and, as for H values, an 
experimentally determined value equal to, or greater than the critical Q value is indicative of 
statistical significance (Heath, 1995). The Q value is calculated by the formula:
where R = mean rank of sample, N = total numbers of values analysed in the Kruskal- 
Wallis test, n = size of each sample (number of repeats per treatment). Significant results 
are stated in the text.
2 . 7 . 2  Spearmans rank correlation coefficient
The effect of age on each parameter was assessed using Spearmans rank correlation 
coefficient calculated using a computer package (SRCC, StatView v4.51). This is a non- 
parametric test which has few underlying assumptions of means and variance. The test 
ranks the two sets of data independently (in this case, age and colony formation or cell 
number) and calculates the correlation coefficient (r) using the formula below:
where rs = Spearmans rho, the calculated value of Spearmans rank correlation coefficient, d 
= the difference between the ranks of the two variables for any sampling unit (d is small with 
a positive correlation, and large with a negative correlation), and n = the number of samples, 
rho tests for the tendency of Y to increase (or decrease) as X increases on a bivariate plot, 
and varies between +1  for a perfect positive correlation and -1 for a perfect negative 
correlation, the sign indicating the direction of correlation. The minimum number of patient 
samples assessable is five.
The Spearman rank correlation coefficient uses the null hypothesis that there is no correlation 
between the two variables. The general null hypothesis used was that there was not an 
association between donor age and the parameter under investigation. The calculated value 
of rho was compared to the critical value at a confidence level of 5%. A two tailed analysis 
(oc2 ) was used to avoid assumption of the direction of correlation, and a one tailed analysis 
(a l)  was used when the direction of correlation could be assumed from a plot.
Q -
R \ - R 2
35
The null hypothesis was rejected if the calculated value was equal to, or larger than, the 
critical value. The results are shown in appendix II, where the p-value in the analysis tables 
shows the associated probability derived from a comparison of the calculated value with the 
critical value for the sample number, n. It was decided that correlations equating to p < 0.05 
showed significance and the null hypothesis was rejected.
2 . 7 . 3  Mann-Whitney U test
The Mann-Whitney U test is a non-parametric version of the two group unpaired t-test, and 
tests the hypothesis that two populations have the same median (Heath, 1995a). Since the 
Mann-Whitney U test does not consider the observations but instead their ranks, it is 
resistant to outliers in either of the groups compared. The requirements for validity of the 
Mann-Whitney test are that the two groups of observations come from continuous 
distributions and are independent of each other. This analysis was calculated using the 
StatView, v4.51 computer package. The U value was calculated as follows. All the 
samples are ordered and ranked as one group. The sum of the ranks for A or B are 
calculated (Ra or Rb), then U a or U b are obtained as below (for A):
U a =  R a -  — m ( n A  + 1 )
2
where, n = the sample size. U is then the smaller of Ua or nAnB - Ua and the critical value 
of U is less than the tabulated value.
2.8 Immunocytochemistry
2 . 8 . 1  Immunocytochemistry of MRC5SV 1TG 1 cells
Cytospins of MRC5SV 1TG 1 cells were prepared to investigate expression of the simian 
virus 40 large T antigen (SV40 large T Ag) by immunocytochemistry. 200 pi of cell 
suspension (2xl05 cells) was placed in the Cytofunnel™ sample chamber, clipped onto the 
microscope slide against a filter card with a Cytoclip™ and centrifuged at 55 x g for 3 mins 
in the Shandon Cytospin 3. The slides were allowed to air dry and then fixed in acetone for 
5 mins at 25°C. Following evaporation of the acetone, a ring was drawn around the cells 
using a Pap pen. Slides could be stored wrapped in foil at -20°C.
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Monoclonal antibody, pAblOl (100 pi of 5 pg/ml in PBS, IgG2a) was placed on the cells 
which was isotype specific for the C-terminal of SV40 large T Ag. The antibody was 
incubated on the slides for 30 mins, in a petri-dish containing moistened filter paper to 
prevent drying. Unbound antibody was rinsed off the slides with PBS, 1% FCS in a Coplin 
jar. The secondary antibody, fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse 
antibody directed against the y-chain of IgG was added (1 in 75 dilution, 200 pi), and 
incubated at 25°C for 30 mins. The 2° antibody was washed off in PBS, 10% FCS. The 
cells were counter-stained with 0.1% ethidium bromide and washed thoroughly. One drop 
of mountant (1:1 mixture of glycerol and PBS) was placed on the labelled cells and a cover 
slip layered over the mountant avoiding incorporation of air bubbles. The slides were 
viewed under a light microscope (100 x objective) with a UV lamp (302 nm).
2 . 8 . 2  Detection of cell surface antigens
Two sets of experiments were carried out using fluorescent activated cell scanning (FACS®) 
to examine the presence of specific epitopes on the cell surface. These were i) intracellular 
labelling with antibodies directed against the PDGF a  or (3 receptor types, and ii) dual 
surface labelling with antibodies against STRO-1 and AP epitopes.
Redistributed BMSC and trabecular bone cells were cultured in the absence or presence of 
test factors. At 75% confluence the cell monolayer was harvested by sequential treatment 
with collagenase-trypsin (section 2.2.2) and resuspended in DMEM supplemented with 1% 
FCS. Cells were incubated at 37°C for 30 mins to allow recovery after trypsin treatment. 
At this stage the cells were counted using a Coulter Counter (section 2.3.1). The cells were 
then centrifuged at 514 x g for 4 mins at 4°C, the supernatant removed by aspiration and the 
cells resuspended in 3 ml of FACS wash buffer. This washing process was repeated twice. 
The cells were finally resuspended at lxlO 6 cells/ml in wash buffer. 500 pi of cell 
suspension (5x l05 cells) were aliquotted into polystyrene FACS tubes (Falcon, Becton 
Dickinson). The aliquots were kept on ice during the following incubation steps.
2 . 8 . 3  Flow cytometric analysis of STRO-1 and alkaline phosphatase
Aliquotted cells were pelleted, and resuspended in blocking buffer (50 pi per tube) and 
incubated for 30 mins to block Fc receptors on the cell surface. The cells were washed in 
wash buffer and then incubated for 45 mins with STRO-1 hybridoma culture supernatant 
(500 pi per tube) containing the purified anti-alkaline phosphatase antibody, B4-78, at 15 
pg/ml.
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For cells from each treatment group the following tubes were set up:
Tube Ab combination
Negative IgM + IgGl
STRO-1+ STRO-1 mAb + IgGl
AP + AP mAb + IgM
Dual positive STRO-1 mAb + AP mAb
After incubation the cells were washed once in 3 ml wash buffer and then resuspended in 
100 pi FITC-conjugated and RPE-conjugated 2° antibodies combined in blocking buffer. 
The cells were incubated for 45 mins then washed once in 3 ml wash buffer. Labelled cells 
were finally resuspended in 200 pi PBS with 200 pi FACS-fix and stored in the dark for up 
to 4 days at 4°C prior to analysis.
2 . 8 . 4  PDGF receptor expression
A rabbit anti-human PDGF receptor antibody directed against an intracellular epitope, was 
used to examine receptor expression on bone-derived cells. Cells were permeabilised with 
saponin during incubation with the antibody to allow access to the antigenic site.
The cells were fixed initially for 5 mins in 200 pi 2% FACS fix in order to fix the cell 
membrane prior to it being permeabilised. The fix was rinsed away with 500 pi FACS 
wash buffer and the cells recovered by centrifugation. The cells were then permeabilised y 
incubation with 500 pi of saponin solution for 5 mins. The cells were again washed and 
then incubated for 60 mins in 100 pi of monoclonal rabbit anti-human PDGF receptor 
antibody diluted to 1 pg/ml in saponin solution. Negative control tubes were set up with 
isotype control antibody (rabbit IgG at 1 pg/ml in saponin solution). Following incubation 
the cells were washed twice in 2 ml saponin solution, and recovered by centrifugation. The 
cells were resuspended in 100 pi FITC-conjugated goat anti-rabbit IgG diluted 1 in 160 in 
FACS wash buffer, and incubated for 30 mins. Finally, the cells were washed once in 2 ml 
saponin solution, and then in FACS wash buffer to 'reseal' the membranes. Labelled cells 
were recovered by centrifugation and resuspended in 500 pi of 1% FACS fix diluted in 
FACS wash buffer and stored in the dark for up to 4 days at 4°C prior to analysis.
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2 .8 .5  Flow cytometry
Samples were analysed on a Becton Dickinson FACStar Plus, equipped with a 100 mW 
argon ion laser and controlled by a Consort 32 computer. The principle of flow cytometry 
is that a single cell suspension passes through a laser light source which causes any bound 
fluorochrome to emit light of a different wavelength. The scattered or fluorescent light 
produced is collected by a photo multiplier tube (PMT), which is converted to electrical 
signals and eventually to digital information. The light produced is reflected by mirrors, 
coated such that they only reflect light of a specific wavelength. Therefore, one cell 
preparation can be labelled with several fluorochromes which all emit a different spectrum 
of light.
Prior to collecting data, the nozzle head was aligned to maximise the detection of fluorescent 
events. This was carried out using a mixture of two latex beads coated with fluorescein 
isothiocyanate (FITC) of different intensities. Control tubes were used to set compensation 
for dual labelled samples as phycoerythrin (R-PE) / propidium iodide (PI) signals interfere 
with the FITC signal and have to be adjusted for. Data analysis was performed using the 
PC-Lysis and CELLQuest® software packages (both from Becton Dickinson, Mountain 
View, CA).
2.9 Experiments to investigate expression of specific proteins
2 . 9 . 1  Dot blotting of total cell lysates
Cell lysates of known protein concentration were serially diluted in NP-40 lysis buffer with 
protease inhibitors (section 2 .6 .1) to produce solutions containing 1 0 0  pg - 10 0  pg of 
protein in 200 pi samples. Protran BA 85 cellulose acetate membrane (Schleicher and 
Schuell) was pre-wet in milli-Q water and soaked in PBS for 5-10 mins before use. The 
filtration manifold was assembled as follows: two sheets of filter paper (Whatman 3 MM) 
pre-wet in PBS were placed on the filter support plate of the filtration manifold. The 
cellulose acetate membrane was placed over the absorbent filter paper, and the sample-well 
plate placed on top and clamped firmly into place. A low pressure vacuum was applied to 
the manifold and individual wells were washed with 500 pi of NP-40 lysis buffer. The 
samples were applied to the wells, filtered through and washed thoroughly with lysis buffer 
(500 pi). The membrane was then removed from the manifold, air dried and stored at 4°C 
until immunodetection was performed using the ECL technique described in section 2.9.5.
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2 .9 .2  Denaturing SDS-PAGE (Laemmli, 1970)
In SDS polyacrylamide gel electrophoresis (SDS-PAGE) polypeptide migration is governed 
by molecular weight. Sodium dodecylsulphate (SDS) is an anionic detergent which binds 
stoichiometrically to proteins by wrapping around the polypeptide backbone in the presence 
of a reducing agent. The resulting SDS-protein complex has a net negative charge 
proportionate to the length of the protein. Migration is affected by the molecular weight of 
the protein with equal charge per unit length.
Glass plates ( 8 x 5  cm) were cleaned and separated with 1.5 mm spacers. Two 7.5% 
separating gels (1.5 mm thick, 8 cm x 5 cm) were prepared using a monomer solution of 
30.8% acrylamide 2.7%: bisacrylamide (v/v, NBL Gene Science Ltd) shown in the table 
below. The mixture was degassed under vacuum for 15 mins prior to addition of 0.04% 
(w/v) ammonium persulphate (APS) and 0.04% (v/v) TEMED (BDH Laboratory Supplies). 
The gel solution was mixed and quickly poured between the glass plates to a depth of 1 cm 
below the bottom of the sample wells. The gel solution was overlaid with water-saturated 
n-butanol (10% (v/v) milli-Q water in n-butanol) and left to polymerise for 2 hours.
Solution 7.5% 4%
Monomer solution 5 ml 0.88 ml
4 x 1.5 M Tris-Cl (pH 8.8) 5 ml
4 x 0.5 M Tris-Cl (pH 6.8) 1.66 ml
10% (W/V) SDS 0.2 ml 66 pi
milli-Q water 9.7 ml 4.06 ml
10% w/v APS 100 pi 33.4 pi
TEMED 6.7 pi 3.3 pi
After polymerisation, the overlay was poured away and the gel surfaces rinsed with 1.5 M 
Tris-Cl (pH 8 .8 ). Two gels were clipped vertically into the electrophoresis apparatus. A 
4% stacking gel was then prepared as shown in the table. The solution was degassed, the 
polymerising reagents mixed and then quickly layered on top of the separating gels. A 
comb was inserted (10-wells x 1.5 mm) and the stacking gel left to polymerise for 1 hour. 
Meanwhile, cell lysates (usually 50 pg total protein per gel) were diluted in 2 x protein 
sample loading buffer (appendix I) upto total volume of 40 pi, boiled for 90 seconds in a 
water bath, then chilled on ice for 30 seconds to denature the proteins prior to 
electrophoresis.
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Following polymerisation, the gels were placed in the Biorad Protean Ilxi Cell® 
electrophoresis tank and submerged in tank buffer. The combs were removed slowly and 
the wells rinsed with electrode buffer. Samples were loaded into the wells, and the lid 
placed on the gel unit and connected to a power supply. High molecular weight pre-stained 
protein marker standards (10 pi per lane, BDH, Laboratory Supplies, Poole) were run 
concurrently with samples. The current was adjusted to 30 mA per 1.5 mm gel, and the 
samples were electrophoresed for 2 hours. When the dye front reached the bottom of the 
gel the power was switched off, the buffer was removed and the apparatus disassembled.
2 . 9 . 3  Coomassie blue stain
A PAGE gel was placed in Coomassie Blue staining solution (appendix I) for 4 hours. The 
staining solution was then replaced with destaining solution (appendix I) for 8 hours. Once 
destained, the gel was then placed between filter paper and saran wrap, and dried on a slab- 
gel dryer (Atto). The band intensity on stained gels was proportional to the amount of 
protein present.
2 . 9 . 4  Western blotting
Proteins were immobilised on Protran BA 85 cellulose acetate membranes (Schleicher and 
Schuell) using a semi-dry western blotting method. The 4% stacking gel was removed 
from the gel and the separating gel equilibrated in Towbin transfer buffer for 15 mins. The 
membrane and 6  pieces of filter paper were cut into rectangles of equal size as the gel, pre­
wet with distilled water, then saturated in Towbin transfer buffer (appendix I). 3 pieces of 
saturated filter paper were stacked horizontally in the transfer apparatus. The membrane 
was placed on top, and then the gel. The remaining 3 sheets of filter paper were stacked on 
top. Air bubbles were removed from the stack by rolling with a pipette and the cathode was 
placed on top to seal the apparatus. Protein was transferred for 75 mins at 0.8 mA/cm2. 
The stack was then dismantled, and the blot labelled and stained with Ponceau S solution 
(Sigma) for 5-30 mins. Excess dye was removed by rinsing in water and the molecular 
weight standard bands were marked with pencil. The blot was then fully destained in water 
and then blocked overnight (section 2.9.5).
2 . 9 . 5  Immunodetection by enhanced chemiluminescence
Non-specific binding sites on western blots were blocked by immersion in 5% (w/v) non-fat 
milk powder, 1% (w/v) goat serum and 1% (v/v) Tween-20 in PBS (Blotto) for one hour at 
25°C on a rocking tray, or overnight at 4°C. The membrane was rinsed in two changes of 
wash buffer and then washed once for 15 mins, and twice for 5 mins with fresh changes of 
wash buffer. During the washing step the 1° antibody was diluted to 10 pg/ml unless 
otherwise stated, in 5 ml of 20% FCS in DMEM.
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The membrane was incubated in 1° antibody solution for 1 hour at 25 °C and washed as 
above. The horse radish peroxidase (HRP) conjugated 2° antibody was diluted to 1 pg/ml in 
20% FCS/DMEM. The membrane was incubated in 2° antibody solution for 1 hour at 25°C 
and washed for 15 mins, and then a further 5 mins in fresh changes of wash buffer. 
Thorough washing was essential to reduce background activity.
An enhanced chemiluminescence kit (ECL, Amersham Life Science) was used to visualise 
immunolabelled peptides immobilised on western blots. An equal volume of detection 
solution 1 (luminol) was mixed 1:1 with detection solution 2  (p-iodophenol, both supplied in 
the kit) to a final volume of 0.125 ml/cm2 membrane. The excess wash buffer was drained 
off the membrane and detection solution was poured onto the protein-bound side of the 
membrane. The membrane was incubated for precisely 1 minute at 25°C after which excess 
solution was drained off. The membrane was placed protein side up onto a piece of saran- 
wrap, taped into an autoradiography cartridge (Cronex Quanta Fast Detail Cassette, 
DuPont). The membrane was covered in saran-wrap, avoiding incorporation of air bubbles. 
In a darkroom autoradiographic film (Fuji, Medical X-ray Film) was placed on top of the 
membrane and exposed for 30 seconds and 5 mins. This film was developed and assessed. 
The exposure time of the next film was adjusted accordingly.
2.10 Preparation of cDNA from mRNA
2 . 1 0 . 1  Purification of mRNA from cultured cells
mRNA was prepared using the QuickPrep® Micro mRNA Purification kit (Pharmacia 
Biotech). This has been optimised for the isolation of mRNA from small numbers of 
eukaryotic cells in the presence of guanidium thiocyanate. lxlO 6 harvested cells were 
aliquotted into sterile universal tubes, washed in PBS and pelleted. Pellets were stored at 
-70°C until use. The mRNA extraction protocol was performed under 'RNase free' 
conditions.
The cell pellet was resuspended in 400 pi extraction buffer and homogenised by inverting 
for 2 mins at 25°C before diluting with 800 pi elution buffer. 1 ml of 01igo(dT)-cellulose 
bead slurry was placed in a sterile microcentrifuge tube. Concurrently, the cell lysate and 
01igo(dT)-cellulose slurry were centrifuged for 1 minute at 10,000 x g. The storage buffer 
was aspirated from the 01igo(dT)-cellulose bead pellet. The cleared homogenate was placed 
on top of the 01igo(dT)-cellulose pellet and mixed by inversion for 3 mins. The slurry was 
then centrifuged for 10 seconds and the supernatant discarded. The 01igo(dT)-cellulose 
bead pellet containing bound poly-adenylated mRNA was then resuspended in 1 ml of high- 
salt buffer, and recovered by centrifugation for 10 seconds as before.
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The beads were washed in this manner 5 times and then washed with 2 volumes of low-salt 
buffer. The pellets were resuspended in 0.3 ml of low-salt buffer and transferred to 
MicroSpin™ Columns placed in microcentrifuge tubes. The beads were spun onto the 
columns for 5 seconds and then washed with 3 x 0.5 ml of Low-salt buffer. mRNA was 
eluted from the column resin with two 200 pi volumes of Elution buffer pre-warmed to 
65°C in a sterile microcentrifuge tube. mRNA in solution was concentrated by precipitation 
following the addition of 10 pi glycogen solution, 40 pi potassium acetate and 1 ml of 95% 
ethanol at -20°C. The mRNA was allowed to precipitate for 30 mins at -20°C and was then 
pelleted by centrifugation in a microcentrifuge tube 10,000 x g for 5 mins at 4°C. The 
precipitate could be stored under ethanol at -70°C for up to one year.
To recover the mRNA, the precipitate was spun for 20 mins at 10,000 x g in a bench-top 
centrifuge (4°C, Biofuge Fresco, Heraeus Instruments). The resulting pellet was washed 
with 70% ethanol, repelleted, then dried briefly by inverting the tube on absorbent paper. 
The precipitated mRNA was redissolved in 10 pi DEPC-treated water and the tube flicked, 
pulse spun and then heated to 65 °C for 2 mins to help resuspend the RNA. The suspension 
was chilled on ice for 5 mins before being used (section 2.10.2).
2 . 1 0 . 2  Reverse transcription of mRNA samples
Complementary DNA (cDNA) was prepared from mRNA template using the Reverse 
Transcription Polymerase Chain Reaction (RT-PCR). 5 pi of mRNA sample were placed 
into RNase-free thin walled 65 pi tubes. A master reaction solution was prepared by 
mixing the regents in the table below (final concentrations are in parentheses).
Solution (PD
DEPC-treated water 5
5 x RT Superscript ™ 1st Strand buffer 5
Pd(N)6 (50 U/pl) 5
dNTPs (10 mM) 2
DTT (0.1 mM) 2
Recombinant RNase inhibitor (2 U/ml) 0.5





The volumes shown in the table were multiplied by the number of samples being prepared. 
Control samples were prepared with 5 pi DEPC-treated water in one tube. A second 
solution was prepared excluding reverse transcriptase (RT) to test for the presence of 
genomic DNA in the mRNA extracts. The reaction solutions were mixed and pulse-spun to 
ensure homogeneity. The solutions were then aliquotted into reaction tubes to produce a 
final reaction volume of 25 pi, and mixed. The solutions were overlaid with 20 pi of 
mineral oil to prevent evaporation, transferred to a thermocycler (Program Temperature 
Control System PC-700, Astec) and incubated at 37°C for 90 mins.
2 . 1 0 , 3  Polymerase Chain Reaction
cDNA samples generated from mRNA isolates by reverse transcription were amplified 
using the Polymerase Chain Reaction® (PCR). 3 pi of template cDNA were added to 
individual 65 pi thin walled tubes. A master reaction solution was prepared by mixing the 
solutions in the table below according to the oligo-primer being used.
Solution







milli-Q water 15.4 16.4 12.4
10 x Thermophilic buffer 2.5 2.5 2.5
M gCl2 (25 mM) 2.5 1.5 2.5
dNTPs (10 mM) 0.5 0.5 0.5
Random Hexamer Primers 0.5 0.5 2
Taq DNA Polymerase 0.1 0.1 0.1
cDNA sample 3 3 3
Total 25jli1 25 pi 25 pi
The volumes were multiplied by the number of samples being prepared, and contained 20 
pmol of each primer and 1U of Taq DNA polymerase (Promega). The reaction mix was 
vortexed, pulsed and quickly added to tubes containing cDNA to produce final reaction 
volumes of 25 pi. The samples were vortexed, and then overlaid with 20 pi of mineral oil.
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The mixtures were placed into a thermocycler (Astec) and subjected to cycles of
denaturation, annealing and extension as follows:
• Glutaraldehyde 3-phosphate dehydrogenase (GAPDH): initial denaturation at 
94°C for 4 mins, 30 cycles at 94°C for 1 minute, 55°C for 1 minute and 72°C for 1 
minute, followed by a final extension at 72°C for 7 mins.
• Osteocalcin: conditions were the same as for GAPDH.
• Bone sialoprotein: initial denaturation at 94°C for 5 mins, 30 cycles at 94°C for 1 
minute, 50°C for 1 minute and 72°C for 2 mins, followed by a final extension at 72°C 
for 3 mins.
• Parathyroid hormone receptor: initial denaturation at 95°C for 5 mins, 30 cycles at 
95°C for 30 seconds, 60°C for 30 seconds and 72°C for 1 minute, followed by a final 
extension at 72°C for 3 mins.
• Oestrogen receptor: initial denaturation at 95°C for 5 mins, 32 cycles at 95°C for 1 
minute, 55°C for 1 minute and 72°C for 1 minute, followed by a final extension at 72°C 
for 3 mins.
• PDGF A chain: initial denaturation at 94°C for 5 mins, 35 cycles at 94°C for 45 
seconds, 60°C for 45 seconds and 72°C for 2 mins, followed by a final extension at 
72°C for 7 mins.
• PDGF B chain: initial denaturation at 94°C for 5 mins and a 5 minute anneal at 60°C 
followed by 35 cycles of 1.5 mins at 72°C, 45 seconds at 94°C and 45 seconds at 60°C 
for 1 minute, followed by a final extension of 10 mins at 72°C.
To calculate the annealing temperature the following rule of thumb was used: 20-50mer with
50-60% GC content): temperature (°C) = 4 x (G + C) + 2 x (A + T) - 6 . cDNA samples
were stored at -20°C for up to one year.
2.10.4 Agarose submerged gel electrophoresis
Following the PCR reaction, the size of the cDNA products were analysed by agarose gel 
electrophoresis to determine their size. Agarose (Routine electrophoresis grade, Flowgen) 
was dissolved in 1 x Tris Acetate-EDTA buffer (TAE, 50 ml) by heating to 95°C, to make 
up a 1.8% (w/v) agarose gel. The gel was cooled to 50°C (hand hot) and ethidium bromide 
(0.05 pil/1 ml of 10 mg/ml stock) was added and mixed. The gel was poured into a sealed 
electrophoresis tray. A comb was inserted and the gel was then left to set at room 
temperature for a minimum of 20 mins. Once set the seal was removed from the tray, the 
gel immersed in 1 x TAE buffer in an electrophoresis tank and the comb removed.
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5 x DNA loading dye (appendix I) was mixed with 5 j l i I  of RT-PCR product. The samples 
were loaded onto the gel and electrophoresed, alongside marker DNA (400 ng (pxl74-RF 
Hae III digest, Pharmacia Biotech) for 30 mins at a constant voltage of 100V. DNA 
migrated towards the anode and was visualised by illuminating the gel with UV light on a 
transilluminator (X = 302 nm, UVP).
2 . 1 0 .5  Southern blotting (Southern, 1975)
Sequence specific probe hybridisation was used to verify the cDNA product of RT-PCR. 
DNA was immobilised onto a nylon membrane by Southern blotting so that a fragment of 
32P-labelled DNA complementary to a sequence of interest could bind to it.
Following separation of DNA fragments by agarose gel electrophoresis (section 2.10.4) and 
examination of the gel by UV analysis, double stranded DNA was denatured by placing the 
agarose gel into two volumes of 500 ml of 0.5 M NaOH at 25°C, with periodic agitation 
each for 30 mins. The Southern blot apparatus was set up as follows (refer to figure 2.1): a 
glass plate was placed on an inverted support inside a tank. A filter paper wick (Whatman 3 
MM) was cut to the same width as the gel, longer than the support, soaked in fresh 0.4 M 
NaOH and placed over the plate with the ends hanging into the tank as a wick. Onto this 
was placed 2 sheets of filter paper cut to the same dimensions as the gel. 500 ml of 0.4 M 
NaOH were poured into the tank to cover the ends of the wick and moisten the paper. The 
filter was smoothed onto the plate by rolling with a pipette to remove trapped bubbles. 
Parafilm was used to seal the edges of the paper. The gel was removed from the denaturing 
solution, flipped over so the lanes faced down, and aligned on top of the wick. The gel was 
smoothed down to remove trapped bubbles. A pre-cut nitrocellulose filter (NC, Hybond 
N+, Amersham Life Sciences), labelled with the date and experiment was placed face down 
onto the gel and smoothed. 2-3 more pieces of filter paper were placed on the NC. 6 sheets 
of flat, dry paper towels were placed over the filters and additional 3 cm thick stacks of 
paper towels were placed on top. A glass plate and a weight (250 g) were placed on top of 
the stack.
DNA was allowed to transfer for 5-16 hours before disassembly. The weight, top glass 
plate and paper towels were removed and the protruding wick ends trimmed. The 
filters/NC/gel 'sandwich' was inverted and the wick removed (now on top). Pencil was 
used to mark sample well positions on the NC. The gel was discarded and the membrane 
placed in 2 x SSC for 5 mins to remove NaOH. The membrane was allowed to dry briefly 












Figure 2.1 Schematic diagram o f  fin a l layered organisation o f  materials
2 .1 0 .6  Probing southern  blots with 5 '-end labelled oligom ers
A complementary 20mer oligonucleotide was labelled for use as a probe. Southern blotted 
NC filters were placed in a hybridisation bottle and blocked in 20 ml prehybridisation 
solution for 2 hours at 65°C, except the BSP probe for which prehybridisation and 
hybridisation were carried out at 55°C. During prehybridisation the probe was 
radiolabelled. The following solutions were placed in a microcentrifuge tube, forming a 
total volume of 10 p.1, mixed, spun and incubated at 37°C for 30 mins, then 65°C for 20 
mins.
S o lu tio n
50 pmol oligo 1
10 x PNK buffer 1
milli-Q w ater 6
T4 Polynucleotide Kinase 1
(lO U /p l)
y-32P ATP 1
The labelled probe was separated from unincorporated label using a Nick column (Sephadex 
G-50 fine DNA grade, Pharmacia Biotech). The column was inverted several times to 
resuspend the gel, and allowed to settle upright held in a retort stand and clamp. The caps 
were removed and the column drained, and tapped to remove air bubbles. 1 ml equilibrium 
buffer (6 x SSC) was added to the column and drained. The column was the placed in a 
centrifuge tube and 2 ml of 6 x SSC were added and the column drained. The column was 
centrifuged for 4 mins at 514 x g in a centrifuge with a swinging-bucket rotor. The eluate 
was discarded. The column was then placed over a 1.5 ml microcentrifuge tube in the tubes 
provided in the kit, and the radiolabelled sample applied to the surface of the gel. The 
sample was eluted by centrifugation at 514 x g for 4 mins. The microcentrifuge tube 
containing the radiolabelled probe was removed.
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After prehybridisation the solution was removed from the blots. These were rinsed in 
hybridisation buffer then replaced into the hybridisation bottles. 5 ml of hybridisation 
buffer (appendix I) was added to the bottles together with the probe solution. Fixed DNA 
was hybridised overnight at 65°C (55°C for BSP) in a rotating hybridisation oven (Hybaid). 
The following day the NC membranes were washed in 10 ml of each of the following 
solutions at 65°C (55°C for BSP) for 2 mins:
Washes Solution
2 2 x SSC + 0.5% (v/v) SDS
2 0.1 x SSC + 0.5% (v/v) SDS
1 0.1 x SSC
Non-specific hybridisation was monitored with a hand-held p-counter (series 900 mini­
monitor, Mini-Instruments Ltd). This was removed with repeated treatments of wash 
buffer. When background radioactivity was depleted, excess liquid was drained the from 
membrane, which was sealed in plastic. The filter was placed against autoradiographic film 
(Fuji, Medical X-ray Film) in an autoradiography cassette (Cronex Quanta Fast Detail 
Cassette, DuPont) and screened at -70°C initially for 2 hours. This film was developed and 
assessed. The exposure time of the next film was adjusted accordingly.
2 .1 0 .7  Image analysis
In order to gauge a change in the level of expression of peptides, DNA or mRNA, the 
relative amount of product on a gel or blot was quantified by densitometry. The gel or blot 
was_placed on a UV transilluminator (UVP) or light box (Fostec) and the image was 
captured using a camera (TM-765 Kinetic Pulnix with cosmicar TV zoom lens) and a 
computer package (Imagedok, Kinetic Imaging Ltd.). Optical densities of bands were 
analysed with using a second computer program (Phoretix, Kinetic Imaging Ltd.). After 
manually selecting the bands, the intensity of each band was calculated and expressed as an 
arbitrary number presented as a table of results.
In experiments measuring levels of mRNA, GAPDH was used as a housekeeping gene. 
The intensity of the signal obtained following blotting and probing of GAPDH RT-PCR 
products reflects the quantity of total RNA and should be equal in all lanes if the same 
number of cells were used, or if the same amount of template was introduced to the 
reaction. Any variation in the GAPDH band intensities was removed by correcting the 
amount of cDNA in RT-PCR preparations. Optical densities were calculated as treatment 
over control ratios. At best this method gives semi-quantitative results.
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2.11 Transfection methods
2 .1 1 .1  Culture of Bacteria Harbouring Plasmid DNA
Plasmid vectors incorporating genes with immortalisation properties were harboured in 
D H 5a (E . coli, RecA" strain) glycerol stocks, stored at -70°C. D H 5a were defrosted and 
suspended in sterile Luria-Bertani (LB) broth. This was prepared by adding 1% (w/v) 
Bactotryptone (Oxoid), 0.5% (w/v) yeast extract (Oxoid) and 1% (w/v) NaCl to milli-Q 
filtered water and adjusting the pH to pH 7.5 with 1 M NaOH. The broth was sterilised by 
autoclaving (123°C, 16" Hg, 20 mins). Ampicillin was added to the media (25 jig/ml 
sodium ampicillin) to select E. coli harbouring plasmid. The inoculated broth was incubated 
at 37°C for 3 hours in an orbital shaking incubator (15 x g, New Brunswick Scientific).
LB agar was made up as the broth, but with the addition of agar (15% w/v) following 
adjustment of the pH. LB agar (15 ml) was poured into 85 mm petri-dishes and stored 
inverted at 4°C until use. Bacteria were plated onto agar using a sterile loop and left to 
incubate overnight at 37°C. LB broth (10 ml) was inoculated with a single large colony 
which had grown on the agar and the culture was incubated overnight (37°C). The culture 
was then made up to 1 litre with fresh broth and antibiotic, and the mixture incubated at 37°C 
with constant agitation to produce large bacterial growth.
2 .1 1 .2  Purification of DNA from Bacterial Cultures
Plasmid DNA was isolated from overnight LB-broth cultures using the Wizard™ Maxipreps 
DNA Purification system (Promega). Cultured bacteria were pelleted by centrifugation at 
10,000 x g for 15 mins and resuspended in Cell Resuspension solution. Cell Lysis solution 
was added for 2 mins and then mixed by inversion with Neutralisation solution. The 
mixture was centrifuged (10,000 x g, 15 mins) and the clear supernatant decanted into a 
clean centrifuge bottle. 0.6 volumes of isopropanol were added to each sample, and after 
thorough mixing, the samples were cooled on ice for 30 mins to precipitate the DNA. DNA 
was recovered by centrifugation (10,000 x g, 15 mins) and the pellet resuspended in Tris- 
EDTA (TE) buffer.
To purify plasmid DNA from the pelleted material, Purification Resin was mixed with the 
resuspended material by swirling. The column apparatus was arranged and the plasmid 
DNA / resin mixture poured into the column. Column Wash solution was applied to rinse 
resin out of the column, and the column was then spin dried. Preheated TE buffer (65°C) 
was applied to the column, left for 1 minute, and centrifuged at 10,000 x g to elute plasmid 
DNA. This DNA was aliquotted and stored at -20°C.
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The composition of solutions used for the Promega Magic™ Maxipreps Purification system 
is shown in appendix I. Wizard™ Maxipreps DNA Purification system provides > 500 pg 
DNA/sample or Qiagen Plasmid Purification Protocol (upto 10 mg DNA/sample). The 
Qiagen protocol employed similar methodology as described in this protocol.
2 .1 1 .3  Spectrophotometric analysis of DNA concentration.
The concentration of DNA solutions were determined spectrophotometrically in a LKB 
Biochrom Ultraspec II. Absorbances were blanked against the buffer of the DNA 
suspension. A sample aliquot was diluted in 250 pi and placed in a quartz cuvette (LKB, 
500 pi ‘H ’ cuvette). The absorbance of DNA was measured at 260 nm and protein 
contaminants at 280 nm. The concentration of DNA was calculated from A2 6 O 
spectrophotometric absorbance values using the equation below where the DNA factor is 50 
pg/ml of DNA when the optical density (OD) is 1 at 260 nm.
Volume of Cuvette (ml) Total sample volume (ml)
[DNA] (mg / ml) = A260 x DNA factor x -------------------------- -— - x -------------- - --------------— -
1000 (ml) sample volume (ml)
The absorbance at 280 nm was equivalent to the protein concentration in the sample, a ratio 
of 1.8 represents a pure DNA sample.
2 .1 1 .4  Phenol Chloroform extraction and Ethanol Precipitation of DNA
A volume of DNA solution was mixed with an equal volume of phenol (equilibrated with 
0.1% (w/v) hydroxyquinoline and 0.2% (v/v) 6-mercaptoethanol) to form an emulsion. The 
mixture was centrifuged for 15 seconds at 10,000 x g (25°C) to separate the organic and 
aqueous phases. The upper aqueous phase was transferred to a fresh microcentrifuge tube. 
An equal volume of 1:1 phenol:chloroform was then added to the aqueous phase, mixed and 
centrifuged as before. An equal volume of chloroform was then added, mixed, centrifuged 
and transferred.
Salt was removed from the solution by ethanol precipitation. DNA was precipitated from the 
aqueous solution with the addition of 0.4 volumes of 5 M ammonium acetate. Two volumes 
of 100% ethanol were added to suspended DNA, the solutions were mixed by inversion and 
cooled to -20°C for 15 mins. The precipitate was centrifuged at 10,000 x g for 15 mins. 
The resulting pellet was washed with 70% ethanol, respun and dried briefly by inverting the 
tube on absorbent paper. The DNA pellet was resuspended in a specific volume of milli-Q 
water to produce a final DNA concentration of 1 pg/pl. DNA was also sterilised prior to 
transfection using this method.
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2.11 .5  Electroporation of adherent cells
CHO and MG-63 cells were cultured to 70% confluence, trypsinised and counted on a 
Coulter Counter (section 2.3.1). The cells were pelleted at 514 x g for 10 mins at 4°C. The 
supernatant was aspirated and the cell pellet washed with cold HBS (4°C). The cells were 
resuspended in HBS at a cell density of lxlO7 cells per ml. Plasmid DNA (10 pg/ml) was 
added to the cell suspension and the mixture left on ice for 5 mins. 500 pi of cell/DNA 
suspension was transferred to a pre-cooled electroporation cuvette (0.4 cm path length) and 
the cells were electroporated in a Biorad Gene Pulser. Following electroporation the 
cuvettes were left on ice for 15 mins. The cells were resuspended in DMEM supplemented 
with 10% FCS, replated into dishes and left to recover at 37°C, 5% CO2 in air. After 48 
hours the medium was aspirated and adherent cells were washed with 5 ml PBS. The 
medium was replaced with 10% FCS in DMEM, containing G418-S (50 pg/ml), ZnCl2 (200 
pM) and CdCl2 (1 pM). The cells were harvested 24-48 hours later and transfection was 
investigated through detection of SV40 large T antigen expression by immunocytostaining, 
western blotting and p-galactosidase staining.
2 .1 1 .6  FACS determination of cell viability of electroporated cells
100  pi of electroporated cell suspension were removed and mixed with propidium iodide 
(PI, 10 pi of 100 pg/ml). The suspension was placed on ice for 10 mins, then diluted into 1 
ml of 10% FCS in DMEM. Following a further 30 mins incubation on ice, the cells were 
pelleted (514 x g, 5 mins), washed in PBS and resuspended in 1 ml PBS. Fluorescein 
diacetate (FDA) was added (0.1 ng/ml) and the suspension incubated at 25°C for 10 mins. 
The labelled cell suspension was placed on ice during inspection by FACS. Cells were 
analysed by FACS as described in section 2.8.5. Detection of labelled cells were displayed 
on the FACS in the distribution as below:
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2 .1 1 .7  In situ (3-galactosidase staining
Cells expressing (3-galactosidase following successful transfection with the pC H llO  
(Pharmacia Biotech, #27-4508-01, used at 50 pg/ml) reporter plasmid were stained with the 
chromogenic substrate 5-bromo-4-chloro-3-indolyl-(3-galactosidase (X-Gal, MacGregor et 
al, 1991). This plasmid contains the X-gal gene which encodes (3-galactosidase. This 
cleaves 5-bromo-4-chloro-3-indolyl-|3-galactose to form a coloured product staining 
transfected cells blue. Medium was aspirated from the transfected cell monolayer which was 
rinsed with 2 x 5 ml aliquots of PBS (pH 7.3). The monolayer was overlaid with 7.5 ml of 
fixative solution and incubated at 4°C for 5 mins. The fixative was aspirated and the cells 
rinsed again. The cell monolayer was overlaid with X-Gal solution and incubated at 37°C 
overnight. The solution was removed and the cells rinsed with PBS. The monolayer was 
then examined for positively stained blue cells using a light microscope (Wilovert, Wetzlar).
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Chapter 3
Effect of culture conditions on CFU-F colony formation
53
3.1 Introduction
Colony forming units fibroblastic (CFU-F) comprise a subset of marrow stromal cells that 
are clonogenic and show a wide variation in their potential for proliferation and 
differentiation. Upon explantation of marrow stromal cells, CFU-F rapidly adhere to the 
culture substratum and proliferate to form colonies. The ex-vivo expansion and 
reimplantation of marrow stromal cells has been proposed as a treatment for a number of 
acquired and inherited diseases of the skeleton, and as an adjuvant in tissue reconstruction 
and repair following injury or surgery. For these therapies to be feasible large numbers of 
viable cells must be obtained in the shortest time possible to minimise the risk of infection, 
and the interval between their harvesting and reimplantation or grafting. The rate of 
expansion of these cells in culture is dependent upon the recruitment of CFU-F to the 
substratum, and subsequent proliferation of the progeny. Thus the aim of the work in this 
chapter was to optimise the growth of CFU-F in culture.
In order to optimise colony formation and expand the osteoblastic cell population in vitro, 
two elementary approaches were investigated. Initially, the influence of supplementing 
culture medium with ascorbate, and the synthetic glucocorticoid, dexamethasone, was 
ascertained. Secondly, the effect of altering the criteria under which human bone marrow 
stromal cells (BMSC) were explanted and cultured was investigated.
L-ascorbic acid (or vitamin C) is an essential factor required to sustain eukaryotic life. A 
deficit in bodily intake results in the condition of scurvy, with tenderness and swelling of 
joints, loosening of teeth, and anaemia (Levine, 1986). It is important in the maintenance of 
the integrity of mesenchymal-derived tissues including bone. Multifactorial activities of L- 
ascorbic acid are reported in many biological systems. In addition to its role as an 
antioxidant, L-ascorbic acid acts as a reductant for the iron prosthetic group of hydroxylase 
enzymes involved in biosynthesis of collagen, an important constituent of the extracellular 
matrix (ECM). A deficiency of vitamin C inhibits procollagen formation, resulting in 
degradation of connective tissues (Hata and Senoo, 1989). L-ascorbic acid (ASC) is very 
unstable in aqueous solution, at neutral pH, having a half-life of 2-3 hours at 37°C in culture 
medium (Peterkofsky, 1972). It is therefore technically difficult to maintain its concentration 
in culture. Treatment with a fluctuating concentration can be achieved with freshly prepared 
and filtered L-ascorbate. Alternatively, L-ascorbate 2-phosphate (ASP, Nomura et al, 1969) 
is very stable in aqueous solution, its activity being retained for 1 week when the derivative 
was dissolved in culture medium at 37°C (Hata and Senoo, 1989). A fixed concentration of 
ASP can be achieved in culture medium when the cells are fed twice weekly.
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Numerous investigations have shown that bone mass is subnormal in patients with raised 
physiological levels of circulating glucocorticoids (Cushings syndrome) or in patients treated 
with steroids for conditions such as asthma and rheumatoid arthritis (Reid et al, 1986, 
Adinoff and Hollister, 1983). In vivo, glucocorticoids stimulate bone resorption and inhibit 
bone formation leading to an overall deficit in skeletal tissue (Delany et al, 1994). 
Glucocorticoid-induced osteoporosis primarily involves decreased width of trabecular bone 
(Adinoff and Hollister, 1983). The decrease in bone formation is thought to occur through a 
direct inhibition of osteoblastic function in vivo (Reid et al, 1986). Paradoxically however, 
at physiological concentrations in vitro, glucocorticoids have been shown to promote 
osteogenic differentiation in primary marrow stromal cultures from a number of species and 
induce formation of mineralised nodules in rat marrow stromal cell cultures (Owen et al, 
1987, Maniatopoulos et al, 1988, Aubin et al, 1990, Bellows et al, 1990, Leboy et al, 1991, 
Davis et al, 1993, Beresford et al, 1994, Croisille et al, 1994, Cheng et al, 1994, Locklin et 
al, 1995). Culture in the continuous presence of a glucocorticoid has also been 
demonstrated to be essential for human marrow stromal cells to form mineralised tissue 
resembling bone when implanted into diffusion chambers in vivo (Gundle et al, 1995). Dx 
acts through glucocorticoid receptors, and exerts its effects on bone metabolism through 
modifications of gene transcription (Shalhoub et al, 1992).
A survey of the literature reveals a lack of consistency in the methods of BMSC culture. In 
this investigation an attempt was made to optimise BMSC seeding density and to increase the 
number of discrete colonies formed, as a linear correlation between colony formation and the 
number of mononuclear cells seeded had been reported (Bellows and Aubin, 1989, Owen et 
al, 1987). In preliminary experiments, it had been observed that removal of non-adherent 
cells from the adherent stromal cell layer after BMSC explant, increased colony formation. 
Since the development of the long-term bone marrow culture by Dexter and Lajtha (1974), 
there has been interest in the ability of the adherent cell layer of stromal cells to support 
haematopoietic cell growth. It is known that these two populations interact, and it is 
possible that the haematopoietic cells have an effect on the stromal cell population in culture 
(Herbertson and Aubin, 1995, Long et al, 1995, Castro-Malaspina et al, 1980, Castro- 
Malaspina et al, 1981, Friedenstein et al, 1992, Rickard et al, 1995). As it was not clear 
whether leaving these cells in culture was beneficial to the cultures, the effect of non­
adherent cells on adherent cell colony formation was also investigated.
In this study, BMSC were explanted into primary culture with the addition of ASC or ASP 
to compare the effects of continuous or intermittent treatment on CFU-F colony formation 
and proliferation in vitro. The osteogenic influence of Dx was also studied. The 
concentrations of ASC, ASP and Dx used in these experiments have previously been shown 
to be optimal for the proliferation and differentiation of human bone-derived cells (Gallagher 
et al, 1996). The functional end-points used were clonogenicity, measured as the number of
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colonies in quadruplicate dishes after 18 days primary culture, and stromal cell proliferation, 
measured as both the mean area per colony and the number of cells harvested from primary 
culture after 28 days growth. The prevalence of osteogenic precursors was estimated by 
counting the number of alkaline phosphatase positive colonies and by determining the 
biochemical activity of alkaline phosphatase in culture lysates.
3.2 Results 
3.2.1 Microscopic observations
Culture of bone marrow stromal cells under standard primary culture conditions resulted in 
the formation of colonies composed predominantly of fibroblast-like cells. Morphologically, 
these varied from long and spindle-shaped to flattened and multipolar with abundant stress 
fibres (figure 3.1). These overlapped in a parallel array to form a dense cellular meshwork. 
It was noted that although many cells initially adhered to the substratum post-seeding, only a 
proportion ( - 1 0 %) subsequently spread and developed a spindle-shaped morphology. 
Many remained as single cells for the duration of culture. Proliferative cells first elongated, 
and then began dividing 4-24 hours post explant. Small colonies (20-100 cells) were visible 
by eye 4-7 days post-explantation. In each culture dish the colonies varied greatly in size 
(range 3-12 mm diameter), reflecting differences in cell morphology (flattened vs bipolar) 
and rates of proliferation. These differences were apparent within, and between donors. 
Colonies also varied in gross morphology. In some, cell density was uniform across the 
colony whereas in others it was greatest in the centre of the colony. In these latter colonies, 
the cells were often observed to radiate in a spiral array out from the centre of the colony. 
Between patient samples, colonies could either be discrete or overlapping, irrespective of the 
seeding density of the mononuclear cells or colony size.
The Fast-red TR dye method used for histochemical demonstration of alkaline phosphatase 
(AP) expression resulted in deposition of a red reaction product at sites of enzyme activity. 
Of 56 donors, 7 (12.5%) gave rise to colonies that all stained positive for AP, irrespective of 
culture conditions. In the remaining patient samples a proportion of colonies were AP 
positive, and this varied according to culture conditions and donor sample. Within AP 
positive colonies the distribution of AP positive cells was not uniform. Generally, they were 
localised in the centre of the colony where the cell density was greatest (figure 3.1ii). Based 
on the staining intensity, there was a wide variation in enzyme activity between AP positive 
colonies, both within and between donors.
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Figure 3.1 Examples o f  colonies derived from  explanted BMSC
Mononuclear cells were isolated from bone marrow stromal tissue and cultured for 18 days 
under standard U conditions. Cells were then fixed with neutral buffered formalin (NBF) and 
stained with Fast-red TR. i) CFU-F colonies formed in a 55 mm diameter petri-dish (aside a 
mm scale, x 2 enlargement), ii) AP+ cells surrounded by AP negative cells of fibroblastic 
morphology in a CFU-F colony (40 x objective).
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3.2.2 Comparison of effects of ascorbate on CFE and CFU-F proliferation
3 .2 .2 .1  CFE
Compared with control, culture in the presence of continuous ASP did not affect total CFE, 
whereas in the presence of ASC it was reduced (figure 3.2). In contrast, both treatments 
increased the proportion of colonies expressing AP by -100%.
3 .2 .2 .2  Cell proliferation
In the presence of ASP, proliferation of CFU-F progeny was increased -3  fold (p < 0.05, 
figure 3.3). In contrast, in the presence of ASC proliferation was unaffected.
3.2.3 The effects of Dx and ASP on CFU-F growth
3 .2 .3 .1  CFE
Total CFE was unchanged in the presence of Dx or ASP and increased when both agents 
were added in combination (figure 3.4i). The observed changes were small in magnitude, 
but treatment with ASP and Dx attained statistical significance. AP positive CFE was 
increased in the presence of Dx and ASP. There was a further increase in AP positive CFE 
when both agents were added in combination. The proportion of total colonies expressing 
AP was increased in the presence of Dx or ASP, with ASP having a greater effect than Dx 
(figure 3.4ii). The effect of Dx and ASP in combination was additive.
3 .2 .3 .2  Proliferation
3 .2 .3 .2 .1  Mean area per colony
Treatment with Dx had no effect on mean area per colony (figure 3.5). Irrespective of the 
absence or presence of Dx, the addition of ASP increased mean area per colony by -20%.
3 .2 .3 .2 .2  Cell number
In the presence of Dx (figure 3.6) there was a small inhibition of cell proliferation (not- 
significant). In contrast, treatment with ASP produced a -4  fold increase in cell number 
which was significant (p < 0.05). The effect of treatment with both agents in combination 
was not different to that of ASP alone.
3 .2 .3 .3  Alkaline phosphatase activity
Treatment with ASP or Dx alone (figure 3.7) increased the AP activity, 4 and 2.5 fold 
respectively. The effect of both agents in combination was slightly less than additive.
3 .2 .3 .4  Mineralisation
Von Kossa positive deposits were observed only in cultures that had been treated with ASP 
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Figure 3.2 The effect o f continuous and intermittent L-ascorbate treatment
on CFE
BMSC were treated from explantation +/- L-ascorbate analogues, and cultured for 18 days. 
Colonies were fixed with NBF and stained for AP activity. Results show the mean of n = 3 
donors +/- inter-donor SE. i) Percentage CFE of AP+ and total colonies compared to controls. 
The mean values for total and AP+ colonies in control cultures were 10.9 (+/- 1.2) and 1.2 (+/- 
0.9) colonies per dish respectively, ii) AP+ colony formation as a percentage of total CFE 
under each treatment.
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Figure 3.3 The effect o f  continuous and intermittent L-ascorbate treatment
on proliferation
BMSC were explanted and cultured for 28 days +/- L-ascorbate analogues (10~4 M). Cells were 
harvested by treatment with sequential collagenase-trypsin and counted electronically. Results 
show the mean (n = 5) as percentage of control treatment +/- SE. * Indicates significantly 
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Figure 3.4 The effect o f ASP and Dx on CFE
BMSC were cultured +/- 10'4 M ASP, and treated +/- 10'8 M Dx for 18 days. Colonies were 
then fixed with NBF and histochemically stained for AP expression. Results show mean of n = 
7 +/- inter-donor SE. i) AP+ and total CFE as a percentage of control treatments (-/+ ASP) and 
ii) CFE of AP+ colonies as a proportion of the total colony formation. Where colony 
formation was 15.6 (+/- 1.6) and 13.6 (+/- 2.0) total colonies per dish, and 12.6 (+/- 3.1) and 
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Figure 3.5 The effect o f ASP and Dx on mean area per colony
BMSC were cultured +/- 10‘4 M ASP, and treated +/- 10'8 M Dx. After 18 days 1° culture, 
colonies were fixed in NBF and stained with methylene blue. Results show the mean area per 
colony, (n = 4) +/- inter-donor SE. The colony diameter was measured (mm) using a ruler and 
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Figure 3.6 The effect o f ASP and Dx on proliferation o f CFU-F progeny
Bone marrow stromal cell 1° explants were cultured for 28 days in the absence or presence of 
10'4 M ASP and 10'8 M Dx. Cells were harvested by treatment with sequential collagenase- 
trypsin and counted electronically. Results are the mean number of cells for n = 9 donors +/- 
inter-donor SE. * Indicates significantly greater proliferation than in control cultures +/- Dx 
(p < 0.05 using Kruskal Wallis Q test).
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Figure 3.7 The effect o f ASP and Dx on AP activity
BMSC were cultured under standard 1° conditions +/- 10'4 M ASP, and treated with 10'8 M Dx 
for 28 days. Cells were harvested by treatment with sequential collagenase-trypsin and AP 








Figure 3.8 Mineralisation in cultures o f  BMSC with Dx treatment
BMSC were treated with 10"8 M Dx under standard culture conditions for 12 days. (3- 
glycerophosphate was added to half the cultures for 5 days prior to their fixation with NBF. 
Colonies were stained with von Kossa stain and then counter stained with methylene blue.
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3.2.4 T he effect of vary ing  the cu ltu re  conditions on BM SC colony 
fo rm atio n
3 . 2 . 4 . 1  Seeding density
P a tien t
sam ple
Seeding density 
(x lO 4 cells/cm2)
A P + 
co lo n ies
T o ta l
co lo n ies
#486 2 1.5 (+/- 0.4) 1.5 (+/- 0.4)
4 17 (+/- 1.3) 17 (+/- 1.3)
6 40 (+/- 2.8) 40 (+/- 2.8)
8 87* (+/- 3.4) 87* (+/- 3.4)
#518 2 4.3 (+/- 0.5) 13.5 (+/- 1.7)
4 6.3 (+/- 1.3) 21.5 (+/- 0.9)
6 4.8 (+/- 1.6) 19.0 (+/- 4.4)
8 6.8 (+/- 2.5) 28.8 (+/- 7.3)
#523 2 0.0 6.0 T i ©
4 1.1 (+/- 0.2) 8.0 (+/- 1.2)
6 5.2 (+/- 2.1) 13 (+/- 3.7)
8 6.0 (+/- 2.3) 23 (+/- 4.2)
Table 3.9 The effect o f  seeding density on CFE
Results show mean (n = 4 petri-dishes) +/- SE for three donor samples.
* indicates a significant effect above 2x10^ cells/cm^ (p < 0.001).
A positive association between total CFE and seeding density was observed in the 3 
experiments (table 3.9, figure 3.10). In contrast, in 2 of 3 experiments the number of AP 
positive colonies formed did not increase with increasing cell density.
3 . 2 . 4 . 2  Time of rem oval of the non-adherent cells post-explantation
In preliminary experiments, it was observed empirically that CFE was reduced when non­
adherent marrow cells were not removed at the first change of medium. On the basis of this 
observation, it was postulated that the population of non-adherent cells which remained 
suspended in culture medium influenced the clonogenicity of the adherent cells. To test this 
possibility, the influence of altering the timing of the removal of the non-adherent population 
on CFE was investigated.
6 6
i)
2 4 6 8
Seeding density (cells x l0 4/c m 2)
ii)
2 4 6 8
Seeding density (cells x l0 4/c m 2)
Figure 3.10 The effect o f seeding density on CFE
Two examples of an increase in colony formation with increased mononuclear cell seeding 
density (from donors i) #486 and ii) #523). BMSC explanted at increasing density were 
cultured for 18 days under standard conditions then fixed with NBF. Colonies were stained 
with Fast-red TR and counter stained with methylene blue.
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Day of Number of colonies in each donor sample
wash
# 3 8 8 # 4 7 2 #481 # 5 1 8 # 5 2 3
1 14.7 (+/- 1.5) 12.7 (+/- 1.1) 6.50 (+/- 0,6) 13.3 (+/- 2.1) 5.80 (+/- 1.1)
2 16.3 (+/- 1.2) 20.8 (+/- 1.8) 5.50 (+/- 0,6) 0.00 1.00 (+/- 0.6)
4 11.0 (+/- 0.5) 30.3 (+/- 2.3) 12.3 (+/- 2.1) 0.00 1.70 (+/- 0.5)
7 7.00 (+/- 2.7) 17.0 (+/- 2.1) N D 1.00 (+/- 0.4) 1.30 (+/- 0.5)
10 6.70 (+/- 1.2) 9.80 (+/- 1.2) 0.50 (+/- 0.3) 0.00 0.00
Table 3.11 The effect o f  removing non-adherent cells from  1°
culture on CFE
BMSC were explanted and cultured under standard conditions in the presence 
o f 10-4 M ASP and 10-8 m  D x. At the indicated tim e-intervals post­
explantation, non-adherent cells and medium were aspirated from the culture 
dish. Adherent cells were washed in two volumes o f PBS and thereafter fed 
twice weekly for 18 days. Colonies were fixed with NBF and total CFE were 
counted. The table shows the means (n = 4 petri-dishes) +/- SE. ND, not done.
The results (table 3.11, figure 3.12) show that colony formation increased in 3 of 5 patient 
samples with time in culture, and peaked within 4 days. Continued co-culture of the 
adherent and non-adherent cell populations beyond 4 days was associated with a reduction in 
CFE.
3 . 2 . 5  C olony form ing potential o f the non-adherent popu lation
Following the observation that non-adherent cells removed from primary BMSC culture at 
the first wash post-explantation formed colonies when replated into fresh petri-dishes, 
experiments were carried out to investigate the colony forming capacity of this population. 
Examples of the propensity of non-adherent cells to form colonies after replating are shown 
in figure 3.13. Colony formation occurred in 6 of 12 non-adherent cell cultures replated 
between 2 and 4 days primary culture. In 50% of these cases, however, only 2 or 3 
colonies formed per 55 mm diameter dish, corresponding to a CFE of less than 10% of that 
seen in the original cell suspension. These colonies expressed AP. Colony formation 
decreased when the supernatant was replated with increasing time post-explanation and no 
colonies were formed when non-adherent cells were replated after 4 days of primary culture. 
Total colony formation was not affected by addition of ASP or Dx to cultures, although the 












Figure 3.11 Removal o f non-adherent BMSC from  1° culture affected CFE
BMSC were explanted and cultured under standard 1° conditions in the presence of 10~4 M 
ASP and 10'8 M Dx. At the indicated time intervals post-explantation, medium and non­
adherent cells were aspirated, and adherent cells washed in two volumes of PBS. Thereafter, 
cultures were fed twice weekly for 18 days. Colonies were fixed with NBF, and counter stained 
with methylene blue.
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Figure 3.13 Colony formation by the non-adherent BMSC population
BMSC were cultured under 1° conditions, (i) +/- ASP and/or Dx and (ii) with ASP and Dx. On 
day 4 post-explantation (i), or intervals between days 2-10 (ii) the suspended non-adherent 
population and medium was removed from adherent cultures and replated into 6-well plates. 
Passaged non-adherent cells were left to adhere for 4 days, then washed in 2 volumes of PBS to 
remove remaining cells in suspension. In (ii) these non-adherent cells were repassaged in fresh 
6-well plates (2b). Cells were then cultured under standard conditions for a further 14 days, 




Explantation of human marrow stromal tissue gave rise to colonies typically composed of 
cells of fibroblastic morphology. The first sign of these cells in culture was the appearance 
of single, isolated, fibroblast-like cells with a characteristic elongated morphology. Marrow 
cell suspensions prepared from different donors showed a wide variation in their propensity 
for colony formation. The observed variation was not obviously attributable to donor's age, 
sex, recent drug history or underlying pathology.
Depending on the influence of culture conditions and/or the level of commitment of the 
individual progenitor cells, colonies of different cellular phenotype formed. Variable rates of 
proliferation gave rise to colonies of different size in the same culture, resulting from 
differences in CFU-F phenotypes, and in their response to growth factors present in the 
serum supplement in culture medium. Most colonies contained AP positive cells, indicative 
of a degree of osteogenic differentiation, with AP negative cells located primarily around the 
colony perimeter, where proliferation is thought to be most rapid. The intensity of Fast-red 
TR stain varied between colonies, indicating that the cells expressed different levels of AP 
and were at different stages of maturation. It was apparent therefore, that the colonies 
formed in primary culture were derived from a heterogeneous population of adherent 
clonogenic cells, an observation in accordance with the findings of other investigators 
(Friedenstein et al, 1976, Owen, 1988, Kuznetsov etal, 1997a).
The effect of L-ascorbate supplementation was tested in primary bone marrow stromal 
cultures, and the use of ASP was found to be preferable to that of ASC. Benefits included 
an increase in cell number and an increase in the proportion of AP positive colonies. This is 
supported by results derived from a variety of tissues in which L-ascorbate alone promotes 
the proliferation and differentiation of BMSC in vitro (Leboy et al, 1989, Aronow et al, 
1990, Ono et al, 1990, Archer et al, 1990, Owen et al, 1990, Gundle et al, 1995). The 
expression of AP induced by ASP treatment is undoubtedly a secondary effect of an increase 
in the synthesis and secretion of collagen type I. The presence of a well organised 
extracellular matrix provides a three dimensional structural support to which the cells adhere 
and modify their shape and behaviour, a permissive environment for cell proliferation and 
differentiation (Franceschi, 1992). It also acts as a binding site and reservoir for a large 
number of autocrine growth factors (Adams and Watt, 1993, Lin and Bissel, 1993, Sharpe 
and Ferguson, 1988). An increase in cell density and/or cell-cell contact is also thought to 
promote differentiation through stimulation of integrin mediated cytoskeletal pathways 
(Harada et al, 1991, Schubert, 1992). This may be responsible for the localisation of AP 
staining to the centre of colony where the cell density is greatest. Recently binding of OSF-2 
to OSE-2 has been found to be upregulated in the presence of ASP (Xiao et al, 1997).
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In the presence of ASP, addition of dexamethasone promoted colony formation. This may 
result from promotion of the adherence of a non-adherent cell population. Results also 
indicate that ASP and Dx promote stromal cell differentiation, and that their effects in this 
cell culture system are additive. Overall, the observed effects are consistent with the known 
beneficial effects of these agents on the proliferation and differentiation of cells of the 
osteoblast lineage (Grigoriadis et al, 1988, Beresford et al, 1994, Cheng et al, 1994, 
Gronthos et al, 1994, Krebsbach etal, 1997).
Although it has been widely found that long-term administration of glucocorticoids, or 
hypersecretion in pathological conditions, leads to profound osteopenia in vivo, 
paradoxically glucocorticoids are an important inducer of osteogenic differentiation in vitro. 
In vivo the effects of glucocorticoids are attributed to increased renal calcium excretion, and 
decreased intestinal absorption of calcium with a consequent increase in parathyroid 
hormone and direct actions of the hormone on osteoblasts and osteoclasts (Defranco et al, 
1992). However, bone loss is considered to result largely from suppression of osteoblast 
function reflected by a reduced level of circulating osteocalcin (Reid et al, 1986a). In vitro 
Dx has been shown to increase total colony number and the number of colonies that express 
AP. However, the effects of Dx are markedly concentration and species specific. Treatment 
of marrow cultures with high Dx concentrations (10"5-10-6 M) have been found to inhibit 
osteogenic progenitor growth and radiolabelled proline incorporation into collagen in 
primary rat cultures (Chen and Feldman, 1979, Scutt et al, 1996). The degree of 
dependence on glucocorticoids for osteogenic differentiation differs between species: in the 
rat it is absolute (Maniatopoulos et al, 1988, Tsuji et al, 1990, Leboy et al, 1991, Kasugai et 
al, 1991, Locklin et al, 1995), in man it is partial (Davis et al, 1993, Cheng et al, 1994, 
Beresford et al, 1994, Kuznetsov et al, 1997) and in the mouse it is inhibitory (Lian et al, 
1997, Frenkel eta l, 1997).
In these studies, treatment with Dx increased the proportion of AP positive colonies, but at 
an expense of decreasing cell proliferation. Dx treated cells became flattened, enlarged, and 
polygonal in long term cultures. The colonies in Dx treated cultures were generally smaller 
than in control cultures and contained more densely packed cells. Previous studies with rat 
and human bone-derived cell cultures demonstrated that Dx increased indices of osteogenic 
differentiation, at the expense of decreasing cell number (Herbertson and Aubin, 1995). Dx 
exerts its effects by modification in expression of osteoblast-related genes (Lian et al, 1997), 
including inhibition of collagen synthesis (Dietrich et al, 1979, Canalis, 1983, Shalhoub et 
al, 1992). In cultures of human bone-derived cells this is corrected in the presence of ASP 
when added in combination, therefore, these agents provide optimal conditions for the 
growth and differentiation of the AP positive cell population. Indirectly, Dx may also 
influence cell proliferation through modification of synthesis or activity of growth factors
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and cytokines secreted by bone, for example expression of IGF-I and TGF6  are directly 
down-regulated by glucocorticoid treatment (Chen et al, 1991, Centrella et al, 1991a).
In the few experiments in which the seeding density was investigated, a linear relationship 
was not evident between total or AP positive colony formation and the number of cells 
explanted. This is in contrast with the results of Bellows and Aubin (1989), who 
demonstrated a direct association between the number of cells plated and the number of 
nodules formed from cultured rat calvarial populations, and the results of Owen et al (1987) 
who showed a linear correlation between AP positive colonies and seeding density. 
However, these studies were carried out using rat marrow stromal cells and variation in 
results may be due to differences in preparation of marrow, culture conditions or species 
differences.
Interactions between cell types within these cultures has been observed in a number of 
studies. Aubin et al (1990) found that a linear relationship between seeding density and 
nodule formation was observed only when non-adherent cells were added into adherent rat 
marrow cell cultures, and that endothelial cell conditioned medium increased osteoprogenitor 
number. In co-cultures of rat fibroblasts and rat bone marrow stromal cells, Ogiso et al 
(1991) observed a reduction in nodule formation. These data and others (Hughes and 
McCulloch, 1991, Ogiso et al, 1991, Herbertson and Aubin, 1995) indicate that the growth 
of osteogenic cells may be under the regulation of other cells in the bone marrow which can 
exert either stimulatory or inhibitory activities. Notably the marrow stromal adherent 
population in vitro contains a great diversity of cell types in addition to cells of the osteoblast 
lineage, including fibroblastic cells, adipocytes (Aubin et al, 1990) and endothelial cells (Fei 
et al, 1990, Penn et al, 1993), and an increase in seeding density is also likely to increase the 
presence of other adherent cells in these cultures. In addition to marrow stromal cells, the 
adherent cell population includes macrophages (Castro-Malaspina et al, 1980, Song and 
Quesenberry, 1984, Herbertson and Aubin, 1992) and granulocytes (Simmons et al, 1991) 
depending on species. Although marrow stromal fibroblasts can stimulate the proliferation 
of these non-fibroblastic cell types there is no evidence of an influence of these cells over 
CFU-F colony formation. However, the juxtaposition of bone and immune tissue in the 
marrow stroma suggests that biochemical events between these cell components are likely to 
occur, and activated macrophages are capable of secreting many cytokines, which may 
interfere with stromal and osteoblastic cell growth. These include IL-1 and EL-6 , which can 
effect bone resorption and formation (Rosen et al, 1990), and TN Fa which directly inhibits 
collagen synthesis (Canalis, 1987, Bertolini etal, 1986).
Non-adherent BMSC have also been shown to both directly influence adherent stromal 
fibroblast proliferation (Castro-Malaspina eta l, 1980, Castro-Malaspina et al, 1981, Hirata 
et al, 1985, Friedenstein, 1990) and mediate effects of other factors under investigation
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(Rickard et al, 1995). Beyond four days primary culture, there was a tendency for the 
number of colonies to decline. This study provides evidence that prolonged co-culture of 
adherent marrow cells with non-adherent population can lead to a decrease in the number of 
fibroblastic colonies formed. It has previously been shown that proliferation of marrow 
stromal fibroblasts are affected by non-adherent cells in primary culture (Castro-Malaspina et 
al, 1980, Rickard et al, 1995). The non-adherent cells remaining in the primary cultures 
after four days were small in size, round, and viable based on the exclusion of trypan blue. 
Maniatopoulos et al (1988) noted the presence of small, round, mononuclear cells in their 
primary cultures, and attributed them to haematopoietic component of bone marrow. The 
cell cycle status of these cells was not investigated, but could be using Hoechst 33342 
(Sigma) of which the staining intensity increases with cell DNA content. Haematopoetic 
cells may be explanted even following density gradient centrifugation (Keifer et al, 1991, 
Lymphoprep® assay protocol), and thus their numbers in culture may also be increased with 
an increase in cell seeding density. Stromal-haematopoietic non-contact cultures described 
by Hurley et al (1995) gave rise to more stromal colonies. Thus in our system removal of 
non-adherent cells with repeated washes of adherent cultures may limit interactions of 
haematopoietic and mesenchymal cells. Scutt and Bertram (1995) however, found that the 
timing of first medium change had no significant effect on CFU-F number, and Majors et al 
(1997) observed no effect on the number of AP positive colonies following removal of non­
adherent cells after 24 hours in primary culture. In a recent publication, Kuznetsov and 
Robey (1997) studied the growth requirements for marrow stromal fibroblast colony 
formation from different species in vitro. In this investigation, the effect of feeder cells 
(irradiated bone marrow cells) on bone marrow cells growth in serum-containing medium 
was assessed. Mouse marrow stromal fibroblast precursors were feeder cell dependent, 
guinea pig were partially feeder cell dependent and human cells were independent, thus the 
effect of non-adherent cells in culture may also be species specific.
The results of this investigation demonstrate clearly that the formation of colonies continues 
up to four days post-explantation. CFU-F are highly adherent and it has previously been 
reported that -95%  will attach in less than six hours (Castro-Malaspina et al, 1980, 
Friedenstein et al, 1992). Surprisingly, recovery of the non-adherent cell population post 
four days revealed the presence of an additional population of cells with colony forming 
potential, when transplanted to a fresh culture dish. The presence of CFU-F in the non­
adherent population has previously been shown in rat (Scutt and Bertram, 1995) and human 
(Oreffo et al, 1995) marrow stromal cultures. These results indicate the presence of two 
populations of potentially adherent cells in primary cultures of BMSC, one population which 
adhere soon after explantation (< 6  hours), and a second which become adherent with time in 
culture, or with a change in culture conditions. This supports the suggestion that 
establishment of an adherent population results in the release of one or more factors that act 
to inhibit the further recruitment of cells from the non-adherent population (Castro-Malaspina
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et al, 1980). The differences in adherence properties in these two populations may relate to 
their expression of adherence receptors such as cellular adhesion molecules, integrins, and 
basal lamina proteins such as laminin. The non-adherent cells are postulated to be at a more 
primitive stage in the mesenchymal lineage than adherent cells. This possibility is supported 
by the work of Long et al (1995), who isolated a population of non-adherent low density 
cells which contained two distinct cell populations, a population which formed clusters of 
mature osteoblastic cells, and a second which formed colonies of highly proliferative 
osteoblastic cells. It may also be true that marrow stromal tissue contains cells that are 
dislodged from bone surfaces which may represent a committed, adherent osteoblastic 
population, whereas the stromal tissue contains less mature cells within the fibrous matrix. 
Recently Rickard et al (1994) identified two bone progenitor cell populations when bone 
marrow stromal cells were stimulated in vitro with Dx and/or bone morphogenetic protein 
type 1 (BMP-1). One population differentiates into mature osteoblasts quickly, whereas a 
second retains its capacity for osteoblastic differentiation with further exposure to inducers.
The improvements obtained in colony formation and cell number through adapting the 
methodology in this study, whilst worthwhile, were of small magnitude relative to the 
variation noted between donor samples. These results impress that colony formation is 
essentially donor dependent. Although the number of cells seeded from each donor was 
constant, the colony forming efficiency was diverse within populations, indicating that the 
number of CFU-F per unit mononuclear cell count varies between patients, or that the 
colony forming efficiency of stromal cells from different individuals varies. A combination 
of these is probable. In two separate studies, Majors et al (1997) and Muschler et al (1997) 
reported a significant 70% variation in the number of CFU-F in marrow aspirates attributable 
to differences between donors; a 20% variation in CFU-F number between aspirates from 
the same donor was attributed to culture conditions. Much of the variation between reports 
of colony formation is likely to be due to differences in the site of bone marrow harvest, the 
harvesting and processing techniques, and the culture conditions used, including the 
concentration of dexamethasone. Lennon et al (1996), and Beresford et al (1993) have also 
shown that FCS is a critical factor in the culturing of marrow cells. Thus many factors are 
of importance when optimising conditions of colony growth. However, in further 
experiments, the seeding density of BMSC was maintained at 2xl04 cells/cm2, and colony 
formation was enhanced by the addition of ASP to primary cultures. These were washed 
extensively at four days post-explantation to remove the effects of non-adherent cells. To 
expand the population of marrow-derived stromal cells other methodologies could be 
evaluated, and the use of cytokines and growth factors to increase colony formation and 
proliferation is worthy of consideration.
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Chapter 4
An investigation of the effect of PGE2 on CFU-F adherence
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4.1 Introduction
Prostaglandin E2 (PGE2) is a locally active factor and one of the few agents known to 
stimulate bone formation in vivo (Kawaguchi et al, 1995). An anabolic effect of PGE2 was 
first seen following its infusion into infants to prevent closure of the ductus arteriosis, which 
produced an increase of periosteal woven bone formation (Ueda et al, 1980). It has since 
been established that the administration of PGE2 results in substantial increases in bone mass 
when applied systemically or locally in a variety of species (Jee et al, 1985, Jee et al, 1987, 
Norrdin and Shih, 1988). In vitro, PGE2 has been found to stimulate the formation of 
mineralised nodules in rat calvarial cultures (Tang et al, 1996) and to increase total alkaline 
phosphatase activity, cell number, and collagen accumulation in rat marrow stromal cultures 
(Scutt and Bertram, 1995). Prostaglandins may also mediate the increase in bone formation 
that occurs in response to mechanical loading (Pead and Lanyon, 1989, Takagaki et al, 
1996), growth factors, such as TGF-a and -P (Tashjian et al, 1985, Lemer, 1996), and 
systemic hormones such as PTH (Klein-Nulend et al, 1991). Prostaglandins are abundant 
in bone and are produced largely by cells of the osteoblast lineage (Kawaguchi et al, 1995). 
The two steps in prostaglandin production are the release of arachadonic acid from 
phospholipids, through the action of phospholipase A2 (PLA2 ) and the conversion of 
arachidonic acid by the bifunctional prostaglandin G/H synthase (PGHS) to PGE2 (Smith, 
1992). It is known that the effects of PGE2 can be mediated by three different receptors 
termed EPi, EP2, and EP3 . The EPi receptor functions via the activation of PLA2 followed 
by the release of diacylglycerol (DAG) and inositol triphosphate (IP3) which in turn activate 
protein kinase C (PKC) and mobilise calcium, respectively. The EP2 and EP3 receptors 
function through an increase or decrease in cAMP synthesis respectively, followed by the 
activation or non-activation of protein kinase A (PKA, Scutt et al, 1995).
The cellular basis for the anabolic activation of PGE2 is poorly understood. Woodiel et al 
(1996) postulated that prostaglandins have a dual mode of action, first stimulating the 
replication of osteoprogenitor cells and then promoting their maturation. In addition to their 
postulated direct effects, prostaglandins may also have indirect effects through the 
stimulation of insulin-like growth factor I (IGF-I) production, a widely expressed, 
abundant, autocrine and paracrine factor that regulates the proliferation and differentiation of 
a variety of cell types. PGE2 potently stimulates IGF-I synthesis in bone through a cAMP 
pathway (McCarthy et al, 1990, McCarthy et al, 1991). Indeed it has been suggested that 
the effects of PGE2 on bone formation are a secondary consequence of increased production 
of IGF-I by cells on the osteoblast lineage (Raisz et al, 1993, Hakeda et al, 1996). The 
results of recent in vitro studies indicate, however, that PGE2 also has important effects that 
are independent of IGF-I (Scutt and Bertram, 1995).
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The results of studies in rats, and rat bone-derived cells, suggest that PGE2 acts on a 
population of primitive inducible osteogenic precursors present at low frequency in the bone 
marrow (Flanagan and Chambers, 1992, Weinreb et al, 1997). Induction of CFU-F colony 
formation in vitro has recently been demonstrated in rat marrow stromal cell cultures (Tang 
et al, 1996), and Scutt et al (1995) found that the PGE2 induced increase in colony formation 
could be attributed to the recruitment of adherent clonogenic precursors from the non­
adherent cell population. These precursors may be distinct from CFU-F, and in a 
subsequent investigation Scutt et al found that the cells which responded to PGE2 treatment 
were present in an erythrocyte-enriched subpopulation, rather than from the bone marrow 
stromal cell subpopulation (personal communication). Recruitment of non-adherent cells 
was enhanced by the addition of physiological concentrations of dexamethasone, and 
subsequently it was shown PGE2-mediated recruitment was mediated via EP2 receptors 
(Scutt eta l, 1995).
The in vitro effects of PGE2 on human bone marrow cells have not been reported in the 
literature. The influence of PGE2 on CFE, proliferation and differentiation in cultures of 
adult human marrow stromal cells has therefore been investigated. Experiments were 
conducted on whole marrow and three subpopulations of human bone marrow, the wash, 
the erythrocyte subpopulation (RBC) and the bone marrow stromal cell (BMSC) population. 
The cell populations were prepared and seeded as in section 2.2.1.1.
The effects of PGE2 on recruitment of CFU-F from the non-adherent population was also 
determined. BMSC and RBC subpopulations of bone marrow were explanted into T 175 
flasks at 4 x l0 5 cells/cm2 and incubated overnight at 37°C to allow attachment of the 
adherent population. Cells in the non-adherent population were recovered after 16 hours by 
centrifugation and re-cultured at a density of 2xl04 cells per cm2 into petri-dishes (+/- lO 8 
M Dx) in the absence or presence of 10-7 M PGE2 . The non-adherent cells were removed 
on day 4 and the adherent population cultured for a further 14 days. In some experiments, 
cultures were treated with PGE2 in the absence or presence of 10-6 M indomethacin from the 
time of explantation until the removal of non-adherent cells at day 4. As clonogenic cell 
recruitment was the parameter being investigated it was unnecessary to treat for longer. 
Thereafter, cells were cultured under standard conditions. The number of clonogenic cells 




4.2 .1  Presence of CFU-F in cell populations of human bone marrow
Figure 4.1 shows colony formation from the different cell populations of human bone 
marrow, and is representative of 3 experiments using cells from different donors. Colony 
formation occurred in cultures of each of the marrow subpopulations. In the first series of 
experiments (figure 4.1i) the greatest number of colonies were derived from the BMSC 
subpopulation. In this population significantly more colonies were formed than from other 
marrow cell populations in the absence of Dx, and than from whole marrow in the presence 
of Dx. Colony formation from the BMSC population was decreased with Dx treatment. 
Supplementation with Dx induced the formation of colonies expressing AP in all cultures 
except those of the RBC population. Noticeably, the number of colonies derived from the 
whole marrow population was not equivalent to the total number of colonies of the 
subpopulations when combined.
The number of single cells in the cell populations explanted in the experiments shown in 
figure 4 .Ii were counted on a haemocytometer. Figure 4 .lii shows an identical series of 
experiments using cells from different donors in which the number of single cells present in 
the cell populations were counted electronically with a Coulter Counter (section 2.3.1). This 
method resulted in an increase in the number of colonies formed from the whole marrow 
population.
In addition to colonies which formed on the base of the petri-dish, in some cell populations 
colonies grew on the sides of the dishes, a phenomenon not normally observed in BMSC 
cultures (figure 4.2). Figure 4.3 shows the number of colonies formed on the sides 
compared to those on the base of the dishes for the experiment described in figure 4.1i. 
Colony formation on the sides was particularly abundant in the wash subpopulation, 
representing -60%  of the total colony formation in this subpopulation. A large proportion of 
the colonies formed from the whole marrow were also found on the sides of the dish. The 
majority of these colonies expressed AP. In contrast, fewer than 5% of BMSC colonies 
formed on the sides.
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Figure 4.1 Presence o f CFU-F in different cell populations o f  bone marrow
Whole marrow (WM) and the Wash, erythrocyte (RBC), and BMSC populations were cultured 
under standard conditions +/- 10' 8 M Dx. Single cells in each cell population were counted 
prior to explantation (i) using a haemocytometer, and (ii) electronically. After 18 days culture, 
colonies were fixed in NBF and histochemically stained for AP expression. The results shown 







Figure 4.2 Colonies form ed on the sides o f  the dishes in cultures o f  
different cell populations o f human bone marrow
Cell populations of bone marrow were cultured for 18 days and colonies were fixed in NBF as 
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Figure 4.3 The number o f colonies form ed on the sides o f  the dishes in 
cultures o f  different cell populations o f human bone marrow
Cell populations of bone marrow were cultured, and colonies were fixed as described in figure 
4.1. Colonies located on the sides of petri-dishes were counted (i), and expressed as a 
proportion of total colony formation (ii). The results shown are mean (+/- SE) data of one 
patient sample representative of 3 donors.
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4 .2 .3  Effect of PGE2 on CFU-F recruitment
The effect of increasing concentrations of PGE2 on colony formation by bone marrow 
stromal cells is shown in figure 4.4. The addition of PGE2 increased total colony formation 
at >10-7 M. At the same doses treatment with PGE2 also modestly increased the formation 
of colonies expressing AP, although the proportion of AP positive colonies formed as a % 
of total remained constant. Cultures were treated with 10-7 M PGE2 in subsequent 
experiments.
PGE2 consistently increased colony formation in the presence of Dx in the BMSC population 
(figure 4.5). However, there was no consistent effect on AP positive colony formation or 
total colony formation in absence or Dx. When cultures were treated with PGE2 and 
indomethacin in combination, total colony formation was reduced in the BMSC population, 
and unchanged from control in the RBC population (figure 4.6). There was no consistent 
effect on AP positive colony formation with indomethacin treatment.
In a single experiment the effect of PGE2 on the production of cyclic adenosine 
monophosphate (cAMP) from BMSC was investigated. A trend for increased cAMP 
production was detected at concentrations of PGE2 > 10-8 M (figure 4.7).
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Figure 4.4 The effect o f PGE2 on colony formation in human BMSC
BMSC were cultured with standard medium with 10' 8 M Dx in the absence or presence of 
P G E 2 . After 18 days, colonies were fixed in NBF and histochemically stained for AP 
expression. The graph represents 2 experiments using different donor samples and shows 
mean (n = 4, +/- SE).
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Figure 4.5 Lack o f an effect o f PGE2 on colony formation in different cell 
populations o f  human bone marrow
Non-adherent cell populations of BMSC and RBC of 2 donor samples (i), and (ii) 
representative of 4 samples were explanted and cultured in the presence of 10' 4 M ASP +/- 1 0 '^ 
M Dx, and treated with 10' 7 M PGE2 . After 18 days the colonies were fixed in NBF and 
histochemically stained for AP expression. Results show mean (n = 4, +/- SE).
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Figure 4.6 The effect o f PGE2 and Indomethacin on CFE in different cell 
populations o f  human bone marrow
Non-adherent cell populations of BMSC and RBC of n = 2 donors (i) and (ii) representative of 
n = 3 donors, were explanted and cultured in the presence 10~4 M ASP and 10"^ M Dx, and 
treated with 10' 7 M PGE2 and /or 10' 6 M indomethacin (I). After 18 days the colonies were 
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Figure 4.7 Dose response relationship fo r  the stimulation o f  adenylate 
cyclase activity by PGE2 in 2° BMSC
Results of one donor sample showing mean (n = 4, +/- SE). BMSC in 1° culture were treated 
with various concentrations of PGE2 . Cyclic AMP synthesis resulting from PGE2 induction 
was detected as in the methods (section 2.6.6). [cAMP] per cell equivalent indicates the 
correction of cAMP synthesis for the number of cells in the cultures using a ratio of the optical 
density of eluted methylene blue stain.
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4.3 Discussion
Studies using animal bone marrow have pointed to the existence of an additional class of 
CFU-F present in the non-adherent population of bone marrow stromal cells and have 
indicated that their transition from the non-adherent to adherent state is influenced by 
osteotropic factors including PGE2 (Flanagan and Chambers, 1992, Scutt et al, 1995, 
Weinreb et al, 1997). Results in this study confirm the presence of potential CFU-F in the 
erythrocyte population of human bone marrow stromal cells, although these were low in 
abundance. It had been found in the rodent model that this population gave rise to many 
more colonies than the BMSC population (Scutt et al, personal communication). However, 
this was not the case in these studies. Generally, a greater number of colonies were derived 
from the BMSC population than from the other cell populations, indicating that the method 
of density gradient centrifugation enriches CFU-F from the human marrow stromal cell 
population. However, these results also show that a proportion of clonogenic cells remain 
present in the wash and RBC populations, and are normally discarded during preparation.
Cell populations of marrow isolated prior to separation of the BMSC population gave rise to 
colonies on the sides of the dishes. These colonies grew at the level of the meniscus of the 
medium. It appeared that this population of cells was removed during normal processing, as 
these colonies were rarely seen in BMSC cultures. It also appeared that the clonogenic cells 
were of a lower density than the CFU-F which formed colonies on the base of the culture 
dish. This clonogenic population gave rise to smaller, less proliferative colonies than those 
on the base, which were largely AP positive. This may demonstrate further, that the CFU-F 
population are not only multipotential, but are also heterogeneous in phenotype (Rickard et 
al, 1994, Long et al, 1995). In effect, buoyant cells with clonogenic capacity may become 
trapped in the surface tension of the meniscus of the medium and adhere to the sides of the 
dish. In this case, cellular differentiation might be enhanced as a result of increased cell 
density, due to restricted cellular migration and the limited expansion area. Although AP 
positive, further studies would be necessary to confirm that these colonies contain cells of 
the osteoblast lineage. Also of interest is the specific density of these clonogenic cells which 
could be determined by isopycnic density gradient centrifugation.
Interestingly, the number of colonies formed from whole marrow did not equal the number 
derived from the BMSC population, or even the total number of colonies from the wash, 
RBC and BMSC populations, and represented 17% (19% with Dx) of the colony formation 
of the combined subpopulations. This may be due to the influence of other stromal and 
haematopoietic cell types present in the cultures as described in section 3.3. This 
discrepancy in colony formation may have resulted also from the difficulty to accurately 
determine the absolute number of mononuclear cells in whole marrow.
88
Results in this study also confirm the presence of potential CFU-F in the non-adherent 
population of human bone marrow stromal cells. The presence of CFU-F in the non­
adherent population has previously been shown in rat (Scutt and Bertram, 1995) and human 
(section 3.3, Oreffo et al, 1995) marrow stromal cultures. No evidence was found to 
confirm that exogenous PGE2 can influence transition of cells from the non-adherent 
population to become adherent human BMSC, as had been suggested by Scutt et al (1995) in 
the RBC population. PGE2 induced a moderate increase in colony formation in the BMSC 
population.
The importance of endogenous PGE2 on colony formation was assessed by the addition of 
dexamethasone or indomethacin to cultures. Exogenous glucocorticoids inhibit PGE2 
synthesis through down-regulation of PLA2 transcription and induction of lipocortin-1 
synthesis, an anti-inflammatory peptide mediator which inhibits the activity of PLA2 (Rang 
et al, 1995). Osteoblasts grown with dexamethasone in vitro have been shown to synthesise 
significantly lower endogenous levels of PGE2 , resulting in interference of osteoblast 
proliferation (Hughes-Fulford et al, 1992). Inducible prostaglandin G/H synthase is 
inhibited by NSAIDS such as indomethacin (Pilbeam et al, 1995).
Cultures treated with Dx provided no evidence of an effect of endogenously produced 
prostaglandins on colony formation, although, inhibition of PGE2 synthesis with 
indomethacin tended to increase colony formation in the BMSC population, and addition of 
exogenous prostaglandin to indomethacin-treated cultures reduced the number of colonies 
formed. A larger experimental sample number is necessary to confirm this observation. In 
addition, incubation of the cells in serum-free medium may have elicited a greater response, 
and pre-treatment of the cultures with the anti-inflammatory compounds would be 
worthwhile to inhibit endogenous prostaglandin synthesis prior to the addition of exogenous 
prostaglandin.
The inability to detect an effect of PGE2 on recruitment of CFU-F from the non-adherent 
population may be the result of a species difference. Differences between colony formation 
of rat and human osteoprogenitors have previously been described (Beresford et al, 1993, 
Lian et al, 1997, Kuznetsov and Robey, 1997), and variations in these experiments may 
result from differences between the ability of clonogenic cells from either species to respond 
to PGE2 treatment. However, differences may also occur due to the differences in skeletal 
site from which the sample was taken. For instance, marrow from human donors was taken 
from rib, a skeletal site which is placed under relatively little strain and therefore may not be 
as responsive to stimulation by factors such as prostaglandins. Marrow samples from 
rodents however, were taken from the femur, a site which is constantly being placed under 
tension and compression.
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This may also reflect discrepancies in the experimental design. For example the dose 
response curve indicates that the concentration of lO 7 M PGE2 used was possibly too low 
and 10"6 M would have been more appropriate. An additional factor is that most of the 
donors used in this study were diagnosed as suffering from lung cancer (appendix III). 
Chasseing et al (1997 and 1997a) have shown recently that endogenous PGE2 is 
overproduced by stromal colonies derived from the marrow of patients suffering with lung 
and advanced breast cancers, and suggest that this may account for the low CFE of marrow 
from this group of patients.
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Chapter 5
The effect of PDGF on the growth of human CFU-F
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5.1 Introduction
The aim of the initial phase of this investigation was to define the basic conditions for the 
isolation of BMSC and their establishment in culture. This having been achieved, the 
primary objective became the identification of one or more growth factors that would support 
ex-vivo expansion of the stromal cells without influencing their potential for osteogenic 
differentiation.
Platelet-derived growth factor (PDGF) is a potent, naturally occurring growth factor known 
to be mitogenic for a variety of mesenchymal cell types (Ross et al, 1974, Heldin et al, 
1992) including cells of the osteoblast lineage. When compared directly, PDGF was 
suggested to be more mitogenic for human cells of the osteoblast lineage than TGFP, IGF-I, 
or EGF (Piche and Graves, 1989), and so was selected for further investigation in our 
culture system.
PDGF was originally identified as a factor released from the a-granules of platelets during 
aggregation and clot formation (Ross et al, 1974, Kohler and Lipton, 1974). However, 
PDGF is also produced by the more mature cells of the osteoblast lineage (Graves et al, 
1989, Zhang et al, 1991, Rydziel et al, 1992, Andrew et al, 1995, Homer et al, 1996) and is 
sequestered in bone matrix (Hauschka et al, 1986). The matrix bound PDGF fraction is 
thought to be released during bone resorption and then act as a paracrine regulator of the 
chemotaxis, proliferation and biosynthetic activity of osteoblastic cells (Centrella et al, 1989, 
Pfeilschifter et al, 1990, Gilardetti et al, 1991). PDGF is secreted as disulphide bonded 
homo or heterodimer of closely related A and B polypeptide chains, forming PDGF AA, BB 
and AB (Heldin et al, 1992). The actions of PDGF are mediated via interaction with two 
different receptor types, termed PDGF receptor a  subunit (PDGFRa) and PDGF receptor p 
subunit (PDGFRp). Binding of divalent PDGF induces dimerisation of the single 
transmembrane glycoproteins with three possible configurations a a ,  PP and aP, which then 
transduce a cell response through intracellular tyrosine kinase activity. Both A and B 
peptides are high affinity ligands for PDGFRa, whereas the B chain only interacts with 
PDGFRp. Ligand interaction with both receptor types induces a mitogenic response, but 
only occupancy of the P-receptor can induce actin reorganisation and chemotaxis (Heldin et 
al, 1992). Receptors are widely distributed on cells of mesenchymal origin including 
fibroblasts and cells of the osteoblastic lineage (Bryckaert et al, 1988, Gilardetti et al, 1991).
Administration of PDGF in vivo increases bone mineral density and strength in rats (Mitlak 
et al, 1996), and stimulates endosteal and periosteal bone formation in rabbits (Nash et al, 
1994). It is known however, that the PDGF isoforms differ in their functional properties 
and studies using the homo and heterodimers have shown that those containing B chain
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subunits have the greatest mitogenic potential for cells of mesenchymal origin (Kelly et al, 
1985, Centrella et al, 1991).
In this chapter the influence of continuous PDGF treatment on the proliferation and 
differentiation of CFU-F derived from adult human BMSC has been investigated. 
Experiments were performed to determine the effects of PDGF A A and BB homodimers on 
colony forming efficiency, and on the subsequent proliferation and osteogenic differentiation 
of the adherent cell population.
5.1.1 Interaction of PDGF with IGF-I responsive pathways
IGF-I is also an important anabolic growth factor in bone (Delany et al, 1994). It is 
expressed by mature osteoblasts in vivo, and stimulates osteoblast cell proliferation and 
protein synthesis in vitro (Middleton et al, 1995, Shinar et al, 1993, Wang et al, 1995). 
Although IGF-I and PDGF are able to induce mitogenic effects on osteoblasts independently 
they have been found to produce a synergistic effect when added in combination (Canalis et 
al, 1989, McCarthy et al, 1989, Delany et al, 1994, Tanaka and Liang, 1995). The PDGF 
and IGF-I receptors (IGF-IR) are both tyrosine kinase regulators and share a common 
transduction pathway. In addition, it has been suggested that the growth factor response is 
not independent of IGF-IR transduction (DeAngelis et al, 1995). In transfectants which 
over-express the PDGFRp but lack the IGF-IR, it has been shown that PDGF BB cannot 
induce mitogenesis or transformation. Thus, it appears that the ability of the activated P 
receptor to stimulate cell proliferation and transformation requires a functional IGF-IR 
(DeAngelis et al, 1995).
It was of interest, therefore, to investigate whether the effects of PDGF in this system were 
mediated in whole or in part by IGF-I. The effects of low and high concentrations of IGF-I 
on BMSC proliferation were studied alone, and in combination with PDGF BB.
5.2 Results
5 . 2 . 1  Synthesis of platelet-derived growth factor by bone-derived cells
The ability of BMSC to synthesise PDGF endogenously was investigated by RT-PCR 
(figure 5.1). The human osteosarcoma cell line MG-63, was included as a negative control 
as it has been reported to not produce PDGF (Hauschka et al, 1988). A and B chain 
transcripts were detected in cultures derived from both donors and, albeit at much lower 
levels in the MG-63 cells. Treatment with Dx increased PDGF A chain transcript expression 
in MG-63 cells, but had no consistent effect on its expression in the normal cells. In 
contrast, treatment with Dx, decreased B chain transcript expression in all normal cell 
cultures studied. In MG-63 cells, however, its expression was increased.
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Figure 5.1 Expression o f PDGF A and B mRNA in cultures o f human bone-
derived cells
cDNA products in a 1.8% ethidium bromide stained agarose gel (i), after RT-PCR 
amplification of mRNA using primers specific for PDGF A and B chains, and GAPDH. mRNA 
was extracted from whole lysates of MG-63 cells, BMSC and HBDC cells of donor #569, and 
BMSC of donor #464. Note that this method does not allow a direct comparison to be made 
between the levels of PDGF A and B transcripts. Relative expression of PDGF A (ii) and PDGF 
B (iii) when cultured in the absence or presence of Dx in the different cell types. The data 
have been normalised for the amount of GAPDH to correct for variation in the amount of 
input mRNA. Cycle number was 35 for all reactions.
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5 .2 .2  Expression of PDGF a  and (3 receptor chains
Greater than 95% of the MG-63 cells expressed receptors for PDGF isoforms (figures 5.2i - 
iv). a  and P receptors were expressed by fewer cells obtained from marrow or trabecular 
explants, although the surface density of receptors on normal bone cells was greater than on 
MG-63 cells. When medium was supplemented with Dx the number of normal bone- 
derived cells expressing a  receptors was reduced, whereas the number of receptor sites per 
cell was not altered. The number of cells expressing the PDGF P receptor was reduced in 
BMSC with Dx treatment, and increased in HBDC. The surface density of the receptors 
was also reduced on BMSC, but on HBDC was unaffected. In the donor samples 
investigated, surface expression of PDGFRa was similar on BMSC and HBDC, whereas 
BMSC expressed greater numbers of PDGFRP at the cell surface.
BMSC HBDC
% total PDGFRa 38.3% (+/- 5.8) - 69.9% (+/- 9.6) 47.7% (+/- 5.4)
PDGFR(3 48.8% (+/- 11.3) 36.5% (+/- 5.4)
MFI PDGFRa 44.7 (+/- 0.4) - 31.6 (+/- 2.4) 36.6 (+/- 1.1)
PDGFRp 52.8 (+/-15.7) 47.8 (+/- 3.9)
Table 5.2iv PDGF receptor chain expression on cultured human 
bone-derived cells: Ranges fo r duplicate donors and 
mean values fo r  single or multiple donors
Analysis by western blotting confirmed that the antibodies used in FACS analyses 
recognised the PDGF receptor chain isoforms (figure 5.3). These were detected as 180 kDa 
bands after electrophoretic separation. No change in receptor peptide expression v/as 
detectable by western blotting with Dx treatment. The presence of other bands visible on the 
blot after immunolabelling was due to non-specific antibody binding and the presence of 
products of receptor degradation.
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Figure 5.2i The expression o f PDGF a  receptor chain by human bone-derived cells
Cells at first passage were cultured in standard medium in the absence or presence of lO 8 M Dx (-/+) for 5 days. At the end of this period the cells were 
harvested by sequential collagenase-trypsin treatment and then immunolabelled using a purified rabbit anti-PDGF a  receptor chain, followed by a FITC- 
conjugated 2 antibody. Results of peak shift in fluorescent intensity (FL-1, log scale) generated from a 5% marker (M l) on the negative control (cell 
labelled with isotype matched control antiserum, IC) histogram are shown in figure 5.2iii. The data shown are representative of 1, 2 and 1 experiments for 
MG-63, BMSC and HBDC respectively.
MG-63 B M S C HBDC
Events Events Events
Figure 5.2ii The expression o f PDGF p receptor chain by human bone-derived cells
Cells at first passage were cultured in standard medium in the absence or presence of 10~8 M Dx (-/+) for 5 days. At the end of this period the cells were 
harvested by sequential collagenase-trypsin treatment and then immunolabelled using a purified rabbit anti-PDGF (3 receptor chain, followed by a FITC- 
conjugated 2 3 antibody. Results of peak shift in fluorescent intensity (FL-1, log scale) generated from a 5% marker (M l) on the negative control (cell 
labelled with isotype matched control antiserum, IC) histogram are shown in figure 5.2iii. The data shown are representative of 2, 6  and 1 experiments for 
MG-63, BMSC and HBDC respectively.
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PDGF a
C e l l  t y p e  T r e a t m e n t  M a r k e r  E v e n t s  %  T o t a l  M F I
A l l 5 0 0 0 1 0 0 . 0 0 2 2 . 9 4
M G 6 3 - M l 4 8 6 8 9 7 . 3 6 2 4 . 4 9
A l l 5 0 0 0 1 0 0 . 0 0 1 6 . 6 1
M G 6 3 + M l 4 8 1 3 9 6 . 2 6 1 8 . 0 2
B M S C -
A l l
M l
5 0 0 0
2 0 4 9
1 0 0 . 0 0
4 0 . 9 8
2 1 . 9 4
4 5 . 0 8
B M S C +
A l l
M l
5 0 0 0
1 0 2 2
1 0 0 . 0 0
2 0 . 4 4
1 6 . 9 0
4 1 . 8 4
A l l 5 0 0 0 1 0 0 . 0 0 1 8 . 7 3
N H B C
M l 2 3 8 4 4 7 . 6 8 3 5 . 7 3
N H B C + A l l 5 0 0 0 1 0 0 . 0 0 1 6 . 9 0
M l 1 8 7 4 3 7 . 4 8 3 4 . 0 1
PDGF (3
C e l l  t y p e T r e a t m e n t M a r k e r E v e n t s %  T o t a l M F I
M G 6 3 A l l 5 0 0 0 1 0 0 . 0 0 1 1 . 5 8
M l 4 8 3 3 9 6 . 6 6 1 2 . 3 4
A l l 5 0 0 0 1 0 0 . 0 0 8 . 8 5
M G 6 3 + M l 4 5 6 3 9 1 . 2 6 9 . 9 0
A l l 5 0 0 0 1 0 0 . 0 0 4 2 . 9 5
B M S C M l 2 6 6 0 5 3 . 2 0 8 4 . 2 4
A l l 5 0 0 0 1 0 0 . 0 0 3 8 . 2 0
B M S C + M l 2 0 7 0 4 1 . 4 0 7 4 . 8 0
A l l 5 0 0 0 1 0 0 . 0 0 1 5 . 7 7
N H B C M l 1 8 2 6 3 6 . 5 2 4 7 . 8 0
N H B C + A l l 5 0 0 0 1 0 0 . 0 0 2 2 . 7 8
M l 2 7 7 6 5 5 . 5 2 4 9 . 0 1
Table 5.2iii PDGF receptor chain expression on cultured human bone-
derived cells
Table showing the results of flow cytometric analyses of cells immunolabelled with antibodies 
against PDGFRa and PDGFRJ3 chains. Experimental details were as described in the legend to 
figures 5.2i and 5.2ii, where cells were cultured +/- Dx (+,-). Ml shows the results of a 5% 
margin marker on the negative control histograms in figures 5.2i and 5.2ii. The MFI (mean 
fluorescent index) is an arbitrary indication of the fluorescent intensity per cell.
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Figure 5.3 Identification o f PDGF receptor protein chains
Whole cell lysates from BMSC of donor sample #546, cultured in the absence or presence of 
Dx (-/+), and MG-63 cells, were electrophoresed on 7.5% polyacrylamide gels and western 
blotted. Following incubation with primary antibody and peroxidase-conjugated secondary 
antibody, the receptor chains were visualised using enhanced chemiluminesence. M, molecular 
weight markers.
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5 . 2 . 3  The influence of PDGF on BMSC proliferation: dose response
In the absence of Dx, treatment with PDGF BB (0.1 - 2.5 ng/ml) resulted in an increase in 
cell proliferation (figure 5.4). In the presence of Dx, the response was more clearly dose 
dependent although the maximal effect was observed over the same dose range (1-5 ng/ml). 
Treatment with 2.5 ng/ml PDGF BB induced a significant response in the absence or 
presence of Dx (p < 0.05). In other experiments using cells from different donors, the 
maximal increase was found to occur reproducibly at 2.5 ng/ml (4.0 +/- 2.0 fold for n = 3 
donors). In contrast to the PDGF BB isoform, treatment with PDGF A A over the same 
dose range was found not to affect BMSC proliferation in the absence of Dx. In the 
presence of Dx, however, a significant increase in proliferation was observed at a dose of
2.5 ng/ml (figure 5.5). On the basis of these observations, PDGF BB and AA were used at
2.5 ng/ml in all subsequent experiments.
5.3 The effect of PDGF on CFU-F growth
5 . 3 . 1  CFE
Colonies formed in primary cultures of human bone marrow-derived stromal cells, cultivated 
in the absence or presence of 10-4 M ASP, 10-8 M ASP, DX or/and 2.5 ng/ml PDGF BB are 
shown in figure 5.6. Neither the PDGF BB or AA isoforms affected total CFE at the dose 
tested (2.5 ng/ml, figures 5.7 and 5.8). In contrast, with a single exception (PDGF BB + 
ASP + Dx), the number of AP positive colonies was reduced, though not significantly, with 
AA or BB treatments under all conditions. This reduction resulted from a decrease in the 
proportion of AP positive colonies formed.
5 . 3 . 2  Proliferation
5 . 3 . 2 . 1  Colony size
Treatment with both PDGF homodimers increased the mean area per colony (figure 5.9). 
The large error bars on these histograms demonstrate the large deviation in colony size 
between patient samples. The greatest increase in colony size in response to PDGF 
treatment occurred in the presence of Dx.
5 . 3 . 2 . 2  Cell number
Treatment of BMSC cultures with PDGF BB and AA induced cellular proliferation, whether 
added alone or combined with ASP or/and Dx (figure 5.10). The largest effect on 
proliferation was observed when the cells were treated with PDGF BB or AA in the presence 
of ASP and Dx. PDGF BB treatment had a slightly greater effect on proliferation than 
PDGF A A. Whilst a significant increase in proliferation was shown in figure 5.4, no 
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Figure 5.4 Dose response fo r  the effect o f PDGF BB on BMSC
proliferation
Results of one donor sample representative of three, showing mean (n = 4) +/- SE. BMSC in 1 ° 
culture were treated with various concentrations of PDGF BB, in the absence (i) and presence 
(ii) of 10' 8 M Dx for 28 days. Cells were harvested by treatment with sequential collagenase- 
trypsin and counted electronically. * Indicates a significant increase in cell number over 
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Figure 5.5 response fo r  the effect o f PDGF AA on BMSC
proliferation
Cultures of BMSC from two donor samples (i and ii) were treated with various concentrations 
of PDGF A A for 28 days in the absence or presence of 10' 8 M Dx (ii = + ASP and Dx). Cells 
were harvested by treatment with sequential collagenase-trypsin and counted electronically. 
Results show mean (n = 4) +/- SE, where * indicates a significant increase in cell number over 
ASP + Dx control culture (p < 0.05).
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F igure  5.6 The e ffec t o f  PD G F BB  on colony fo rm a tio n  by h um an  m arrow -derived bone cells
BMSC were cultured in the absence or presence of ASP, Dx and/or PDGF BB under standard 1° culture conditions for 18 days. Cultures were fixed with NBF, 
then stained sequentially with Fast-red TR and methylene blue stains.
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Figure 5.7 The effect o f PDGF BB on CFE in cultures o f  human BMSC
BMSC were treated with 2.5 ng/ml PDGF BB, alone or in combination with 10' 4 M ASP and 
10 ' 8 Dx. Colonies were fixed with NBF on day 18 and histochemically stained for AP and 
counter stained with methylene blue. Data have been expressed as percentage of the total 
number and number of AP+ colonies formed in the control (-Dx, -ASP) cultures (i), and AP+ 
colonies as a percentage of the total colonies formed (ii). Results shown are the mean +/- SE 
for n = 6  donors. Control cultures contained 15.8 (+/- 4.4) total, and 11.12 (+/- 4.7) AP+ 
colonies respectively (+/- SE).
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Figure 5.8 The effect o f PDGF AA on CFE in cultures o f human BMSC
BMSC were cultured with 2.5 ng/ml PDGF AA and stained as described in the legend to figure 
5.7. Data have been expressed as percentage of the total number and number of AP+ colonies 
formed in the control (-Dx, -ASP) cultures (i), and AP+ colonies as a percentage of the total 
colonies formed (ii). Results shown are the mean +/- SE for n = 4 donors. Control cultures 
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Figure 5.9 The effect o f PDGF on colony area in cultures o f  human BMSC
BMSC were cultured and treated with PDGF BB (i) or AA (ii) as described in figure 5.7. The 
colony diameter was measured (mm) and the mean area of the colonies under each treatment 
calculated using 7tr2, assuming the colonies are round. Data are the mRNA +/- SE for n = 5 
donor samples. The mean area of control colonies was 69.8 (+/- 42.0) and 46.9 (+/- 22.0) 
mm2, for PDGF BB and AA treatments respectively (+/- SE).
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Figure 5.10 The effect o f PDGF on the proliferation o f CFU-F progeny
BMSC were cultured in the absence or presence of 10-4 M ASP and 10' 8 M Dx and treated with
2.5 ng/ml PDGF BB (i) or AA (ii). Cells were harvested after 28 days in 1° culture by treatment 
with sequential trypsin-collagenase and counted electronically. Results are the mean cell 
number (n = 8 (i) and 6  (ii) donors) +/- SE. Control values were 78364 (+/- 27027) and 
130476 (+/-16337) cells per T25 for BB and A A treated cultures respectively (+/- SE).
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5.4 The effect of PDGF on differentiation of CFU-F progeny
5 . 4 . 1  Expression of alkaline phosphatase
With a single exception (PDGF BB + ASP) the AP activity of BMSC was increased by 
treatment with either PDGF homodimer (figure 5.11). A significant induction of enzyme 
activity resulted in the presence of ASP + Dx (p < 0.05). Irrespective of the absence or 
presence of ASP or Dx, the effect of the AA homodimer on AP expression was greater than 
that of the BB homodimer.
5 . 4 . 2  Mineralisation
Mineral deposition was only detected in cultures treated with ASP + Dx (visual observation, 
figure 5.12). PDGF BB treatment augmented this effect, but did not induce mineralisation 
when added to culture medium with ASP alone.
5 . 4 . 3  Surface marker expression of STRO-1 and AP
Single label experiments revealed small changes in the expression of STRO-1 and AP on 
BMSC when cultured in the presence of PDGF. Treatment with PDGF BB in the absence 
of Dx, slightly reduced the proportion of the total cell population that expressed STRO-1 
(figure 5.13i) and the mean cell surface density (MFI) of STRO-1. In contrast, PDGF BB 
treatment in combination with Dx modestly increased the percentage of cells that expressed 
STRO-1, and increased the mean cell surface expression of the antigen. The proportion of 
cells expressing AP and the MFI were not substantially altered by PDGF BB treatment in the 
absence or presence of Dx (figure 5.13ii).
Dual labelling of BMSC with the monoclonal antibodies STRO-1 and B4-78 (anti-AP) 
consistently revealed the presence of 4 subpopulations; STRO -l'/AP- (Ri), STRO-1+/AP- 
(R2), STRO-1+/AP+ (R3) and STRO-1/AP+ (R4 , figures 5.13iii, 5.14i, 5.14ii). Treatment 
with PDGF BB (figure 5.13iii) had little influence over the distribution of the cells in these 
populations in the absence of Dx. In the presence of Dx, treatment with PDGF BB modestly 
increased the proportion of cells in R3, and reduced the proportion in R4 .
Treatment with Dx alone (figures 5.13iii, 5.14i, 5.14ii) uniformly increased the size of the 
STRO-1+/AP+ (R3) and STRO-1 VAP+ (R4 ) populations, whilst decreasing that of the 
STRO-1 +/AP' (R2) population. In the two donor samples investigated (figures 5.14i, 
5.14ii), PDGF AA treatment did alter the distribution of cells in the four subpopulations, but 
the effect were inconsistent between the samples.
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Figure 5.11 The effect o f PDGF on AP biochemical activity
BMSC were cultured under standard conditions +/- 10' 8 M Dx in the absence or presence of
2.5 ng/ml PDGF BB or AA. Cells were harvested after 28 days in primary culture, lysed and 
the biochemical activity of AP measured by the conversion of p-NPP to p-NP, at pH 9.2. Due 
to the existence of a large inter-donor variation in AP activity, the data have been presented as a 
% of the control value (+/-SE) for n = 3 and 4 donors for PDGF A A and BB respectively. * 
Indicates a significant increase in activity over ASP + Dx control culture (p < 0.05). The mean 
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Figure 5.12 Mineralisation in cultures o f BMSC treated with PDGF BB
BMSC were treated with or without 10~8 M Dx and/or 2.5 ng/ml PDGF BB under standard 1° culture conditions for 12 days. (3-glycerophosphate ((3-GP) was 
added to half the plates for 5 days before the colonies were fixed. Cultures were fixed with NBF, stained with von Kossa stain and counter stained with 
methylene blue. Experiments of n = 4 donors showed similar results.
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Fluorescent intensity (log scale) ----------
D x / B B M a r k e r %  T o t a l M e a n M R
A l l 1 0 0 . 0 0 9 . 9 9 4 . 8 4
I C M l 5 . 7 0 9 3 . 4 3 4 6 . 3 6
- / -
A l l 1 0 0 . 0 0 4 7 . 2 6 1 2 . 9 0
M l 32.10 1 3 2 . 7 1 73.90
A l l 1 0 0 . 0 0 3 6 . 3 1 1 1 . 7 6
- / + M l 27.64 1 1 1 . 2 5 54.30
A l l 1 0 0 . 0 0 4 0 . 4 5 2 1 . 1 0
+ / - M l 49.90 7 0 . 2 0 45.02
+ / +
A l l 1 0 0 . 0 0 5 8 . 8 4 2 6 . 0 5
M l 58.44 9 3 . 0 7 52.90
Figure 5.13i The effect o f  PDGF BB on BMSC expression o f  STRO-1
BMSC were cultured for 28 days +/- 10' 8 M Dx in the absence or presence of 2.5 ng/ml PDGF 
BB. Harvested cells were dual-labelled with mAbs against STRO-1 and AP and fluorescent- 
conjugated 2° antibodies. Labelled cells were analysed by FACS. The results shown are 
representative of n = 4 donors which demonstrate similar results. The table is based on the 
results of the M l marker aligned on 5% fluorescent cells in the negatively stained population. 





Fluorescent intensity (log scale)
D x / B B  M a r k e r  %  T o t a l  M e a n  M F 1
A l l 1 0 0 . 0 0 3 . 8 5 3 . 0 7
M l 4 . 8 8 1 5 . 2 9 1 2 . 3 1
A l l 1 0 0 . 0 0 7 3 . 0 9 2 2 . 7 7
M l 6 9 . 0 6 1 0 4 . 2 7 5 8 . 8 2
A l l 1 0 0 . 0 0 9 7 . 8 1 2 8 . 3 0
M l 7 2 . 8 2 1 3 2 . 5 3 5 8 . 0 3
A l l 1 0 0 . 0 0 2 6 4 . 6 4 1 3 0 . 4 2
M l 9 7 . 1 2 2 7 2 . 3 7 1 4 5 . 8 9
A l l 1 0 0 . 0 0 2 3 1 . 2 1 1 0 3 . 1 0
M l 9 3 . 8 8 2 4 6 . 0 1 1 2 9 . 2 3
Figure 5.13ii The effect o f  PDGF BB on BMSC expression o f AP
BMSC were cultured, harvested and stained as described in the legend of figure 5.13i. The 
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Negative isotype control
Region Events % Total X Mean Y Mean
R1 4754 95.08 5.09 3.61
R2 203 4.06 120.50 3.15
R3 16 0.32 49.48 29.59
R4 13 0.26 12.21 69.46
Control
Region Events % Total X Mean Y Mean
RI 1532 3 0 . 6 4 7.57 6.68
R2 656 1 3 . 1 2 168.43 4.98
R3 687 1 3 . 7 4 141.37 130.03
R4 2108 4 2 . 1 6 7.90 124.70
PDGF BB
Region Events % Total X Mean Y Mean
R1 1790 3 5 . 8 0 8.16 8.10
R2 435 8 . 7 0 171.96 6.79
R3 592 1 1 . 8 4 120.90 164.10
R4 2145 4 2 . 9 0 9.13 174.67
Dx
Region Events % Total X Mean Y Mean
R1 338 6 . 7 6 9.37 10.95
R2 117 2 . 3 4 156.79 9.47
R3 1764 3 5 . 2 8 81.70 320.11
R4 2792 5 5 . 8 4 13.21 271.33
Dx + PDGF BB
Region Events % Total X Mean Y Mean
R1 457 9 . 1 4 8.93 9.16
R2 216 4 . 3 2 214.32 9.59
R3 2101 4 2 . 0 2 101.57 270.51
R4 2248 4 4 . 9 6 13.86 261.13
Figure 5.13iii The effect o f  PDGF BB on BMSC expression o f  STRO-1
and AP
BMSC were cultured, harvested and stained as described in the legend of figure 5.13i. The dot 
blots indicate the staining patterns of both antigens, where Ri = STRO-17AP-, R2 = STRO- 
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Region Events % Total X Mean Y Mean
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Control
Region Events % Total X Mean Y Mean
R1 1021 2 0 . 4 2 9.26 8.69
R2 604 1 2 . 0 8 302.43 7.25
R3 1116 2 2 . 3 2 284.44 231.79
R4 2248 4 4 . 9 6 9.52 168.86
PDGF AA
Region Events % Total X Mean Y Mean
R1 1205 2 4 . 1 0 6.56 8.40
R2 296 5 . 9 2 123.49 10.15
R3 623 1 2 . 4 6 251.20 168.13
R4 2868 5 7 . 3 6 6.05 138.92
D x
Region Events % Total X Mean Y Mean
R1 264 5 . 2 8 6.39 7.30
R2 147 2 . 9 4 508.12 7.22
R3 2142 4 2 . 8 4 264.42 363.69
R4 2440 4 8 . 8 0 9.51 310.85
Dx + PDGF AA
Region Events % Total X Mean Y Mean
R1 360 7 . 2 0 8.39 7.91
R2 256 5 . 1 2 129.54 10.55
R3 2802 5 6 . 0 4 310.94 264.44
R4 1564 3 1 . 2 8 11.21 218.69
Figure 5.14i The effect o f  PDGF AA on BMSC expression o f  STRO-1
and AP: donor 1
BMSC were cultured, harvested and stained as described in the legend of figure 5.13i with 2.5 
ng/nil PDGF A A. The dot blots indicate the staining patterns of both antigens, where R] = 
STRO-17AP-, R2 = STRO-1+/AP-, R3 = STRO-1+/AP+ R4  = STRO-17AP+
R4 R3
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Negative isotype control
Region Events % Total X Mean Y Mean
R1 4696 93.92 3.81 3.04
R2 205 4.10 118.76 8.83
R3 72 1.44 551.20 268.78
R4 33 0.66 15.97 40.85
Control
Region Events % Total X Mean Y Mean
R1 3931 7 8 . 6 2 5.68 3.93
R2 416 8 . 3 2 95.82 5.25
R3 96 1 . 9 2 1494.73 668.13
R4 568 1 1 . 3 6 7.64 100.71
PDGF AA
Region Events % Total X Mean Y Mean
R1 3968 7 9 . 3 6 7.27 4.32
R2 641 1 2 . 8 2 199.16 5.61
R3 103 2 . 0 6 1495.45 556.13
R4 295 5 . 9 0 9.48 86.38
Dx
Region Events % Total X Mean Y Mean
R1 1009 2 0 . 1 8 6.17 9.17
R2 197 3 . 9 4 103.21 8.24
R3 755 1 5 . 1 0 210.66 193.08
R4 3058 6 1 . 1 6 10.57 133.49
PDGF AA + Dx
Region Events % Total X Mean Y Mean
R1 934 1 8 . 6 8 5.96 9.70
R2 146 2 . 9 2 257.79 7.53
R3 435 8 . 7 0 265.51 241.08
R4 3502 7 0 . 0 4 8.68 170.62
Figure 5.14ii The effect o f  PDGF AA on BMSC expression o f STRO-1
and AP: donor 2
BMSC were cultured, harvested and stained as described in the legend of figure 5.13i with 2.5 
ng/ml PDGF AA.
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5 .4 .4  Expression of bone marker mRNA
The expression of selected 'osteoblastic' mRNAs was assessed using RT-PCR. 
Complementary DNA encoding bone sialoprotein, osteocalcin, oestrogen receptor, and 
parathyroid hormone receptor was amplified from mRNA extracts with specific 
oligonucleotide primers. Using this method of analysis, which at best is semiquantitative, 
there was no consistent effect of any of the treatment regimens on the expression of 
transcripts for the parathyroid hormone receptor, and oestrogen receptor (figures 5.15i and 
5 .15ii). Treatment with Dx, and albeit to a lesser extent, PDGF BB increased the expression 
of BSP transcripts in cultures derived from 3 of 4 donors. When added in combination the 
effect on BSP transcript expression was intermediate between that of Dx and PDGF alone. 
In cultures derived from 3 of 4 donors PDGF BB treatment, irrespective of the absence or 
presence of Dx, slightly decreased osteocalcin transcript expression.
5 . 4 . 5  Osteocalcin synthesis
Secretion of 1,25-dihydroxyvitamin D3-induced osteocalcin was measured in the culture 
medium of two experiments using cells from separate donors, one treated with PDGF BB, 
the other with PDGF AA. PDGF BB reduced the amount of osteocalcin secreted by BMSC 
-/+ Dx, but no consistent effect of PDGF AA treatment was observed (figure 5.16).
5 .5  Interaction of PDGF with IGF-I responsive pathways
PDGF BB increased proliferation measured as the incorporation of [3H]-thymidine in the 
absence or presence of Dx (figure 5.17). In contrast, IGF-I treatment increased [3H]- 
thymidine incorporation only in the presence of Dx, and its effect was not clearly dose 
dependent. Irrespective of the absence or presence of Dx, the effect of both agents added in 
combination was no different to that observed in the presence of PDGF BB alone.
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Figure 5.15i The effect o f PDGF BB on osteoblast marker mRNA expression in BMSC
cDNA prepared from BMSC cultured in medium alone (1) or medium + 10" 8 M Dx (2), 2.5 ng/ml PDGF BB (3) or Dx and PDGF in combination (4). PCR 
was performed using primers for the indicated osteoblast markers and the production separated by agarose gel electrophoresis. Southern blots were then 
prepared and hybridised with radiolabelled probes complementary to sequences internal to those of each primer pair. Digitised images of the resulting 
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Figure 5.15ii The effect o f PDGF BB on expression o f osteoblast
mRNAs in 1° cultures o f BMSC: Results o f  image analysis
The data from images in 5.15i have been corrected for differences in the amount of input 
cDNA using the GAPDH product as an internal standard and expressed as a T/C ratio. 
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Figure 5.16 The effect o f PDGF on 1,25-dihydroxy vitamin D ^.induced
secretion o f osteocalcin
BMSC were cultured under standard 1° conditions for 20 days (+/- Dx) in the absence or 
presence of 2.5 ng/ml (i) PDGF BB or (ii) AA. To induce the secretion of osteocalcin, the 
cultures were additionally supplemented with 1,25-dihydroxy vitamin D3 for the final 48 hours. 
Osteocalcin secreted into the medium was measured using a commercially available ELISA kit 
(Novocalcin, Metra Biosystems Inc. section 2.6.5). Results are the mean of n = 4 +/- SE, and * 
indicates significant (p < 0.05) inhibition compared to ASP + Dx control treatment.
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Figure 5.17 The effect o f IGF-I combined with PDGF BB on BMSC
proliferation
Secondary BMSC were seeded into 96 well plates at lxlO4 cells per cm2 and treated with IGF-I 
(25 or 100 ng/ml) in the absence or presence of PDGF BB (2.5 or 10 ng/ml). The experiments 
were performed in medium + 10% FCS +/- 10~8 M Dx. Cultures were treated for 48 hours and 
then pulsed with [^H]-thymidine for 24 hours. [^H]-thymidine incorporation was measured 
on a 3-counter. The results shown are the mean +/- SE for n = 3 donors.
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5.6 Discussion
For therapies involving reimplantation of ex-vivo expanded stromal cells, progenitor cells 
are often more appropriate for treatments in which restoration of a functional cell population 
is necessary. Local growth factors can then influence the commitment of the cells and 
restore widespread cell activity. Terminally differentiated cells have a limited lifespan and 
are non-proliferative, and thus are only biologically active on a short term basis. In this 
investigation the ability of PDGF to promote the ex-vivo expansion of human bone marrow 
stromal cells without altering their potential for osteogenic differentiation was investigated.
Initial characterisation studies determined that PDGF A and B chains were synthesised by 
human bone-derived cells, a  and P receptor subunits were also found to be expressed on 
-40-60% of the cultured cell population. The size of the PDGF receptor chains determined 
by PAGE was consistent with the reported sizes of 180 kDa (PDGFRP, Bowen-Pope et al, 
1985) and 200 kDa (PDGFRa, Centrella et al, 1992). Expression of the PDGF A and B 
isoforms and the presence of a  and P receptors supports the role of PDGF as important 
autocrine and/or paracrine regulators of BMSC proliferation, and possibly differentiation.
With Dx treatment, RT-PCR suggests that expression of the PDGF B chain is decreased, 
whereas expression of the PDGF A chain is increased. It would be necessary to confirm 
this using Northern analysis, and direct measurement of PDGF A and B chain proteins by 
ELISA with a greater sample number. Flow cytometry data indicates that the proportion of 
the BMSC population that express PDGFRa and PDGFRP was also decreased with Dx 
treatment. As Dx is a known inducer of osteogenic differentiation these responses suggest 
that more mature cells of the osteoblast lineage have reduced expression of PDGF B or 
receptor peptides. As PDGF is reported to induce a mitogenic response in mesenchymal 
cells, this may present a rationale for the decrease in proliferation observed in Dx treated 
osteoblastic cells. This suggests, therefore, that in normal unstimulated cells, Dx treatment 
could alter the PDGF mediated autocrine or paracrine pathways. Also these cultures 
represent a heterogeneous population of cells of multiple mesenchymal stromal lineages and 
it is not clear whether receptors are expressed exclusively on the cells committed to the 
osteoblastic lineage, and if so at what stage(s) during their differentiation. A multiparameter 
flow cytometric analysis using fluorescently labelled antibodies recognising STRO-1, AP 
and PDGF receptors might be informative in this regard. It is known that the proliferative 
potential of cells of the osteoblastic lineage in inversely related to their extent of 
differentiation (Stein et al, 1990). Whether down regulation of the receptors and PDGF B 
chain is a direct result of Dx treatment or an increased maturity of the cells remains to be 
determined. The responsiveness of more immature cells to PDGF is supported by Hsieh 
and Graves (1998) who found that PDGF BB stimulated DNA synthesis in cultures of foetal 
rat calvarial cells soon after explant, but this diminished as the cells matured. Yu et al (1997)
121
also showed that expression of PDGF receptor subtypes on rat foetal calvarial cells reached a 
maximum coincident with the upregulation of AP expression, but then declined as the cells 
underwent further maturation.
PDGF increased the number of cells in cultures of BMSC. This was the result of increased 
proliferation demonstrated by an increase in cell number and colony size, rather than in CFE. 
These results are consistent with PDGF acting in the initial stages of culture to increase the 
size of the adherent cell population (Herbertson and Aubin, 1995a, Yu et al, 1997, Hsieh et 
al, 1998), and concordant with the finding of Gronthos and Simmons (1995) who 
demonstrated an increase in the size, but not the total number of colonies formed in PDGF 
supplemented serum-free medium when compared with serum-replete conditions. PDGF is 
known to be an essential requirement for mesenchymal cell proliferation in vitro (Graves et 
al, 1989) and it is now well documented that PDGF is required in the early stages of colony 
formation. Recent studies investigating factors that regulate growth and development of 
primitive bone marrow precursors have recently defined that clonogenic growth of CFU-F 
can be supported under serum-deprived conditions, in the presence of ASP and Dx, but is 
absolutely dependent on an exogenous source of growth factor, with PDGF and epidermal 
growth factor (EGF) demonstrating the greatest ability to support growth (McIntyre and 
Bjomson, 1986, Gronthos and Simmons, 1995). In a recent study, Kuznetsov et al (1997) 
demonstrated that only anti-PDGF antibodies specifically suppressed colony formation, 
when neutralising antibodies against several growth factors were used.
In this study, PDGF was found to limit the number of clonogenic cells that became 
committed to the osteogenic lineage shown by a reduction in the proportion of AP positive 
colonies. The PDGF isoforms were found to differ in their functional properties, with 
PDGF A A having a greater effect on osteogenic differentiation than PDGF BB, based on 
expression of AP. However, markers of osteoblastic differentiation did not reveal any 
specific induction of osteogenic differentiation by PDGF BB. Flow cytometry using mAbs 
recognising the STRO-1 antigen and BLK isoenzyme of AP sub-divides the human BMSC 
cultures into four distinct populations representing cells at different stages of osteogenic 
differentiation (section 5.4.3, figure 5.18). A working hypothesis has been assigned that 
the cells within these populations are functionally distinct and form part of a lineage 
progression: multipotential precursors being present in the STRO-1+/A P ' population, 
committed osteoprogenitors in the STRO-1+/AP+ population, and maturing osteoblasts in 
the STRO-1 "/AP+ population. The STRO-1-/AP“ population is thought to contain cells that 
are not of the osteoblastic lineage. When analysed by flow cytometry, treatment of BMSC 
with PDGF BB, even when added in combination with Dx and/or ASP did not significantly 
alter the distribution of cells within these populations, indicating that the mitogenic effects of 
this growth factor are non-selective and not coupled specifically to the proliferation of cells 
of the osteoblast lineage.
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Figure 5.18 Analysis of human marrow stromal celts by flow cytometry using STRO-1 and B4-78 (a-AP) mAbs
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Certainly neither isoform appeared to substantially alter the ability of Dx to increase the 
proportion of cells present in the STRO-1+/AP+ and STRO-1-/AP+ populations. This is in 
marked contrast to that of basic fibroblast growth factor (FGF-2), which in addition to being 
a potent mitogen also promotes osteogenic differentiation in this cell culture system (Walsh 
and Beresford, 1995).
Analysis of the effects of PDGF BB on the expression of AP in this cell culture system, 
revealed that a modest increase in AP activity observed in PDGF-treated cultures could not 
be accounted for by an increase in the mean fluorescent index. This suggests that PDGF BB 
exerts its small effect on the expression of AP by modulating the catalytic activity of pre­
existing enzyme in this culture system. This may otherwise be attributed to the increase in 
proliferation of cells expressing AP. Further evidence based on the deposition of mineral 
and expression of markers of the osteoblast lineage (parathyroid hormone, osteocalcin, 
oestrogen and BSP) demonstrated that PDGF BB did not substantially alter the 
differentiation of these cells, and acted to moderate the effects of Dx on osteogenic 
differentiation. A decrease in osteocalcin mRNA and peptide expression compared to 
control cultures demonstrated the maintenance of an immature osteoblastic population in 
PDGF BB treated cultures.
Attempts to show the interaction of PDGF with IGF-I did not reveal any further mitogenic 
effect of the growth factors in combination above that of PDGF alone. The lack of a 
response may have been due primarily to one of the doses of IGF-I or PDGF being too 
high, thus producing a maximum response alone and masking a dual effect. IGF-I is 
abundantly produced by cells of the osteoblastic lineage which might also have masked the 
effect of exogenously added growth factor. This was addressed by attempting to block the 
IGF-I autocrine loop using an anti type I IGF receptor antibody (aIR-3, Kappel et al, 1994), 
and antisense oligo-deoxynucleotides directed against type I receptor mRNA. However, 
these experiments did not lead to any alteration in cell proliferation even when the 
experimental design was varied and various methods of evaluating viable cell numbers 
assessed ([3H]-thymidine incorporation, MTT (Mossmann, 1983), neutral red (Lowik et al, 
1993) and cell counts).
In conclusion, the major effect of PDGF BB in this culture system, was therefore mitogenic, 
acting to promote ex-vivo expansion of human BMSC without altering the potential for 
osteogenic differentiation. The results suggest that the actions of the two isoforms in this 
cell culture system are distinct and although both isoforms of PDGF induced proliferative 
response in human marrow stromal cells at all stages of osteoblast maturity in this system, 
PDGF AA moderately promoted osteoblast maturation. Overall, these results are supported 
by Cassiede et al (1996) and Yu et al (1997) who found PDGF to be mitogenic for less 
differentiated cells of the osteoblastic lineage. In rat marrow stromal cultures Tanaka and
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Liang (1995) found PDGF BB treatment alone increased expression of osteopontin mRNA, 
with no effect on expression of collagen type I or AP. Addition of PDGF to Dx treated cells 
reduced collagen type I and AP expression in this rat model and under both conditions, 
expression of osteocalcin was inhibited. Furthermore, in foetal rat bone, AP activity was 
reduced with PDGF treatment (Herbertson and Aubin, 1992, Cassiede et al, 1996, Hsieh 
and Graves, 1998), with PDGF BB having a greater effect than AA (Centrella et al, 1991). 
Thus expression of markers of osteoblastic differentiation support evidence that PDGF BB 
maintains an early osteoprogenitor population. However, in contrast to these results, it has 
recently been found that pulse treatment of PDGF induced mineralisation in contrast to 
continuous treatment which inhibits differentiation (Hsieh and Graves, 1998).
PDGF is thus a candidate mitogen for the ex -vivo expansion of human bone marrow stromal 
cells that retain an immature phenotype, but possess osteogenic potential, and might be used 
for tissue reconstruction and the healing of bone defects. To evaluate whether these cells are 
able to produce bone in vivo, and to fully establish the effects of PDGF on the osteogenic 
capacity of the cells in the absence or presence of Dx, it would be of value to test these 
populations in an in vivo assay of osteogenesis, by implanting PDGF treated cells into 
diffusion chambers, or into open-transplant assay with incorporation of a nuclear marker as 
in experiments of Krebsbach et al (1997).
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Chapter 6
An investigation of the effects of ageing and gender on BMSC
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6.1 Introduction
Osteoporosis is a disease which is manifested as a result of the combination of a large 
number of factors. These are based on the age of onset, sex, incidence pattern, distribution 
of bone loss, and the effects of a decline and/or loss of gonadal steroids on a predisposing 
factor. A progressive decline in bone mass and strength which occurs as a consequence of 
the ageing process leads to idiopathic (age related), type I osteoporosis. Post-menopausal 
osteoporosis (type II) is characterised by a rapid phase of bone loss associated with a 
decrease in circulating oestrogen at menopause. Later on men and women lose bone at 
similar rates (Riggs and Melton, 1986). At the tissue level, bone loss is due to an increase in 
the number and activity of osteoclasts with a possible prolongation of their functional 
lifespan (Riggs et al, 1998). This afflicts cortical and trabecular bone to a similar extent. 
Age-related changes in osteoblast function may play an important role in further bone loss, 
and a gradual decline in thickness of the remaining trabeculae is postulated to be due to a 
decline in the osteoblast number relative to the amount of bone formation required, rather 
than a change in osteoblast activity. Since osteoblasts are the primary effectors of bone 
formation in vivo, age-related changes in osteoprogenitor number may have an important 
effect on the production of osteoblasts. In adults, osteoblasts are derived from clonogenic 
precursors CFU-F, which are associated with the soft fibrous tissue of the marrow stroma 
(Beresford, 1989). It is postulated that a deficit in osteoblast numbers could be due to a 
secondary consequential decline in the CFU-F population with age.
Studies in experimental animals (Tsuji et al, 1990, Egrise et al, 1992, Liang et al, 1992, 
Jilka et al, 1996) have yielded results consistent with the hypothesis that there is an age- 
related decline in bone marrow CFU-F. The data from human studies have been less 
unequivocal with evidence for and against a decline in osteoblasts and precursor cells having 
been reported (Morike et al, 1993, Shigeno and Ashton, 1995, Glowaki, 1995, Cheng et al, 
1996, dePollak et al, 1997, Oreffo et al, 1998).
Hence, the purpose of this investigation was to determine whether the size of the CFU-F 
population in human marrow is related to donor age, as a total population or in donors aged 
above 50 years, and whether it is associated with gender. To establish whether such 
associations exist, we analysed the colony forming efficiency and proliferative capacity of 
marrow stromal cells in primary culture, in a study of 56 human patients (table 6.1). The 
prevalence of osteogenic precursors was estimated by counting AP positive colonies. 
Secondly, this study also investigated the influence of gender on colony formation and 
proliferation, irrespective of the effects of donor age. The effect of treatment with Dx was 
also evaluated.
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6.1 .1  Statistical analysis
The effect of age on growth parameters of CFU-F was assessed using Spearmans rank 
correlation coefficient (SRCC, StatView v4.51). Data is shown as bivariate scatterplots, 
with regression lines of which the slope is indicated by R2, the lines either side being the 
95% confidence limits of the mean. The size of the cohort was not large enough to allow 
multivariate analysis, so a subset analysis was performed in an attempt to examine the 
possible effects of gender and Dx treatment while controlling for any effects of age. Results 
of BMSC colony formation, and proliferation, arising under culture conditions in the 
absence or presence of Dx were grouped, and comparisons between treatments and gender 
were made using the Mann-Whitney U test. Statistical tests are described in detail in the 
section 2.7. Results of the analyses correlating to figures in this section are shown in 
appendix II.
6.2 Results
BMSC from 56 human donors were cultured under standard primary conditions (section 
2.2.1.1) in the absence or presence of Dx. The ages of these patients are shown in figure 
6 . 1 .
Total donors Donors aged > 50 years
Male Female Both Male Female Both
CFE Age range 15 - 84 36-84 15-84 50-84 60-84 50-84
Mean age 60.5 64.5 61.8 65.5 70 66.9
(n) 34 22 56 24 14 38
Proliferation Age range 19-85 26-80 50-85 57-80
Mean age 57.9 58.4 58.1 64.5 70.6 66.2
(n) 20 10 30 16 7 23
Table 6.1 Summary statistics for the donors used in this study
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6.2.1 CFE
6 . 2 . 1 . 1  The effect of age on CFE
In the cohort studied, there was no evidence for an effect of donor age on colony formation 
(total or AP positive) irrespective of the absence or presence of Dx (figure 6.2).
6 . 2 . 1 . 2  The influence of gender
Analysis of the data for male and female donors separately did not reveal the existence of a 
gender specific effect of ageing on colony formation, either in the absence or presence of Dx 
(figures 6.3 and 6.4).
6 . 2 . 1 . 3  The influence of gender in donors > 50 years of age
Due to evidence for decreased bone mass with an increase in age, particularly in post­
menopausal women, the colony formation arising from marrow of donors older than 50 
years was analysed independently (figures 6.3 and 6.4). The analysis did not reveal any 
relationship between total or AP positive colony formation and the age of male or female 
donors, either in the absence or presence of Dx.
6.2.2 Proliferation
6 . 2 . 2 . 1  The effect of age on proliferation
The influence of donor age on the proliferation of BMSC in primary culture was investigated 
in the absence or presence of Dx. In both cases, the number of cells harvested at the end of 
primary culture was independent of the age of the donor (figure 6.5).
6 . 2 . 2 . 2  The influence of gender
Analysis of the data for male and female donors separately did not reveal the existence of a 
gender specific effect of ageing on cell number, either in the absence or presence of Dx 
(figure 6 .6 ).
6 . 2 . 2 . 3  The influence of gender in donors > 50 years of age
Analysis of the data for patients > 50 years split by gender did not reveal the existence of a 
statistically significant association between ageing and proliferation in cultures established 
from either male or female donors (figure 6 .6 ).
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Figure 6.2 Influence o f donor age on total and AP+ colony formation
BMSC were cultured for 18 days under standard 1° conditions in the absence or presence of 10' 8 M Dx. Colonies were then fixed, and stained with Fast-red 
TR and methylene blue. The scattergrams show CFE plotted against the age of the donor from whom the marrow sample was taken. R2 indicates the slope of 
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Figure 6.3 Influence o f male and female donor age on total and AP+ colony formation
BMSC were cultured for 18 days under standard 1° conditions in the absence of Dx. The results in figure 6.2 were divided according to donor gender.
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Figure 6.4 Influence o f male and female donor age on total and AP+ colony formation
BMSC were cultured as described in figure 6.2 in the presence of Dx. The results shown in figure 6.2 were divided according to the gender of the donor.
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Figure 6.5 Influence o f donor age on proliferation
BMSC were cultured for 18 days under standard 1° conditions in the absence or presence of Dx. Cells were harvested by sequential collagenase-trypsin 
digestion and counted electronically. The scattergrams show the cell count plotted against the age of the donor from whom the marrow sample was taken. R2 
indicates the slope of the regression line which is plotted with 95% confidence limits.
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Figure 6.6 Influence o f male and female donor age on cell proliferation
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BMSC were cultured for 28 days under standard 1° conditions in the absence or presence of Dx. Cells were harvested by sequential collagenase-trypsin 
digestion and counted electronically. The results described in figure 6.5 were divided according to the gender of the donor.
6.3 Comparisons between genders and treatment irrespective of age
6 . 3 . 1  CFE
Analysis of the data of CFE for the whole population revealed a range in colony formation of 
0-74 (mean = 21) and 0-59 (mean =16) total colonies per dish, in the absence or presence of 
Dx, respectively. In the whole population Dx treatment decreased total colony formation by 
24%, but increased the number of colonies expressing AP -50%  (figure 6.7). In the 
absence of Dx, the CFE of marrow derived from the whole population of female samples 
was significantly lower than that of the male samples (p = .0317, figure 6 .8 i). In contrast 
there was no difference in the number of AP colonies formed. W hen the growth 
characteristics of BMSC from female donors of > 50 years of age were analysed 
independently, the CFE of the female samples was significantly lower than that of the male 
samples (p = .0022 and .0111, -/+ Dx respectively, figure 6 .8 ii). These comparisons 
demonstrate that the difference between the male and female populations was greater in the 
absence of Dx, than in its presence.
6 . 3 . 2  Proliferation
In the population as a whole (figure 6.9), treatment with Dx had no significant effect on the 
proliferation of BMSC in primary culture (mean change = 23%, p = 0.276). However, 
when the data were split by gender it was apparent that in the absence of Dx, proliferation of 
cells from female donors was significantly less than those from male donors (mean change = 
47%, p = .0347, figure 6.10i). When the data for donors of age > 50 years was analysed 
separately, the difference between males and females was significant in the absence or 
presence of Dx (mean changes of 69% and 73%; p = .0134 and .0274, respectively, figure 
6 .10 ii).
Proliferation of BMSC from the whole population was reduced to 23% of total cell number 
with Dx treatment (figure 6.9). Furthermore, proliferation of female cells cultured in the 
absence of Dx was significantly less than that of male samples (p = .0347, figure 6.10i). 
When the growth characteristics of BMSC from female donors of > 50 years of age were 
analysed independently (figure 6 .1 0 ii), the cell number of the female samples was 
significantly lower than that of the male samples. Again, this demonstrates the difference 
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Figure 6.7 The effect o f Dx treatment in a cohort study o f total and AP colony formation
Results of total (T) and AP+ (AP+) colony formation were grouped into control and Dx treated cultures (-/+)• The descriptive statistics for the data points in 
the univariate scattergraphs are shown in the table. These groups were compared using the Mann-Whitney U test. Results of the analyses are in appendix II.
136






g.  4 0
8  3 0
o 20  o
o  10
0 1  2 3 4 5 6 7 8 9
o (1) M T - Dx
□ (2) M T + D x
A (3) M A P + - Dx
o (4) M AP+ + Dx
• (5) F T  - Dx
■ (6) X
Q+1-U_
▲ (7) F A P + - Dx
♦ (8) F AP+ + Dx
8 0  
7 0  
£  6 0  
=5 5 0  
I  40 
8  3 0
0 1  2 3 4 5 6 7 8 9
o (1) M T - D x
□ (2) M T + D x
A (3) M AP+ - Dx
O (4) M AP+ + Dx
• (5) F T  - Dx
■ (6) F T  + Dx
▲ (7) F A P + - Dx
♦ (8) F AP+ + Dx
Variables (see  legend) Variables (see  legend)
Group (n) Mean CFE +/-SE CFE range mean ranks Group (n) Mean CFE +/-SE CFE range mean ranks
1 34 25 (+/- 3.3) 2-74 33.765
2 28 2 0  (+/- 2 .8 ) 0-59 28.750
3 2 2 5 (+/- 1.3) 0-18 20.341
4 21 7 (+/- 1.5) 0-25 23.738
5 17 11 (+/- 3.4) 0-40 17.176
6 15 9 (+/- 2.8) 0-33 15.733
7 16 3 (+/- 1.3) 0-18 14.438
8 15 5 (+/- 2.0) 0-30 17.667
1 30 24 (+/- 3.5) 2-74 29.083
2 24 19 (+/- 3.3) 0-59 25.521
3 2 0 5 (+/- 1.3) 0-18 18.475
4 19 6  (+/- 1.6 ) 0-25 21.605
5 17 14 (+/- 3.4) 0-40 17.412
6 15 12 (+/- 3.1) 0-33 16.562
7 16 4 (+/- 1.3) 0-18 15.912
8 15 6  (+/- 2 .0 ) 0-30 18.156
Figure 6 . 8  The influence o f gender and Dx treatment on total and AP colony formation
The results of colony formation (i, all donors, ii, samples from donors >50 years) were divided according to gender (M, male, F, female), and treatment with 
13*7 Dx (-/+). T, total and AP+, alkaline phosphatase positive colony formation.
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Figure 6.9 The effect o f Dx treatment in a cohort study o f BMSC proliferation
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Results of BMSC proliferation were grouped into control and Dx treated cultures (-/+). The descriptive statistics are shown in the table. Results of the 
analyses are in appendix II. CN, cell number.
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Figure 6.10 The influence o f gender and Dx treatment on BMSC proliferation
Results of BMSC proliferation (i, all donors, ii, samples from donors >50 years) were grouped according to gender, and treatment with Dx (-/+). M, male, F, 
female, CN, cell number.
6.4 Discussion
The influence of age on CFE and proliferation has been investigated in primary cultures of 
BMSC from a cohort of 56 donors (mean age of 61.8 years; range 15-84). Using this cell 
culture model we were unable to obtain evidence for the existence of an age-related decline in 
bone marrow CFU-F harvested from ribs, or in the proliferation of their progeny. This was 
true whether the population was treated as a whole or split by gender, and irrespective of the 
absence or presence of Dx. The demonstration of a lack of an association between donor 
age and the CFE or proliferation of the mesenchymal cells, may be of true biological 
significance and indicate that the number of CFU-F does not change with age in humans. 
These results are consistent with those published recently by Oreffo et al (1996, 1998) who 
also failed to detect an age-related decline in the CFE of human bone marrow harvested from 
the spine. They differ, however, from those of Majors et al (1997) who demonstrated a 
negative correlation between AP positive colony formation and donor age in human marrow 
harvested from the iliac crest.
These findings in human cell cultures are in marked contrast with those obtained using 
animal bone marrow in which it has been shown consistently that there exists an age-related 
decline in the number of CFU-F and/or nodule forming cells (Bab et al, 1984, Nimni et al, 
1988, Tsuji et al, 1990, Quarto et al, 1995). In these experiments, the in vitro osteogenic 
maturation of the cells appeared to be normal, as AP continued to be expressed by the 
colonies, irrespective of donor age. This supports the proposal of Marie and De Vemejoul 
(1993) that differentiation of osteogenic precursors is normal in age-related osteoporosis.
The findings of this study do not preclude the possibility that a relationship between ageing 
and CFE (total or AP positive) does exist at other, more clinically relevant skeletal sites, for 
example the vertebra, or neck of femur (Davis et al, 1994, Bonjour et al, 1991). Our 
marrow samples were derived from rib, a non load-bearing site, which might not be as 
physiologically active as sites which have large strains imposed upon them. Site-related 
differences in human osteoblastic cell metabolism have been reported (Marie et al, 1992, 
Marie and De Vemejoul, 1993, Kasperk et al, 1995, Aerssens et al, 1997). Alternatively, 
our results may simply indicate that the changes in humans are less dramatic than those 
reported to occur in experimental animals. Also, in a study of human donors using surgical 
waste, many factors in addition to age may influence cellular activity including smoking, 
malnutrition, levels of exercise, endocrine status, drug history, underlying pathology, and 
race. These might influence the experimental outcome and confound interpretation of data.
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A farther possibility to explain these findings is that the decrease in bone formation observed 
in vivo may not occur as a consequence of a decrease in CFU-F number. A number of 
studies have found a reduction in the proliferation potential of human osteogenic cells with 
age (dePollak et al, 1997, Fedarko et al, 1992) and a decrease in the number of osteoblastic 
cells on the bone surface in vivo (dePollak et al, 1997, Shigeno and Ashton, 1995). The 
failure of the osteogenic population to expand appropriately may be due to impaired 
responsiveness to mitogens as suggested by Pfeilschifter et al (1993) and d'Avis et al 
(1997). Under standard culture conditions the response of CFU-F to growth factors is not 
apparent, but could be revealed by challenging BMSC with specific growth factors. A 
decrease in bone associated peptides, or reduced paracrine production of growth factors, 
could result in a remodelling imbalance, and contribute to the gradual loss of bone that 
occurs with age. Circulating levels of growth hormone and IGF-I have been observed to 
decrease with age (Bouillon et al, 1995) and to be decreased further in patients with 
idiopathic osteoporosis (Reed et al, 1995). Nicolas et al (1994) demonstrated an age-related 
decrease in the bone content of IGF-I, and in the ratio of stimulatory: inhibitory IGF binding 
proteins (IGFBP-5:IGFBP-3). Nicolas et al (1994) also reported an age-related decline in 
the TGFp content in femoral cortical bone from both men and women.
Clearly insufficient samples were present in the perimenopausal population to make a critical 
analysis of this data alone. This study also emphasises that colony formation of individual 
donor samples is unpredictable, indicated by the many samples from which no colonies 
formed. In 28% of total donors samples cultured with Dx (3 samples of less than 30 years, 
and 9 of 57-84 years), less than 5 colonies formed per dish (i.e. 1 colony per 10,000 single 
cell seeded, or 1 colony per 4 cm2 area). Likewise, the proliferation of these colonies was 
highly variable. As a large variation in inter-donor colony formation has been described 
(Majors et al, 1997, Muschler et al, 1997), a large number of donors are necessary in such a 
study to compensate for intrinsic errors. Also, from appendix III, it can be seen that the 
majority of patient samples used during the course of this research were suffering from lung 
cancer. A recent paper by Chasseing et al (1997) shows that this condition is correlated with 
a reduction in the colony forming potential of bone marrow. However, as the majority of 
patients were suffering from similar conditions the data are internally comparable, and the 
results valid.
Improvements to this study should include recruitment of larger number of normal donors, 
with marrow samples abstracted from a more clinically appropriate site such as the iliac 
crest. These volunteers could also be scanned to determine their bone mineral density, 
which could be correlated with the CFU-F census to determine the influence of age on either 
or both of these parameters. CFU-F census correlated with biochemical markers of bone 
turnover such as serum bone alkaline phosphatase (Duda et al, 1988) or osteocalcin
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(bone formation, Price et al, 1980), urinary deoxypyridinoline crosslinks (Beardsworth et 
al, 1990) or tartrate-resistant acid phosphatase (bone resorption, Stepan et al, 1983) could 
indicate a relationship between the number of CFU-F observed in vitro and osteoblastic 
activity or the rate of bone turnover in vivo. In addition assessment of CFU-F by functional 
and immunochemical criteria such as STRO-1, with vascular cell adhesion molecule 
(VCAM-1, Benayahu et al, 1995), HOP-26 (Joyner et al, 1997) or MUC18 (Filshie et al, 
1998) would allow the observed CFE to be compared with the expected CFE based on 
immunophenotyping.
An alternative hypothesis for consideration is that age-related osteopenia may not result from 
a decrease in absolute numbers of CFU-F, but from an imbalance in the proportion of 
progenitor cells that differentiate to form cells of other mesenchymal lineages as opposed to 
osteoblasts, for example adipocytes. This theory is supported by long standing observations 
of age-related changes in the composition of the marrow stroma including an increase in fatty 
tissue (Rozman et al, 1989), a concurrent decrease in osteoblast numbers (Uchiyama et al, 
1994) and a marked increase in adipocytes in idiopathic osteoporosis (Meunier et al, 1971, 
Burkhard et al, 1987, Martin and Zissimos, 1991). The propensity of cells to enter the 
adipocytic lineage could be assessed by the proportion of colonies containing adipocytes 
following treatment of cultures with adipogenic agonists, for example thiazolidinedione 
(Ibrahimi et al, 1994), a ligand for the peroxisome proliferator-activated receptor y (PPARy) 
known to be of primary importance in the regulation of adipogenesis (Chawla et al, 1994, 
Tontonoz et al, 1994, Teboul et al, 1995, Nuttall et al, 1998).
Although no effect of ageing could be demonstrated in these studies further statistical 
analysis did reveal a significant effect of gender on CFE and on cell proliferation. Thus 
when compared with male samples, those from females were found to have significantly less 
total colony forming potential. Proliferation in cultures derived from female donors was also 
significantly decreased compared to that of male cultures. The difference in CFE and 
proliferation was independent of the absence or presence of Dx in donors > 50 years. The 
number of AP positive colonies formed however, did not vary between male and female 
donors. This suggests that the proportion of colonies which express AP is greater in the 
female population than in the male. This is in contrast with recent report of Majors et al 
(1997) in which women older than 43 years were found to have a lower prevalence of AP 
positive colony forming units in marrow samples than males. Thus, marrow from female 
donors may contain more CFU-F which become committed to the osteogenic lineage, or 
CFU-F that begin to undergo osteogenic differentiation more rapidly.
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It is probable that the reduction in total number of cells after 28 days culture is directly 
related to the reduction in colony formation, but whether this is a direct effect remains to be 
determined. Again, differentiation of a larger proportion of the cells in the female population 
may result in a lower proliferation rate, and fewer cells in the total population after 28 days 
in culture. In accordance with theories of Stein et al (1990), an upregulation of AP 
expression may be linked to a concurrent decline in preosteoblastic cell proliferation. This 
study may provide, therefore, tenuous evidence for premature differentiation and limited 
expansion of pre-osteoblastic cells in females, thereby reducing the number of cells capable 
of producing bone matrix. It also appears that the difference in the bone forming potential of 
the marrow is detectable at a very early stage in the cell life-span.
143
Chapter 7
Conditional immortalisation of BMSC with SV40 large T antigen
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7.1 Introduction
Normal diploid cells in culture can only divide a limited number of times, during which they 
undergo many changes culminating in the cessation of cell division. This phenomenon of 
cellular ageing was first described by Hayflick (1965) and is now generally known as the 
Hayflick phenomenon. Cells undergo a process of ageing which is evident in vitro and have 
a limited lifespan of around 32 cumulative population doublings (Kassem et al, 1997). 
Immortalisation of mesenchymal cells overcomes this process of ageing, increasing the 
number of population doublings and delaying the onset of senescence. This significantly 
raises the number of cells available for analysis and allows investigation of the cell 
population over an increased length of time.
Transfection is an important laboratory tool which provides a means of introducing foreign 
DNA, normally in the form of a circular double stranded DNA vector, into proliferating cells 
in vitro. Immortalising vectors are integrating or episomally replicating DNA molecules that 
fulfil three specific requirements: they carry genetic material for expression of specific 
proteins, they contain origins of replication for both prokaryotic and eukaryotic replication, 
and they encode a drug resistance marker.
The prokaryotic selection marker DNA within the vector encodes resistance genes for 
antibiotic action. This allows large amounts of vector DNA to be generated following 
transformation of host bacteria such as Escherichia coli (E . coli) and manipulation and 
characterisation of the vector DNA to be undertaken rapidly. Another DNA sequence 
confers antibiotic resistance in the eukaryotic host and enables successfully transfected cells 
to survive in culture under conditions that are cytotoxic for the non-transfected population.
Immortalisation of transfected cells can occur through many molecular mechanisms. 
However, the plasmids chosen in this study, permutations of pMTiSV.neo, act through 
expression of simian virus 40 large tumour antigen (SV40 large T Ag), an early protein 
originating from the monkey DNA tumour virus, simian virus 40. SV40 large T Ag is a 94 
kilodalton oncoprotein, which alters host metabolic functions, primarily through binding to 
the tumour suppressors, retinoblastoma protein (Rb) and p53. These are recognised 
independently by different domains of the SV40 large T antigen (Stahl and Knippers, 1987). 
Wild type p53 and Rb are nuclear phosphoproteins involved in the control of cell-cycle 
progression. Sequestration of p53 prevents activation of target genes and results in DNA 
amplification. Similarly SV40 large T antigen binds and sequesters the non-phosphorylated 
form of Rb. This form of Rb is present in resting cells (Go/Gi) where it inhibits activation 
of transcription and represses gene expression through binding to several proteins including 
E2F, and C and D cyclins. Thus expression of SV40 large T Ag affects the cell-cycle 
control mechanism (Lewin, 1994).
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The immortalising plasmid selected for initial evaluation in these studies was PMT4S V.neo 
(Peden et al, 1989) which has previously been used to immortalise human stromal cell lines 
(Cicuttini et al, 1992). The four synthetic repeats of the mouse metallothionein (MT) 
promotor present in this plasmid contain metal regulatory elements and are responsive to 
heavy metal cofactors including zinc (Zn2+) and cadmium (Cd2+). Supplementation of the 
culture medium with these cofactors (the permissive state) stimulates expression of SV40 
large T Ag gene, removing normal constraints on the cell-cycle. In the absence of Zn2+ or 
Cd2+ the basal activity of the MT promoter, and thus SV40 large T Ag expression, is barely 
detectable (Peden et al, 1989), resulting in rates of proliferation and differentiation similar to 
those of non-transfected cells.
The most commonly used techniques for introduction of DNA into recipient mammalian cells 
are calcium phosphate-DNA co-precipitation, liposomal-mediated gene transfer and 
electroporation. However, it should be noted that irrespective of the method of introduction, 
the efficiency of stable transfection is determined by the cell type used, and may vary 
between different cell types by orders of magnitude. These methods are considered below:
Method Description Pros/Cons Reference
Calcium Phosphate 
co-precipitation
Most widely used method. 




Does not work with 
all cell types.
Graham and van der 
Eb, 1973
Liposome mediated Encapsulation of DNA within Non-toxic.
liposomes which fuse with Does not interfere
the cell membrane.
Behretal, 1989




Electroporation Application of a brief high 
voltage electrical pulses to 
cells leads to formation of nm 
sized pored in plasm a 
membrane through which 
DNA is taken up.
Causes damage 
cells.
to Smithies et al, 1985
The objectives of this work were to prepare large amounts of pure plasmid DNA suitable for 
transfection, and to optimise the transfection protocols.
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Successful transfection was detected by monitoring cellular expression of SV40 large T Ag. 
A reporter plasmid, pCH llO  (Pharmacia Biotech) containing the Lac-Z gene was co­
transfected to facilitate optimisation of the transfection technique.
7.2 Results: Preliminary experiments
7 . 2 . 1  Preparation of DNA
The concentration and purity of plasmid DNA following purification using two commercially 
available kits are shown in table 7.1. The absorbance at 280 nm was equivalent to the 
protein concentration in the sample, a ratio of 1.8 represents a pure DNA sample.
Preparation Plasmid a 260/a 280 [DNA] (ng/pl)
Maxiprep Kit pMT4SV.neo 2.16 378
pMT4SV.neo 1.87 843
pCHllO 1.77 1410
Qiagen kit pMT4SV.neo 1.8 1279
pCHllO 1.8 422.5
Table 7.1 Results o f purification o f plasmid DNA from E. coli.
A substantial amount of DNA was purified. The purity of DNA extracted using a Qiagen kit 
was better than using a Maxiprep Kit.
7 . 2 . 2  Detection of SV40 large T Ag in a positive cell-line
As a preliminary investigation it was necessary to determine whether cellular expression of 
S V40 large T Ag could be detected by immunocytochemistry using the monoclonal antibody 
pAblOl. MRC5SV 1TG 1 cell cytospins (figure 7.2) stained positive for SV40 large T Ag. 
Using the same antibody expression of SV40 large T Ag was also detected in cell lysates of 
M RC5S V 1T G 1 immobilised on nitrocellulose (figure 7.3). The antigen was detected in 






Figure 7.2 Expression o f SV40 large T antigen by MRC5S V jTG  j cells
MRC5 S V 1T G 1 and CHO cells were harvested and fixed on glass slides (section 2.8.1). A FITC 
conjugated anti-mouse IgG was used to immunolocalise bound 1° antibody. Cells were counter 
stained with 0.1% ethidium bromide solution, i) Green fluorescence in MRC5 S V 1T G 1 cells 
highlights expression of SV40 large T antigen, ii) CHO cells were used as a negative control.
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Figure 7.3 Detection o f SV40 large T Ag in positive and negative cell
lysates
MG-63 cells and MRC5 S V 1T G 1 cells were lysed and soluble protein dot blotted onto a 
cellulose acetate membrane. Membranes were probed with pAblOl mAb (5 pg/ml in PBS). 
Bound antigen was detected using enhanced chem ilum inesence, and exposure to a 
photosensitive film for 30 seconds.
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7.2 .3  Electroporation of cells with plVH^SV.neo
Initial attempts to introduce plasmid DNA into BMSC by methods of calcium phosphate co­
precipitation and liposome-mediated transfection were unsuccessful. The potential of 
transfection by electroporation was therefore explored. Electroporation does not have the 
limitations of chemical treatment, and can be used for stable transfection of cell types which 
may normally be refractory to other methods. However, in preliminary investigations the 
cells subjected to electroporation did not proliferate when replated onto plastic, indicating 
that cell viability was substantially reduced using this method. It was known that for many 
cell types optimal transfection occurs at an electroporation field strength that results in cell 
death of 50% or more, so it was of importance that the conditions of electroporation were 
optimised (Andreason and Evans, 1988).
7 . 2 . 4  Optimisation of electroporation conditions
The critical factor in electroporation is the time constant. This can be altered by varying the 
four key parameters; the field strength (which is a function of the capacitance, distance 
between electrodes, and the voltage applied), the duration of the current pulse, the pulse 
shape, the conductivity of the electroporation buffer (type and volume), the DNA 
concentration and the cell concentration. It is possible to increase the time constant by 
increasing the voltage or capacitance across the cuvette or by reducing the volume of the cell 
suspension as these are directly and inversely related respectively. The equation describing 
these properties is shown below:
^ / x  Potential difference (V) _ .Time Constant (ms) = --------------------------------- x Capacitance (F)
Current (I)
Experiments were carried out varying the voltage, capacitance and suspension volume as 
above in an attempt to achieve different time constants. Experimental conditions are shown 
in table 7.4 and results in table 7.5.
Conditions Experiment
1 2 3 4
Cell type CHO MG-63 CHO MG-63
Buffer PBS PBS HBS HBS
Volume of Cell Suspension (pi) 200 500 500 500
Fixed Capacitance (pF) 125 125 250 125
Potential Difference (V) 300 200, 300 300, 350 300, 350
Plasmid (lOpg/ml total) pMT4SV.neo pMT4SV.neo pMT4SV.neo pMT4SV.neo
pCHllO pCHllO pCHllO





300 V 3.2, 3.7 u> w bo
350 V 5.8 5.3
Table 7.5 Summary of time constants resulting from the above experiments
To gauge the extent of cell poration and viability, an aliquot of electroporated cells was 
stained with propidium iodide (PI) and fluorescein diacetate (FDA). PI is only taken up by 
cells of which the cell membrane has been rendered permeable, FDA is taken up into viable 
cells by endocytosis. Uptake of the fluorescent markers was analysed by FACS analysis. 
CHO and MG-63 cells were resuspended at lxlO 7 cells/ml in HBS and electroporated as in 
section 2.11.6, with modification to the variables shown in table 7.6.
Variables Constants
volume in cuvette HBS buffer
voltage 107 cells /ml
capacitance electrode distance, 0.4 cm
Table 7.6 Properties o f electroporation
Examples of FACS analysis of viability and poration following electroporation of MG-63 
and CHO cells are shown in figure 7.7. Importantly, viable, porated cells are represented in 
the upper right quartile of the scatter plot. The FACS plots shown in figure 7.7 represent the 
same experiment as the bars indicated with an asterisk in figure 7.8, which shows the results 
of the percent poration of viable cells gained from FACS analysis overlaid with the results of 
the respective time constant attained.
Figure 7.7i demonstrates that although 8 6 % of the CHO cells were porated, only 40% of the 
porated cells remained viable. Of the MG-63 cells, 98% were porated, but again only 40% 
of the total population remained viable following electroporation. Thus, a viability of -50% 
of the cells was maintained.
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Hi, 125 HF, 400 V
Events % Total X Mean
UL 2903 58.06 4.88
UR 1964 39.28 286.07
LL 30 0.60 4.17
LR 103 2.06 819.65





Figure 7.7 Viability and poration o f CHO and MG-63 cells following
electroporation
CHO i) and MG-63 ii) cells were electroporated under the conditions of volume, capacitance 
and voltage shown. Cells were stained using the method in section 2.11.6. UL (upper left) 
quartile indicate porated, but dead cells, UR (upper right) quartile: porated, but live cells, LL 
(lower left):, non-viable unporated and LR (lower right): viable, unporated cells.
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Figure 7.8 Poration and cell viability follow ing electroporation
i) CHO and ii) MG-63 cells were electroporated under different conditions, and the time 
constant recorded. An aliquot of cells was analysed for poration and viability by FACS 
analysis. The histograms show the percentage of porated, viable cells derived from FACS 
results, plotted in the order of increasing time-constant (overlaid line-graph). The FACS data 
corresponding to the columns marked with an asterisk are shown in figure 7.7.
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Figure 7.8 shows that the most suitable conditions for electroporation of CHO or MG-63 
cells were 125 pF, 300 pi and 300 or 400 volts respectively. These conditions resulted in 
high levels of viability and poration, with a time constant of 7 ms for both CHO and MG-63 
cells. Of the variables tested, the capacitance had the greatest effect on the time constant. 
125 pF consistently produced the greatest percentage of porated cells whilst maintaining 
viability. A volume of 300 pi was found to be preferable to 500 pi, and the difference 
between 300 and 400 volts was negligible.
Following optimisation of the electroporation method with these cells, immunocytochemistry 
of SV40 large T Ag in MG-63 and CHO cell cytospins showed no fluorescence, and thus 
transfection appeared to have been unsuccessful. Even when the transfected CHO cells were 
treated with various concentrations of Zn2+ for 7 days, SV40 large T Ag was not expressed 
(figure 7.9). Similarly, cells did not survive in selection medium or express p-galactosidase 
when cells were transfected with pCHl 10 using these conditions. Further electroporations 
were carried out using the conditions established in these experiments, but without success.
7 . 2 . 5  Transfection of BMSC
Using the conditions evaluated for MG-63 and CHO cells, even though transfection had not 
been successful, an attempt was made to transfect BMSC. When transfected with reporter 
plasmid, BMSC were found to express P-galactosidase as shown in figure 7.10. However, 
negative control cells also stained blue. Thus, it could not be concluded that the peptide 
expressed by the cells was translated from the plasmid DNA.
Following transfection with pMT4SV.neo, BMSC cultures maintained for one month in the 
presence of selection medium and Zn2+, contained a mixture of cell debris and small 
spherical structures that contained densely packed cells, presumably of clonal origin (figure 
7.11). These structures were harvested, and disaggregated by repeated passage through a 
0.8 mm needle (Becton Dickinson) and then replated into 96 well microtitre plates, but none 
of the cells isolated in this way gave rise to cultures.
7 . 2 . 6  Characterisation of transfected human bone-derived cells
Despite these initial difficulties, several strains of SV40 transfected cell lines were eventually 
obtained (unpublished data; K. Stewart, N. Fairweather and C. Jefferiss). Initial 
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Figure 7.9 Lack o f  expression o f SV40 large T Ag in transfected CHO cells
Following electroporation CHO cells were cultured for 72 hours -/+ Zn^+ at various 
concentrations, then harvested and lysed. Cell lysate was loaded onto a 7.5% PAGE gel in the 
amounts shown, and blotted onto cellulose acetate. Fixed protein was probed with pAblOl 
(5(ig/ml) antibody, and bound antigen was detected using enhanced chemiluminesence, and 
exposure to a photosensitive film for 30 seconds. SV40 large T Ag was detectable in the 
positive control lane (+, MRC5SV 1TG 1 protein lysate) only.
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Figure 7.10 Positive (5-galactosidase stain in BM SC cells transfected
with pCHl lO
BMSC were electroporated with pCHl 10 and then cultured for 72 hours. Cells were fixed and 
stained with X-Gal following the protocol in section 2.11.7. Cells which stained blue were 
positive for (3-galactosidase expression. Cells were observed under a light microscope (x 100).
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Figure 7.11 Ball o f cells form ed in transfected cell cultures post­
electroporation
BMSC were electroporated with pMT4 SV.neo and then reseeded in culture. Cells were 
maintained for one month in selection medium containing G418-S, Z n -+ and C d -+. During 
this time balls of cells developed (observed at x 100 magnification). These were surrounded 
by cell debris.
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7 . 2 . 7  Cell morphology
A striking feature of these cell strains was the change in morphology and growth kinetics 
when compared to the parental cells. Initially the cells grew into clumps, or spheres, from 
which spindle-shaped cells migrated out from the dense mass (if this remained attached to 
the substratum). The cells then proliferated to form a monolayer, which became 
multilayered over 14 days. With more time in culture, the cells lost contact inhibition and 
continued to proliferate post-confluence figure 7 .1 2 .
7 . 2 . 8  Expression of SV40 large T Ag
An initial experimental requirement was to determine whether SV40 large T Ag was 
synthesised by the transformed cells, and to eliminate suggestions that spontaneous 
immortalisation had occurred, or that the cells had been contaminated with cells of a cell-line. 
A dot blot (figure 7.13) demonstrated that SV40 large T Ag expression was detected in 50 
pg total protein of cells (patient #546 transfected with pMT iSV.neo). S V40 large T Ag was 
also detected in 10 pg of MRC5SV1TG1 cells, but was not detected in SaOS-2 cell lysates. 
Thus the cells were definitively transfected with immortalising plasmid.
7 . 2 . 9  Control of SV40 expression by heavy metal control
Regulation of SV40 large T Ag expression by induction by the pMT promotor was 
established by culturing the transfected cells in the absence or presence of 200 pM ZnCl2 
and/or 1 pM CdCl2. When compared with extracts prepared from the control cell-line 
(SaOS-2), the expression of SV40 large T Ag was barely detectable in cells cultured in 
control medium (figure 7.14). The addition of Zn2+ or Cd2+ resulted in a significant 
increase in SV40 large T Ag expression, which was increased further when both agents 
were added in combination. The amount of protein synthesised was greater than that of cells 
transfected with pSV3.neo in which expression of SV40 large T Ag is controlled by a wild 
type promotor and is therefore constitutive.
Treatment pM TiSV.neo pSV .neo +
Mg2+ Zn2+ Cd2+ Zn/Cd
Relative OD (T/C) 1 18 26 46 27 67 0
Table 7.15 SV40 large T Ag expression after treatment with heavy metals
Relative optical density (OD) of bands on western blot in figure 7.10, compared 
when OD of control (200 pM MgCl2) treated cells = 1.
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Figure 7.12 Growth o f cells transformed with SV40 large T antigen.
Trabecular cells from patient #546 were transfected with pM TiSV.neo. Cell cultures were 
maintained in medium supplemented with G418-S, Zn^+ and Cd~+. After 6  weeks cells began 
to proliferate and formed cell monolayers with areas of cells at high density. In a few cultures 
cells became multilayered and formed nodule-like structures (as seen in the photograph). The 
culture was observed under a light microscope at x 1 0 0  magnification.
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Total protein (|ig) 5 10 50 100 5
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SV40 large T Ag
Figure 7.13 Detection o f SV40 large T Ag in human HBDC transfected with pMTj SV. neo
Various amounts of protein of #546 cells transfected with pMTiSV.neo (transfected cells), SaOS-2 (negative control) and MRC5S V 1T G 1 (positive control) 
whole cell lysates were applied onto cellulose acetate membrane. Antigen was immunolabelled with anti-SV40 large T Ag and bound antibody was detected 
by enhanced chemiluminesence and exposure to a photoreactive film for 30 seconds. SV40 large T Ag was detectable in 50 pg of the transfected cells lysate, 
and 1 0  pg of the positive cell line.
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Figure 7.14 Detection o f SV40 large T Ag in transfected human HBDC
#546 cells transfected with pM TiSV.neo were cultured in the presence and absence of 200 pM ZnCl2 and/or 1 pM CdCl2 for 7 days. Control cells were 
treated with magnesium chloride (200 pM). These cells and pSV3 .neo transfected cells were harvested and lysates prepared. 50 pg protein was separated on a 
PAGE gel and fixed onto cellulose acetate membrane by western blotting. Antigen was immunolabelled with pAblOl, and bound antibody was detected by 
enhanced chemiluminesence. SV40 large T Ag was detected in conditionally immortalised cells treated with heavy metals and cells immortalised with plasmid 
containing the wild type promotor, and the positive control cell line (MRC5 SV 1TG 1). The antigen was not detected in the negative cell line (SaOS-2).
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The intensities of the SV40 bands demonstrate numerically an increase in antigen expression 
through Zn2+ and Cd2+ treatment and a co-operative response when cells were treated 
simultaneously with the two factors.
7 . 2 . 1 0  Alkaline phosphatase expression and mineralisation
The ability of the transfected cells to express AP and deposit mineral was investigated in 
cultures treated with or without Dx. AP was expressed in all cultures which had been treated 
with Dx (an indicative culture is shown in figure 7.16) irrespective of the presence of heavy 
metal cofactors. In these cultures, Fast-red TR stain was localised to areas of high cell 
density. These areas also contained mineral deposits as demonstrated by von Kossa 
staining.
7 . 2 . 1 1  Characterisation of osteoblastic lineage markers AP and STRO-1
Cell surface expression of STRO-1 and AP was inspected by dual fluorescent staining and 
FACS analysis on cells cultured with or without Dx. The FACS histograms representative 
of the results of #546 pMTiSV.neo (passage 6 ) shown in figure 7.18 are also summarised 
in table 7.17.
Surface expression Effect of Dx 
Transfectant Passage # STRO-1 AP STRO-1 AP
546pM TiSV.neo 6 * ****** + ++
546pM TiSV.neo 11 * * + +
Table 7.17 Summary of STRO-1 and AP expression of immortalised human
bone cells.
Analysis by FACS revealed that the pMTiSV.neo transfected cells (#546) expressed STRO- 
1 and AP on their cell surfaces, and these were recognisable by the monoclonal antibodies 
post-transfection. Only low levels of STRO-1 were detectable. At passage 6 , pMTiSV.neo 
expressed AP in abundance. However, AP expression decreased with an increase in 
passage number. Treatment with Dx increased surface expression of STRO-1 and AP, 
although this had a greater affect on AP expression at passage 6  than 11.
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Figure 7.16 AP expression and mineral deposition in cells transfected with
p M T  jSV.  n eo
#564 cells transfected with pMTiSV.neo were cultured in medium containing Z n -+ and C d -+ 
and treated without (i) or with (ii) Dx for 5 days. Cultures were then fixed with NBF and 







Figure 7.18 Expression o f  STRO-1 and AP on 11546 pM TiSV.neo cells
#546 pMTiSV.neo cells (passage 6) were treated in the absence or presence (-/+) and without 
Dx (-) for 5 days. Cells were dual stained with STRO-1 (i) and B4-78 (ii), and labelled with 
RPE and FITC conjugated secondary antibodies. An isotype control antibody was used as a 
negative control (IC). The cells expressed both STRO-1 and AP antigens on their surfaces.
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7.3 Discussion
Investigation of bone marrow stromal cells in culture is limited by their inherent tendency to 
differentiate and/or become senescent after a limited number of population doublings. It was 
therefore considered advantageous to immortalise primary BMSC and generate cell lines. 
After much trial and error, adherent cells derived from human bone marrow stroma were 
successfully transformed with SV40 large T Ag present in a conditionally regulated plasmid. 
These were selected in medium containing G418-S and have now undergone twelve 
passages post-transformation. To date nine lines have been transformed.
Initial attempts showed the marrow-derived cells to be resistant to transfection using calcium 
phosphate and Lipofectamine. In retrospect, the difficulties experienced early on were 
probably due to the age of the patients from whom the marrow samples were taken. The 
samples used were derived from a female donor of 57 years, and two males of 63 and 74 
years. BMSC from these donors grew slowly (visual observation), and were in culture for 
6 -8  weeks compared to the usual 4-6 in order to generate sufficient cells for transfection. In 
addition these donors were diagnosed as having lung cancer, and it has been shown recently 
(Chasseing et al, 1997) that this is associated with a significant reduction of CFE and 
proliferation of BMSC in vitro. The success of these methodologies is dependent on the 
cells actively dividing to ensure expression of the SV40 large T Ag. Consistent with the age 
and underlying pathology of the original donor being confounding factors, the cultures that 
were successfully transformed were derived from younger male patients (#546 was 15 years 
old, and #532 was aged 56) who were not suffering from any form of malignancy.
Another factor which may have hampered the transfection efficiency may have been an 
abundance of extracellular matrix in these cultures. The highly negative charge of DNA may 
have resulted in binding to polypeptide moieties in the extracellular matrix, reducing its 
availability for transferral into cells. To limit this effect, adherent cultures were treated with 
collagenase prior to transfection, and cell suspensions were washed thoroughly before 
electroporation. The absence of S V40 large T Ag expression after transfection of MG-63 
and CHO cells, however, remains baffling. Either the plasmid DNA did not enter the cells, 
or SV40 large T Ag was not expressed by the cells. It was recently observed however, that 
MG-63 cells behave in an unpredictable manner following transfection, failing to express 
SV40 large T Ag when transfected with immortalising plasmids alone or co-transfected with 
a reporter construct (J. Hodgekinson and P. Sharpe, unpublished data; A. Grigoriadis, 
personal communication). Expression of |3-galactosidase by negative control mesenchymal 
cells (nontransfected cells) is suggested to be due to a high incidence of senescent cells in 
these cultures which were derived from elderly donors. Senescent human mesenchymal 
cells are known to express a novel form of p-galactosidase (Dimri et al, 1995).
165
Characteristic changes were observed in cells transformed with SV40 large T Ag. On 
observation by microscopy, the cells had altered growth characteristics, their morphology 
changed from spindle-shaped to an epithelial-like cell morphology, and they were noticeably 
reduced in size. Contact inhibition of the cells was lost, and when confluence was reached 
the culture became multilayered. These are all reported characteristics of immortalised cells 
cultured in vitro (Darnell et al, 1986). Additionally, the proliferation rate of the cells was 
much increased, the cells required passaging at three day intervals, rather than the usual 1-2 
weeks required in non-transformed BMSC cultures.
On primary analysis, these cells had an phenotype similar to osteoprogenitor cells with an 
ability to express AP and STRO-1, and deposit a mineralised extracellular matrix in response 
to Dx treatment. AP expression also appeared to be induced by increased cell density. 
Expression of S V40 large T antigen was controllable by the addition of Zn2+ and/or Cd2+ to 
the culture medium, and the proliferation rate was noticeably reduced in cultures maintained 
in the absence of cofactors. Future investigation requires identification of the characteristics 
of the cells cultured in the absence or presence of cofactors.
These cell lines are presently strains. Due to the nature of the experimental protocol and the 
inherent multipotential properties of CFU-F, cells from a number of heterogeneous colonies 
were pooled and transformed as a single population. Thus the lineage, age and 
differentiation state of the cell, or indeed the number of different cells, that was/were 
transformed is unknown. In essence, these cultures are expected to consist of a 
heterogeneous population. It is thought that the cultures will metamorphose with an increase 
in passage number. With time in culture, cells of a particular phenotype and possibly a 
greater proliferative potential, may become dominant. Also, the dominant phenotype may 
change with passage number due to differentiation, de-differentiation, or as a result of other 
culture conditions such as cell density or presence of growth factors. Once the in vivo 
potential of the cells to form mineralised tissue has been determined, and the multipotentiality 
of each of the lines investigated, the cells will be cloned in the hope of obtaining a 
mesenchymal cell lines that differ in their potential for proliferation and differentiation.
Conditional immortalisation has been successfully used to develop several osteoblastic cell 
lines. These include lines from BMSC primary cultures derived from the iliac crest (Hicock 
et al, 1998) and rib (Houghton et al, 1998), and from osteoblasts derived from human foetal 
trabecular bone (Harris et al, 1995) and from elderly donors (Bodine et al, 1996). Two of 
these lines are reported to be bipotential with the ability to differentiate into osteoblasts or 
adipocytes under specific culture conditions (Hicock et al, 1998, Houghton et al, 1998). 
However, all of these lines were immortalised with a gene coding for a temperature-sensitive 
(ts) mutant of SV40 large T antigen which is expressed at a permissive temperature of 34°C.
166
The return to a nonimmortalised state can be induced by incubating the cells at a restrictive 
temperature of 39.5°C. Temperature sensitive immortalisation thus has practical 
complications as multiple incubators are required to maintain and manipulate these lines.
In future studies it will be of importance to fully characterise the transfection effects in terms 
of the cells ability to undergo osteogenic differentiation and to give rise to cells of other 
marrow stromal cell lineages in both the absence and presence of inducers. Various stage 
and lineage specific markers such as CBFA-1, a potential genetic marker of osteoblastic 
commitment and differentiation (Ducy et al, 1997), collagen type I, STRO-1, BSP, PTHR1 
and OC could be measured as an indication of the osteogenic potential of the cells. It will be 
necessary to observe the proliferation rate and the total number of passages which the cells 
undergo as an indication of an increased cellular life-span, and to observe whether the cells 
return to a pretransformed state on the removal of cofactors. Alternatively the capacity of the 
cells to form bone in vivo could be investigated through implantation into ceramic carriers 
and placement into a recipient animal. This has the added advantage of providing a local 
environment that is more permissive and physiological and likely to give a more accurate 
impression of the cells potential to proliferate and differentiate in vivo. Identification of 
strains or lines capable of providing support for haematopoiesis could be evaluated in open- 
transplant assays such as described by Krebsbach et al (1997). In summary, these studies 
have validated the use of plasmids expressing SV40 large T antigen under the control of an 
inducible promoter to generate strains of BMSC from adult human bone marrow. Although 
at an early stage, it is anticipated that this work will lead to the development of marrow 
stromal cell lines applicable to the identification of the factors that regulate lineage 
commitment expansion and maturation and to the elucidation of the changes in gene 
expression that accompany these events.
Transfected cells do not grow indefinitely, however, despite the continued expression of 
SV40 large T Ag, and after a certain number of cell divisions the cells enter crisis (Price et 
al, 1994). In human cells, in contrast to rodent cells, immortalisation is inefficient and viral 
genes such as SV40 large T Ag are capable only of reliably extending the lifespan amounting 
to 20-60 population doublings post-transfection (Boulanger and Blair, 1991, Shay and 
Wright, 1991). During crisis, cell growth is balanced by cell death, as cells lose viability as 
they attempt to divide. Continued expression of S V40 large T Ag and at least one mutational 
event is required for cells to exit crisis and become immortal (Shay and Wright, 1989). To 
date, although transformed, the cells described in this study have not yet passed through 
crisis and are therefore not yet truly immortalised.
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However, it is thought that the phenotype of transformed cells pre-crisis is more akin to that 
of normal cells (Spelsberg et al, 1995) and phenotypic characterisation should be carried out 
prior to crisis where possible. Post-crisis, however, it is suggested that immortalised cells 
continue to be reversibly controlled by SV40 large T Ag inactivation (Wright et al, 1989), 
and immortalisation does provides cells of reduced phenotypic variation, and of indefinite 
lifespan.
This methodology provides a useful tool to study the differentiation of mesenchymal cells. 
Transformation of a heterogeneous marrow cell population in vitro could result in 
immortalisation of progenitor cells at different levels of differentiation and maturity, 
including multipotential stem cells. Cloning a range of cell phenotypes could form a library 
of cells, and gene expression banks at various levels of osteogenic commitment and 
differentiation. Secondly, investigation of phenotypic and genotypic alterations during 
differentiation has become possible through transfection of plasmids which conditionally 
immortalise cells and are extracellularly inducible enabling regulation of proliferation rates 
and differentiation. Use of these plasmids would also allow investigation of factors that may 
influence commitment to, and differentiation through, the osteogenic lineage.
Ultimately, transformation of foetal stem cells will unveil the potential for understanding the 
derivation of mesenchymal cells in the body. This will also enable evaluation of switching 
between the various lineages, establishment of control over the differentiation pathway of the 
cells, and investigation of the effects of ageing in health and disease. In the near future it is 
of interest to immortalise a STRO-1'/AP- population, or a non-adherent population, which 






It is now well established that bone marrow serves as a repository for osteoblast precursors 
in the adult. Currently there is considerable interest in these cells as: a) a target for 
therapeutic intervention in vivo in the prevention or treatment of osteoporosis, and b) as a 
source of autologous cells for tissue reconstruction or wound repair following their 
expansion in vitro. For either approach to become a reality there is a need to identify the 
factors that regulate the size and developmental potential of this precursor population, and to 
understand how their number and activity are influenced by gender and age. This work has 
focused on the use of in vitro culture of human marrow stromal cells to evaluate some of 
these issues.
At the outset of this work two important assumptions were made based largely on the 
pioneering work of Friedenstein (1980, 1990): a) that osteogenic precursors are present 
within the CFU-F population of human bone marrow, and b) that the expression of alkaline 
phosphatase by cells within a colony is indicative of the onset of osteogenic differentiation 
(Aronow et al, 1990, Owen et al, 1990). Over the course of these experiments, it became 
apparent that the technical ease with which cultures of marrow stromal cells can be 
established from adult human bone marrow belies the biological complexity of the model. 
One of the major limitations is the reliance on a purely functional readout i.e. colony 
formation, to assess the marrow content of CFU-F. It quickly became apparent that 
relatively small changes in conditions of culture could dramatically alter the CFE of marrow 
cell suspensions, indicating that for a given set of culture conditions only a subset of CFU-F 
are being detected using this approach. It also became apparent that colony forming potential 
persists in the non-adherent subpopulation of cells for several days post-explantation, 
whereas the results of previous investigation had suggested that essentially 100% of CFU-F 
will adhere within 24 hours of their explantation (Friedenstein, 1971, Castro-Malaspina et 
al, 1980). It is as yet unknown whether the clonogenic cells in the non-adherent 
subpopulation represent a different class of CFU-F, or simply cells earlier in the 
developmental hierarchy than CFU-F. There is an urgent need to distinguish between these 
possibilities and to determine their developmental potential, and to identify the factors that 
regulate their transition from the non-adherent to the adherent state.
An attempt was made to standardise the conditions of isolation and culture of bone marrow 
stromal cells and to optimise CFE, but this was unsuccessful due largely to the existence of 
substantial inter-donor variation which was not obviously attributable to the donor age or 
sex. Recent drug history may have been an important factor, and at an early stage donors 
receiving high dose glucocorticoid therapy were excluded. Towards the end of the 
investigation, it also became apparent patients with lung cancer have depressed colony 
forming potential (Chasseing et al, 1997), a factor that was not anticipated at the start of this 
investigation and one which must be considered in the future.
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A first step towards circumventing some of the difficulties described would be to utilise 
immunochemical as well as functional criteria to assay CFU-F. A number of antibodies 
have been developed recently that appear to recognise primitive osteogenic precursors and/or 
CFU-F (STRO-1, HOP-26, MUC18). Ideally, these would be used in combination to assay 
'potential' CFU-F in the original cell population and in the adherent and non-adherent 
subpopulations at different times post explantation. The observed number of colonies 
formed under any given set of culture conditions could then be expressed as a percent of the 
theoretical maximum calculated from the immunochemical data. In the experiments 
described this would have enabled a rational approach to the optimisation of isolation and/or 
culture conditions for CFU-F as it would then be possible to track the fate of the precursor 
cells.
It is evident from this investigation that there is still much to learn regarding the basic 
biology of the marrow stromal cell system. For example, it is currently unknown whether 
CFU-F numbers are the same or different at different skeletal sites, and this may influence 
the design of protocols for their harvest and/or ex-vivo expansion. There is also evidence 
that the behaviour of cells of the osteoblastic lineage at different sites does differ (Marie et al, 
1992, Marie and De Vemejoul, 1993, Kasperk et al, 1995, Aerssens et al, 1997). In this 
context, it was noticed that during the course of the experiments described, despite the use of 
conditions known to support the differentiation of adipocytes, adipogenesis was never 
observed in rib-derived marrow stromal cell cultures, although it was observed in cultures 
derived from the femur or femoral head. This represents further, albeit circumstantial 
evidence that there exist real differences in the developmental potential of marrow stromal 
cells at different skeletal sites, and in future studies the experimental design should reflect 
this.
The results of this investigation provide additional evidence for an important influence of 
cells in the non-adherent population, presumably haematopoietic in origin, on the adhesion 
and proliferation of stromal precursors in the early stages of culture. In the literature both 
positive and negative influences have been reported, although the cells types responsible and 
the factors they produce remain poorly characterised. Although few antibodies are as yet 
available for identification and separation of stromal precursor cells, many are available for 
cells of the haematopoietic lineage, and have been used extensively to separate cells within 
this population. To evaluate the interactions between haematopoietic and CFU-F in vitro, 
and identify key cells types which affect the stromal cell component, colony forming 
experiments could be performed in which specific immune cell subsets could be selectively 
depleted from BMSC using antibodies directed against CD antigens. The validity of this 
approach has been demonstrated recently (Hurley et al, 1995, Waller et al, 1995, Rickard et 
al, 1996). Alternatively, in reconstitution experiments specific immune cell subsets could be
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added back to cultures of highly enriched CFU-F populations to observe their effects, alone 
or in combination, on growth and differentiation.
Another contributing variable in the colony forming assays described here is the presence of 
serum in the culture medium. An increase in colony formation normally accompanies an 
increase in percent serum, although significant batch to batch variation has been reported to 
occur with foetal calf serum (Aronow et al, 1990, Tsuji et al, 1990). This was a problem 
that was taken into account at the outset of this work, and all experiments were conducted 
using serum from only two batches that were selected for their ability to support colony 
formation from isolates of human bone marrow. However, use of different sera makes the 
comparison of data generated in different laboratories at best difficult, and at worst 
sometimes of little real value. The use of serum-free medium would avoid this problem, but 
it is currently not possible to obtain complete osteogenic differentiation in the absence of 
serum. Some progress has been made in identifying serum-free conditions that will support 
the ex -vivo expansion of adult human marrow stromal cells (Gronthos and Simmons, 1995, 
Kuznetsov et al, 1997), but their developmental potential has not been reported.
For autologous marrow stromal cell therapy to become a reality, it will be necessary to 
identify factors that promote their expansion ex-vivo in the shortest possible time without 
altering their potential for osteogenic differentiation. The results of this investigation suggest 
that PDGF fulfils this criteria, and that it is effective in the absence and presence of Dx. 
Additional and more rigorous studies will be required to confirm this possibility, including a 
more detailed assessment of the resulting cell populations' potential for osteogenic 
differentiation in vivo.
It is apparent from this investigation that before further attempts are made to elucidate the 
cellular mechanisms responsible for the decline in osteoblast numbers in osteoporosis, it will 
be necessary to establish baseline parameters for the normal population in relation to the age, 
sex and hormonal status of the donors. Ideally this would be achieved using marrow 
obtained from a clinically relevant site (hip or spine) using both immunochemical and 
functional criteria to determine its content of CFU-F and their developmental potential. In 
addition, for each donor, whole body and regional estimates of bone mineral density should 
be obtained as well as urine and serum samples for the analysis of biochemical markers of 
bone turnover. Once this information had been accumulated it would be possible to conduct 
meaningful studies on the population dynamics of the marrow stromal system in 
osteoporosis and in response to therapy.
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A major objective of future studies should be the determination of the precise number and 
hierarchy of marrow stromal cell lineages. This is important because a major contributing 
factor in the development of osteoporosis may be an imbalance between differentiation of 
osteoblasts and cells of other marrow stromal cell lineages, in particular adipocytes. It is in 
this regard that the conditionally immortalised marrow stromal cell strain will have their 
greatest utility. It will be necessary first to evaluate the developmental potential of the 
different strains in vivo. An attempt should then be made to clone from those strains with 
the greatest developmental potential, mono-, bi- or tri-potential cell lines. These would then 
be used to establish the interrelationships between cells of different marrow stromal cell 
lineages and the extent to which interchange can occur between them.
The utility of the conditionally immortalised lines would not be limited to the definition of the 
number and hierarchy of marrow stromal cell lineages. An additional application would be 
the generation of a panel of monoclonal antibodies recognising lineage and differentiation- 
stage specific cell surface antigens. These would prove invaluable in the diagnosis of 
skeletal disorders and in monitoring the response of cells of the marrow stromal system to 
therapy. They would also enable conditions of culture to be optimised for the ex-vivo 
expansion of cells of defined developmental potential and the enrichment of specific cell 
populations prior to re-implantation.
The conclusions drawn from this study indicate that an enormous amount of ground work is 
necessary to lead to a greater understanding of these cells and their development. The 
process of osteoblastic commitment, expansion and maturation remains highly complex and 
much research is necessary to elucidate the sequence of events leading to osteopenia, and 
ultimately to develop methods for treatment or prevention of osteoporosis.
In summary, the need to develop new therapeutic treatments for the prevention and treatment 
of osteoporosis and the potential of using ex-vivo expanded cells for tissue reconstruction 
and gene therapy make compelling arguments for continuing to study the stromal system of 
bone and marrow. Much work is still required, however, before these goals are realised.
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Appendix I
Preparation of culture solutions and reagents
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Cell culture
1 x DMEM (Dulbecco's Modified Eagle's medium (product # 52100-021) was prepared by 
mixing the following:
This was made up to 1 litre with milli-Q water (Millipore Ltd., U.K.) and adjusted to pH 7.2 
with fresh 5 M sodium hydroxide before it was sterilised by filtration. It was then aliquotted 
into 500 ml autoclaved bottles and stored at 4°C for a maximum of two weeks. All tissue 
culture stocks were supplied by Gibco BRL.
Foetal calf serum (FCS) supplement was obtained from Globepharm, U.K. (batch #2704) 
or Sigma Chemical Company (lot #105 H3350). Serum was heat inactivated at 56°C for 30 
mins prior to use, sterilised by filtration and stored in 50 ml aliquots at -20°C.
A 10 mg/ml solution of L-ascorbic acid, sodium salt (Sigma) was prepared fresh in serum- 
free DMEM and filter sterilised.
A 10 mg/ml stock solution of L-ascorbic acid 2-phosphate (magnesium salt n-Hydrate, 
Wako Pure Chemical Industries Ltd.) was prepared in serum-free DMEM and filter 
sterilised. ASP was stored frozen in small aliquots at -20°C. Once thawed ASP was kept 
for up to two weeks at 4°C.
Phosphate buffered saline (calcium and magnesium free, Oxoid). Ten PBS tablets were 
dissolved in 1 litre of milli-Q water. The solution was adjusted to pH 7.2, autoclaved at 
115°C for 10 mins and allowed to cool to room temperature before use.
10% (v/v) neutral buffered formalin (NBF) was made up by dissolving 100 ml 
formaldehyde, 16 g Na2HPC>4.12H20 and 4 g NaH2P0 4 .2 H2 0  in 1 litre of distilled water.
0.1 M Tris buffer was prepared by dissolving 12.1 g Tris in 1 litre of distilled water. The 
pH was adjusted to pH 8.2 with 5 M HC1.
5 mM inorganic phosphate (Pi) solution was prepared as a 0.01% (v/v) mixture of a 4:1 
(v/v) ratio of 500 mM Na2HP04.12H 20: 500 mM N aH 2P04.2H 20. The solution was 
adjusted to pH 7.4 with fresh 1 M NaOH and filtered.










25 IU/ml: 25 pg/1
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A  0.1% (w/v) toluidine blue O solution was prepared in 30% (v/v) ethanol.
Borate buffer was prepared by titrating a 10 mM sodium borate solution, prepared in milli-Q 
water, with 10 mM boric acid to pH 8.8.
1% (w/v) methylene blue was prepared in 10 mM borate buffer, pH 8.8.
Protein Determination
Nonidet P-40 buffer was made up by dissolving 150 mM NaCl, 1% (v/v) NP-40 and 50 
mM Tris in PBS. The solution was adjusted to pH 8.0 with fresh 1 M NaOH.
A 25 x stock protease inhibitor solution was prepared according to the manufacturers 
instructions (Complete™ Protease Inhibitor Cocktail Tablets, Boehringer Mannheim). One 
tablet was dissolved in 2 ml milli-Q water. 100 pi aliquots were stored at -20°C for up to 1 
month.
20 g of sodium hydroxide pellets were dissolved in 50 ml milli-Q water to make a 10 M 
solution.
Growth factors
Serum-free medium was made up by adding 500 pg/ml BSA-linoleic acid (BLA), 200 ng/ml 
sodium selenite (NaS) and 5 pg/ml human apo-transferrin (APO-T) to serum-free DMEM.
1.25-dihvdroxvvitamin (334 pM stock, gift from Roche, Welwyn Garden City) was 
stored at -70°C under an atmosphere of nitrogen. This was diluted 5 pi in 167 pi of DMEM, 
and added to serum-free medium at 1 in 1000 dilution (10-8 M final concentration).
Immunocvtochemistrv
FACS wash buffer was prepared with 10 mM HEPES and 5% FCS in Hanks Balanced salt 
solution adjusted to pH 7.35 with 1 M HC1.
Blocking buffer: 10% (v/v) normal human serum and 1% (w/v) BSA were diluted and 
dissolved in FACS wash buffer.
FACS fix was prepared as 2% (v/v) paraformaldehyde in FACS wash buffer.
0.1% (w/v) saponin was dissolved in FACS wash buffer.
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Western Blot solutions




2 x Protein sample loading buffer was prepared with the following reagents in milli-Q water 
and adjusted to pH 6.8. It was stored in 0.5 ml aliquots at -20°C for up to 6 months.
4 x 0.5 M Tris-Cl (pH 6.8) 0.125 M




Towbin Transfer buffer was prepared with the following reagents in milli-Q water and 





0.025% (w/v) Coomassie Brilliant blue R 250 was dissolved in 40% (v/v) methanol and 7% 
(v/v) acetic acid in milli-Q water.
Destaining solution was 40% (v/v) methanol and 7% (v/v) acetic acid in milli-Q water.
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Preparation of cDNA





High salt buffer 




25 mg/ml suspended in a storage buffer containing 
0.15% Kathon ® CG.
Buffered aqueous solution of guanidium thiocyanate 
and N-lauroyl sarcosine.
10 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.5 M NaCl 
10 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.1 M NaCl 
Glycogen at 5-10 mg/ml in DEPC-treated water. 
2.5 M potassium acetate (pH 5.0)
10 mM Tris-HCl (pH 7.5), 1 mM EDTA
DEPC-treated water was prepared as a 0.1% (v/v) solution of diethyl pyrocarbonate (DEPC) 
in distilled water. It was allowed to stand overnight at room temperature and then 
autoclaved, and allowed to cool before use.
Wash buffer was 1% (v/v) Tween-20 in PBS.
20 x SSC was prepared by dissolving 175.3g NaCl and 88.2g Na Citrate in 800 ml milli-Q 
water, adjusted to pH 7.0, then made up to 1 litre and autoclaved.
Blotto was prepared with 5% (w/v) non-fat milk powder, 1% (w/v) goat serum and 1% 
(v/v) Tween-20 in PBS.
Prehybridisation solution was a mixture of 6 x SSC and 0.05% (v/v) Blotto in milli-Q water.
Hybridisation buffer was a mixture of 6 x SSC and 0.5 % (w/v) SDS in milli-Q water.
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DNA methods
The contents of the DNA isolation kit included:
Cell Resuspension solution 50 mM Tris-HCl, pH 7.5 
10 mM EDTA 
100 pg/ml RNase 
2 mM NaOHCell Lysis solution
0.1% SDS
Neutralisation solution (pH 4.8) 2.55 M Potassium Acetate
TE buffer (pH 7.3) 10 mM Tris-HCl
1 mM EDTA
Column Wash solution (pH 7.5) 200 mM NaCl
20 mM Tris-HCl 
5 mM EDTA
Diluted 1:1 with 95% ethanol prior to use.
10 x TAE buffer (Tris-acetate final concentration was 0.04 M, pH 8.3) was prepared by 
mixing 48 g Tris base and 11.42 ml Glacial acetic acid in 20 ml 0.5 M EDTA (pH 8.0) 
solution:
5 x DNA loading dye was prepared with the following reagents in milli-Q water:
















This solution was then sterilised through a 22 pm filter.
Solutions used for ft-galactosidase staining were:
Phosphate buffered Saline (pH 7.3) Sodium Chloride 150 mM
Sodium Phosphate 15 mM
Fixative Solution Glutaraldehyde 1%
MgCl2 1 mM
Sodium Phosphate 0.1M







Statistical analyses of ageing data
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The following tables of Spearmans rank correlation coefficient analyses indicate the 
influence of age on BMSC colony formation and proliferation. The data for these analyses 
are described in chapter 6, and the graph to which the table relates is stated in parentheses.
Analyses of CFE
A nalysis 1.1 Donor age vs total (i) and AP (ii) colony form ation - Dx
(figure 6.2)
i)   ii) __________
Sum  of Squared D ifferences 19091 .500 Sum  of Squared D ifferences 718 8 .0 0 0
Rho .136 Rho .213
Z-Value .963 Z-Value 1.299
P-Value .3358 P-Value .1941
n 51 n 38
critical value (a1) .2329 critical value (a1) .2710
A nalysis 1.2 Donor age vs total (i) and AP (ii) colony form ation + Dx
(figure 6.2)
i) ii)
Sum  of Squared D ifferences 12084 .500 Sum  of Squared D ifferences 640 0 .0 0 0
Rho .088 Rho .176
Z-Value .567 Z-Value 1.043
P-Value .5705 P-Value .2969
n 43 n 36
critical value (a1) .2543 critical value (a1) .2788
Analysis 2.1 Male (i) and female (ii) donor ages vs total colony
form ation - Dx (figure 6.3)
i) ii)
Sum  of Squared D ifferences 4 6 29 .500 Sum  of Squared D ifferences 1428 .000
Rho .293 Rho .194
Z-Value 1.681 Z-Value .888
P-Value .0927 P-Value .3748
n 34 n 22




Male (i) and female (ii) donor ages vs AP+ colony
form ation in - Dx (figure 6.3)
ii)
Sum  of Squared D ifferences 8 1 4 .0 0 0 Sum  of Squared D ifferences 420 .500
Rho .002 Rho .382
Z-Value .010 Z-Value 1 .478
P-Value .9922 P-Value .1394
n 17 Rho corrected for ties 16
Critical value (a2) .4877 Tied Z-Value .5029
A nalysis 2.3
i)
Male (i) and female (ii) donor age > 50 years vs total
colony form ation - Dx (figure 6.3)
ii)
Sum  of Squared D ifferences 3 2 5 2 .5 0 Sum  of Squared D ifferences 440 .00
Rho .28 Rho .21
Z-Value 1.49 Z-Value .80
P-Value .1366 P-Value .4227
n 30 n 15
Critical value (a2) .3624 Critical value (a2) .5214
A nalysis 2.4 Male (i) and female (ii) donor age > 50 years vs AP+
colony form ation - Dx (figure 6.3)
ii)
Sum  of Squared D ifferences 1318 .50 Sum of Squared D ifferences 326 .50
Rho .01 Rho .42
Z-Value .04 Z-Value 1.56
P-Value .9699 P-Value .1187
n 20 n 15
Critical value (a2) .4466 Critical value (a2) .5214
Analysis 3.1
i)
Male (i) and female (ii) donor ages vs total colony
form ation + Dx (figure 6.4)
ii)
Sum  of Squared D ifferences 2 7 1 8 .0 0 0 Sum of Squared D ifferences 60 2 .000
Rho .256 Rho -.075
Z-Value 1.331 Z-Value -.281
P-Value .1832 P-Value .7790
n 28 n 15
critical value (a2) .3755 critical value (a2) .5214
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Analysis 3.2 Male (i) and female (ii) donor ages vs AP+ colony
form ation + Dx (figure 6.4)
ii)
Sum  of Squared D ifferences 1333 .500 Sum  of Squared D ifferences 4 2 6 .0 0 0
Rho .134 Rho .239
Z-Value .600 Z-Value .895
P-Value .5487 P-Value .3706
n 21 n 15
Critical value (a2) .4364 Critical value (a2) .5214
A nalysis 3.3 Male (i) and female (ii) donor age > 50 years vs total
colony form ation + Dx (figure 6.4)
ii)
Sum  of Squared D ifferences 1951 .500 Sum  of Squared D ifferences 4 3 1 .0 0 0
Rho .152 Rho .053
Z-Value .727 Z-Value .190
P-Value .4674 P-Value .8492
n 24 n 14
Critical value (a2) .4070 Critical value (a2) .5385
Analysis 3.4 Male (i) and female (ii) donor age > 50 years vs AP+
colony form ation + Dx (figure 6.4)
ii)
Sum  of Squared D ifferences 1258 .000 Sum  of Squared D ifferences 2 7 6 .0 0 0
Rho -.104 Rho .393
Z-Value -.439 Z-Value 1.418
P-Value .6606 P-Value .1561
n 19 n 14
Critical value (a1) .3912 critical value (a2) .5385
Analyses of pro liferation  
Analysis 4.1
i)
Ages of all donors vs BMSC pro liferation  trea ted  - (i) or
+ (ii) Dx (figure 6.5)
ii)
Sum  of Squared D ifferences 4968 .500 Sum of Squared D ifferences 5 0 3 3 .0 0 0
Rho -.105 Rho -.240
Z-Value -.567 Z-Value -1 .268
P-Value .5705 P-Value .2047
n 30 n 29




Comparison of male (i) and female (ii) donor age with
cell p ro liferation  -Dx (figure 6.6)
ii)
Sum  of Squared D ifferences 1650 .000 Sum  of Squared D ifferences 230 .000
Rho -.241 Rho -.394
Z-Value -1 .049 Z-Value -1 .182
P-Value .2943 P-Value .2373
n 20 n 10
critcal value (a2) .4466 critical value (a1) .5636
Analysis 5.2 Com parison of male (i) and female (ii) donor age with
proliferation + Dx (figure 6.6)
ii)
Sum  of Squared D ifferences 1974 .500 Sum  of Squared D ifferences 184.000
Rho -.282 Rho -.533
Z-Value -1 .262 Z-Value -1 .508
P-Value .2070 P-Value .1314
n 21 n 9
critical value (a2) .4364 critical value (a 1 ) .6000
Analysis 5.3 Male (i) and female (ii) donor ages > 50 years vs cell
p ro lifera tion  -D x(figure 6.6)
ii)
Sum  of Squared D ifferences 7 3 7 .500 Sum  of Squared D ifferences 86.000
Rho -.085 Rho -.536
Z-Value -.327 Z-Value -1 .312
P-Value .7433 P-Value .1894
n 16 n 7
critical value (a2) .5029 critical value (a1) .7143
A nalysis 5.4 Male (i) and female (ii) donor ages > 50 years vs cell
p ro liferation  + Dx (figure 6.6)
ii)
Sum  of Squared D ifferences 1323 .000 Sum  of Squared D ifferences 40 .0 0 0
Rho -.365 Rho -.143
Z-Value -1 .506 Z-Value -.319
P-Value .1320 P-Value .7494
n 18 n 6
critical value (a2) .4716 critical value (a2) .8857
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The following tables show results of Mann-Whitney U comparisons and demonstrate the 
influence of donor gender (+/- Dx) independent of the influence of age on colony formation 
and proliferation. The data for these analyses are described in chapter 6, and the graph to 
which the table relates is stated in parentheses. Comparisons resulting in significant 
differences where p < 0.0500 have been italicised.
A nalysis 16 The effect of Dx treatm ent in a cohort study of total and
AP colony form ation (figure 6.7)
Comparison U value P value
1 vs 2 935.5 .2217
3 vs 4 566 .0 .2019
A nalysis 17 The influence of gender and Dx trea tm en t on total and AP
colony form ation (figure 6.8i)
Comparison U value P value
1 vs 2 399 .0 .2761
3 vs 4 194.5 .3752
5 vs 6 116.0 .6641
7 vs 8 95 .0 .3230
1 vs 5 181 . 5 . 0 3 1 7
2 vs 6 152.0 .1429
3 vs 7 153.5 .5059
4 vs 8 146.0 .7121
Analysis 18 The influence of gender and Dx trea tm en t on total and AP
colony form ation of donors of > 50 years (figure 6.8ii)
Comparison U value P value
1 vs 2 312.5 .4083
3 vs 4 159.5 .3915
5 vs 6 129.0 .8009
7 vs 8 117.5 .5052
1 vs 5 117. 0 . 0022
2 vs 6 100. 0 . 0111
3 vs 7 126.5 .1849





The effect of Dx treatment in a cohort study of BMSC 
proliferation (figure 6.9)
Comparison U value P value
1 vs 2 367 .276
The influence of gender and Dx treatment on BMSC 
proliferation (figure 6.10i)
Comparison U value P value
1 vs 2 152 .1941
3 vs 4 33.0 .5340
1 vs 3 52 .0 .0 347
2 vs 4 46.5 .0884
The influence of gender and Dx treatment on proliferation 
of BMSC from donors of > 50 years (figure 6.10ii)
Comparison U value P value
1 vs 2 104 .2490
3 vs 4 15 .3914
1 vs 3 19.0 .0134





The following table summarises the available characteristics of the donors used in this study. 
All samples are rib unless stated otherwise. U, unknown.
D o n o r  # S e x A g e  (y rs) D ia g n o s i s D r u g s
343 F 77 U U
347 M 55 U u
348 F 56 U u
352 F 57 U u
353 M 63 u u
356 M 27 u u
361 M 74 u u
362 M 74 u u
367 M 56 u u
372 M 74 u u
374 F 84 u u
375 M 71 u u
386 M 66 u u
387 F 71 u u
388 M 61 u u
393 F 26 u u
395 F 73 u Thyroxine
Aspirin
Amilodipine
399 M 66 u U
409 F 39 u U
418 M 75 osteoarthritis Nifedipine
Naprosyn
422 M 62 lung carcinoma Ventoline
Becotide
428 M 55 U U
429 M 54 lung carcinoma U
434 M 73 U u
439 M 66 u Heparin
Cefuroxine
441 M 66 u Omerplazole
Amilodipine
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D o n o r  # S e x  Age (yrs)  D i a g n o s i s D r u g s









464 M 58 small cell carcinoma Naproxam
Lansoprazole





468 F 36 spinal Fusion U
A ll M 67 U U
475 F 60 lung carcinoma u
480 M 80 lung carcinoma Dothiapan
481 F U U
482 M U squamous cell carcinoma Innovace
Bendrofluazide




491 F 55 hiatus hernia Lansoprazole
Metaclopramide
496 F 74 U Framil
500 F 70 bronchial carcinoma Nifedipine
Dothiepin
Bendrofluazide
507 F 72 U U
518 M 54 6th rib Propranol
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Donor # Sex Age (yrs) D iag n o sis D rugs
520 F 76 lung carcinoma U
523 F 62 lung carcinoma Zantac
Clomipramin
526 F 63 lung carcinoma Amilodipine
Naproxen
527 F 42 achalasia U
530 M 52 lung carcinoma u







539 M 71 U U




550 M 75 oesophago- U
gastrectomy
552 F 73 acimyosarcoma 
of uterus
U
562 M 71 lung carcinoma U
571 F 58 lung carcinoma Tendnormlin LS
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